

6,011,068

17

loaded bovine parathyroid cells. The initial $[Ca^{2+}]_i$ was 0.5 mM (using $CaCl_2$) and, at each of the arrows, was increased in 0.5 mM increments.

FIGS. 3a-3c are graphical representations showing mobilization of $[Ca^{2+}]_i$ in bovine parathyroid cells. The initial $[Ca^{2+}]_i$ was 0.5 mM and was decreased to $<1 \mu M$ by the addition of EGTA as indicated. (a) Extracellular Mg^{2+} (8 mM final) elicits an increase in $[Ca^{2+}]_i$ in the absence of extracellular Ca^{2+} . (b) Pretreatment with ionomycin ($1 \mu M$) blocks the response to Mg^{2+} . (c) Pretreatment with 5 μM molecule 1799 (a mitochondrial uncoupler) is without effect on the response to Mg^{2+} .

FIGS. 4a-4c are graphical representations showing preferential inhibitory effects of a low concentration of Gd^{3+} on steady-state increases in $[Ca^{2+}]_i$ and that a high concentration of Gd^{3+} elicits a transient increase in $[Ca^{2+}]_i$ in bovine parathyroid cells. Top panel: Control. Initial concentration of extracellular Ca^{2+} was 0.5 mM and was increased by 0.5 mM at each of the arrowheads. Middle panel: Gd^{3+} ($5 \mu M$) blocks steady-state, but not transient increases in $[Ca^{2+}]_i$ elicited by extracellular Ca^{2+} . Lower panel: Gd^{3+} ($50 \mu M$) elicits a transient increase in $[Ca^{2+}]_i$ and abolishes both transient and sustained responses to extracellular Ca^{2+} . In the middle and lower panels, just enough EGTA was added to chelate preferentially Gd^{3+} , the block of Ca^{2+} influx is removed and $[Ca^{2+}]_i$ rises promptly.

FIGS. 5a-5c are graphical representations showing that the effects of phorbol myristate acetate (PMA) on $[Ca^{2+}]_i$, IP_3 formation, and PTH secretion are overcome by increasing concentrations of extracellular Ca^{2+} in bovine parathyroid cells. For each variable, there is a shift to the right in the concentration-response curve for extracellular Ca^{2+} . The concentration-response curves vary sigmoidally as $[Ca^{2+}]_i$ increases linearly. The open circles refer to no PMA. The closed circles refer to 100 nM PMA.

FIG. 6 is a graphical representation showing that increases in $[Ca^{2+}]_i$ elicited by spermine are progressively depressed by increasing $[Ca^{2+}]_o$ in bovine parathyroid cells. Spermine ($200 \mu M$) was added at the time shown by arrowheads. In this and all subsequent figures, the numbers accompanying the traces are $[Ca^{2+}]_i$ in nM.

FIG. 7 is a graphical representation showing that spermine mobilizes intracellular Ca^{2+} in bovine parathyroid cells. EGTA was added to reduce $[Ca^{2+}]_i$ to $<1 \mu M$ before the addition of spermine ($200 \mu M$) as indicated (left trace). Pretreatment with ionomycin ($1 \mu M$) blocks the response to spermine (right trace).

FIGS. 8a and 8b are graphical representations showing that spermine increases $[Ca^{2+}]_i$ and inhibits PTH secretion in bovine parathyroid cells similarly to extracellular Ca^{2+} . The data points for the spermine dose concentration-response curves are the means of two experiments.

FIGS. 9a-9c are graphical representations showing the contrasting effects of PMA on responses to extracellular Ca^{2+} and on responses to ATPyS in bovine parathyroid cells. Left panel: The concentration-response curve for extracellular Ca^{2+} -induced inhibition of cyclic AMP formation is shifted to the right by PMA (100 nM). Middle panel: PMA does not affect the ability of ATPyS to increase $[Ca^{2+}]_i$. The concentration-response curve to ATPyS shows classical sigmoidal behavior as a function of the log concentration, in contrast to extracellular divalent cations.

FIGS. 10a-10c are graphical representations showing mobilization of intracellular Ca^{2+} in human parathyroid cells evoked by extracellular Mg^{2+} . Cells were obtained from an adenoma and bathed in buffer containing 0.5 mM extracel-

18

lular Ca^{2+} . (a) Transient and sustained increases in $[Ca^{2+}]_i$ elicited by extracellular Mg^{2+} (10 mM, final) shows that sustained increases are not affected by nimodipine ($1 \mu M$) but are depressed by La^{3+} ($1 \mu M$) and return promptly when La^{3+} is selectively chelated by a low concentration of EGTA ($50 \mu M$). (b) La^{3+} ($1 \mu M$) blocks the sustained, but not the transient increase in $[Ca^{2+}]_i$ elicited by extracellular Mg^{2+} . (c) Cytosolic Ca^{2+} transients elicited by extracellular Mg^{2+} persist in the absence of extracellular Ca^{2+} .

FIGS. 11a-11i are graphical representations showing mobilization of intracellular Ca^{2+} evoked by neomycin or protamine in bovine parathyroid cells. In all traces, the initial $[Ca^{2+}]_i$ and $[Mg^{2+}]_o$ was 0.5 and 1 mM, respectively. In traces (a) and (b), the Ca^{2+} and Mg^{2+} concentrations were increased to 2 and 8 mM, from 0.5 and 1 mM, respectively. In the other traces, (c) through (i) neomycin B ($30 \mu M$) or protamine ($1 \mu g/ml$) were added as indicated. La^{3+} ($1 \mu M$), EGTA (1 mM), or ionomycin (100 nM) were added as indicated. Each trace is representative of the pattern seen in 5 or more trials using at least 3 different cell preparations. Bar=1 minute.

FIG. 12 is a graphical representation showing that neomycin B blocks transient, but does not block steady-state increases in $[Ca^{2+}]_i$ elicited by extracellular Ca^{2+} in bovine parathyroid cells. Left control: $[Ca^{2+}]_i$ was initially 0.5 mM and was increased in 0.5 mM increments at each of the open arrowheads before the addition of neomycin B ($30 \mu M$). Right: Neomycin B ($30 \mu M$) was added before $[Ca^{2+}]_i$. Bar=1 minute.

FIGS. 13a and 13b are graphical representations showing that neomycin B or protamine inhibit PTH secretion at concentrations which evoked increases in $[Ca^{2+}]_i$ in bovine parathyroid cells. Cells were incubated with the indicated concentrations of organic polycation for 30 minutes in the presence of 0.5 mM extracellular Ca^{2+} . Bovine cells were used in the experiments with protamine and human (adenoma) parathyroid cells were used in the experiments with neomycin B. Each point is the mean \pm SEM of 3 experiments. Circles refer to PTH levels in the presence of 0.5 mM extracellular Ca^{2+} in the presence (closed circles) and absence (open circles) of neomycin B (FIG. 13a) or protamine (FIG. 13b). Diamonds refer to $[Ca^{2+}]_i$ levels in the presence of 0.5 mM extracellular Ca^{2+} in the presence (closed diamonds) and absence (open diamond) of neomycin B (FIG. 13a) or protamine (FIG. 13b). The open square refers to PTH secretion in the presence of 2 mM extracellular Ca^{2+} .

FIG. 14 is a graphical representation showing the preferential inhibitory effects of PMA on cytosolic Ca^{2+} transients elicited by spermine in bovine parathyroid cells. Initial $[Ca^{2+}]_i$ was 0.5 mM; PMA (100 nM), spermine ($200 \mu M$) or ATP ($50 \mu M$) were added as indicated. Bar=1 minute.

FIGS. 15a and 15b are graphical representations showing that PMA shifts to the right the concentration-response curves for extracellular Ca^{2+} - and neomycin B-induced increases in $[Ca^{2+}]_i$ in bovine parathyroid cells. Cells were either untreated (open circles) or pretreated with 100 nM PMA for 1 minute (closed circles) before increasing $[Ca^{2+}]_o$ or before adding neomycin B as indicated. Each point is the mean \pm SEM of 3 to 5 experiments.

FIGS. 16a and 16b are graphical representations showing that PMA shifts to the right the concentration-response curves for extracellular Ca^{2+} - and spermine-induced inhibition of PTH secretion in bovine parathyroid cells. Cells were incubated with the indicated $[Ca^{2+}]_o$ and spermine for 30 minutes in the presence (closed circles) or absence (open circles) of 100 nM PMA. Each point is the mean \pm SEM of 3 experiments.

6,011,068

19

FIG. 17 is a graphical representation showing that protamine increases the formation of inositol phosphates in bovine parathyroid cells. Parathyroid cells were incubated overnight in culture media containing 4 $\mu\text{Ci/ml}$ ^3H -Myo-inositol, washed, and incubated with the indicated concentration of protamine at 37° C. After 30 seconds, the reaction was terminated by the addition of $\text{CHCl}_3\text{:MeOH:HCl}$ and IP_1 (circles) and IP_3 (triangles) separated by anion exchange chromatography. Each point is the mean of 2 experiments, each performed in triplicate.

FIGS. 18a and 18b are graphical representations showing that PMA depresses the formation of IP_1 evoked by extracellular Ca^{2+} or spermine in bovine parathyroid cells. ^3H -Myo-inositol-labeled cells were exposed to the indicated $[\text{Ca}^{2+}]_i$ or spermine for 30 seconds before terminating the reaction and determining IP_1 by anion exchange chromatography. Hatched columns: Cells were pretreated with PMA (100 nM) for 5 minutes before increasing $[\text{Ca}^{2+}]_i$ or adding spermine. Each value is the mean of 2 experiments, each performed in triplicate.

FIG. 19 is a graphical representation showing transient and sustained increases in $[\text{Ca}^{2+}]_i$ elicited by neomycin B in human (adenoma) parathyroid cells. Extracellular Ca^{2+} was 0.5 mM. (a) The sustained increase in $[\text{Ca}^{2+}]_i$ elicited by neomycin B (10 μM) was depressed by La^{3+} (1 μM). (b) The transient increase in $[\text{Ca}^{2+}]_i$ evoked by neomycin B (10 μM) was unaffected by La^{3+} (1 μM). (c) Transient increases in $[\text{Ca}^{2+}]_i$ persisted in the absence of extracellular Ca^{2+} (1 mM of EGTA and 10 μM of neomycin B).

FIGS. 20a and 20b are graphical representations showing that neomycin B evokes oscillating increases the Cl^- current in *Xenopus* oocytes expressing the calcium receptor. Upper trace from an oocyte three days after injection with human (hyperplastic) parathyroid cell poly(A)⁺-mRNA. Lower trace from an oocyte injected with water. Neomycin B failed to elicit a response in five water-injected oocytes and carbachol elicited a response in one, which is shown. In both traces, the holding potential was -76 mV.

FIG. 21 is a graphical representation showing that neomycin B fails to affect basal or evoked increases in C-cells. Control, left trace: fura-2-loaded rMTC 6-23 cells were initially bathed in buffer containing 1 mM Ca^{2+} before increasing $[\text{Ca}^{2+}]_i$ to 3 mM. Right trace: pretreatment with 5 mM neomycin B.

FIG. 22 is a graphical representation showing that extracellular Ca^{2+} evokes increases in $[\text{Ca}^{2+}]_i$ in rat osteoclasts. Microfluorimetric recording in a single rat osteoclast loaded with indo-1 and superfused for the indicated times (bars) with buffer containing the indicated $[\text{Ca}^{2+}]_o$. Normal buffer, superfused between the bars, contained 1 mM Ca^{2+} .

FIG. 23 is a graphical representation showing that spermine or neomycin B fail to evoke increases in $[\text{Ca}^{2+}]_i$ in rat osteoclasts. An indo-1-loaded osteoclast was superfused with the indicated concentration of spermine or neomycin B (open bars) alone or together with 20 mM Ca^{2+} (solid bars).

FIG. 24 is a graphical representation showing the differential effects of argiotoxin 659 and argiotoxin 636 on $[\text{Ca}^{2+}]_i$ in bovine parathyroid cells (structures shown in FIG. 1e). The initial $[\text{Ca}^{2+}]_i$ was 0.5 mM and was increased to 1.5 mM where indicated (right trace). Where indicated, argiotoxin 659 (300 μM) or argiotoxin 636 (400 μM) was added.

FIGS. 25a-25c are graphical representations showing that extracellular Mg^{2+} or Gd^{3+} evoke oscillatory increases in Cl^- current in *Xenopus* oocytes injected with bovine parathyroid cell poly(A)⁺-mRNA. In trace (a), the concentration of extracellular Ca^{2+} was 1 μM and in traces (b) and (c) it was

20

0.7 mM. Trace (c) shows that extracellular Mg^{2+} fails to elicit a response in an oocyte injected only with the mRNA for the substance K receptor, although superfusion with substance K evokes a response. Holding potential was -70 to -80 mV.

FIG. 26 is a graphical representation showing that extracellular Ca^{2+} elicits oscillatory increases in Cl^- current in *Xenopus* oocytes injected with human (hyperplastic) parathyroid tissue poly(A)⁺-mRNA. The oocyte was tested for responsiveness to extracellular Ca^{2+} three days after injection of 50 ng poly(A)⁺-mRNA. Holding potential was -80 mV.

FIG. 27 is a graphical representation showing the mobilization of intracellular Ca^{2+} in bovine parathyroid cells elicited by budmunchiamine. Budmunchiamine (300 μM , structure shown in FIG. 1a) was added where indicated.

FIGS. 28a and 28b are graphical representations showing that the ability of molecules to mobilize intracellular Ca^{2+} in cells expressing a calcium receptor is stereospecific. Different cells were tested for response to pure stereoisomers and racemic mixtures. HEK 293 cells stably transfected with a cDNA clone corresponding to pHuPCaR4.0 (top panel, FIG. 28b), the rat C-cell line 44-2 isolated from a medullary thyroid carcinoma (middle panel, FIG. 28b) and bovine parathyroid cells (FIG. 28a and bottom panel FIG. 28b) were loaded with fura-2 and suspended in buffer containing 1.0 mM (top and middle panels FIG. 28b) or 0.5 mM extracellular Ca^{2+} (FIG. 28a and bottom panel FIG. 28b). Intracellular Ca^{2+} was monitored using a fluorimeter. Each point on the graph represents the peak response (highest concentration of intracellular calcium achieved) to the addition of the indicated concentration of the indicated compound. In FIG. 28a, NPS 457 is a racemic mixture containing compound 1B (see FIG. 36a) and the corresponding S isomer; NPS 447 is R-fendiline; and NPS 448 is S-fendiline.

FIG. 29 is a graphical representation showing effects of La^{3+} on $[\text{Ca}^{2+}]_i$ in osteoclasts. A representative trace from a single rat osteoclast loaded with indo-1 is shown. At low concentrations, La^{3+} partially blocks increases in $[\text{Ca}^{2+}]_i$ elicited by extracellular Ca^{2+} .

FIGS. 30a and 30b are graphical representations showing the mobilization of intracellular Ca^{2+} elicited by extracellular Mn^{2+} in rat osteoclasts. Extracellular Mn^{2+} evokes concentration-dependent increases in $[\text{Ca}^{2+}]_i$ (FIG. 30a) that persist in the absence of extracellular Ca^{2+} (FIG. 30b).

FIGS. 31a and 31b are graphical representations showing mobilization of $[\text{Ca}^{2+}]_i$ in rat osteoclasts elicited by prenylamine (shown in the figures as NPS 449). Isolated rat osteoclasts loaded with indo-1 were superfused with the indicated concentrations of prenylamine in the presence (FIG. 31a) or absence (FIG. 31b) of 1 mM extracellular CaCl_2 .

FIG. 32 is a graphical representation showing the mobilization of intracellular Ca^{2+} in C-cells evoked by NPS 019 (see FIG. 1a). rMTC 6-23 cells were loaded with fura-2 and bathed in buffer containing 0.5 mM $[\text{Ca}^{2+}]_o$. Where indicated, NPS 019 was added to a final concentration of 10 μM . Representative traces show that the transient increase in $[\text{Ca}^{2+}]_i$ elicited by NPS 019 is refractory to inhibition by La^{3+} (middle trace) and persists in the absence of extracellular Ca^{2+} (right trace, 1 mM EGTA).

FIG. 33 is a graphical representation showing that fendiline (shown in the figure as NPS 456) evokes oscillatory increases in Cl^- current in *Xenopus* oocytes which have been injected with 50 ng bovine parathyroid cell poly(A)⁺-mRNA.

FIG. 34 is a graphical representation showing that extracellular Ca^{2+} evokes oscillatory increases in Cl^- current in

6,011,068

21

Xenopus oocytes which have been injected with human osteoclast mRNA. The oocyte was tested for responsivity to extracellular Ca^{2+} three days after injection of 50 ng of total poly(A)⁺-mRNA.

FIG. 35 is a graphical representation showing that the parathyroid cell calcium receptor is encoded by mRNA in a size range of 2.5–3.5 kb. Bovine parathyroid cell poly(A)⁺-mRNA was size fractionated on glycerol gradients and pooled into ten fractions. Each fraction was injected (50 ng/fraction) separately into Xenopus oocytes. After three days, the oocytes were examined for their ability to respond to neomycin B (10 mM) with oscillatory increases in the Cl-current.

FIGS. 36a–36n show the chemical structures of molecules based on the lead structure diphenylpropyl- α -phenethylamine (fendiline), illustrating a family of molecules which were synthesized and screened to find the useful molecules of the invention.

FIGS. 37a and 37b are graphical representations showing that NPS 021 is a calcilytic compound that blocks the effects of extracellular Ca^{2+} on $[\text{Ca}^{2+}]_i$ in bovine parathyroid cells. Cells were initially bathed in buffer containing 0.5 mM CaCl_2 and, where indicated, the $[\text{Ca}^{2+}]_o$ was increased to a final of 2 mM (left trace). The addition of NPS 021 (200 μM) caused no change in $[\text{Ca}^{2+}]_i$, but inhibited the increase in $[\text{Ca}^{2+}]_i$ elicited by extracellular Ca^{2+} (right trace).

FIG. 38 is a graph showing the in vivo serum Ca^{2+} response to NPS R,S-467 in a test animal (a rat). The dosage is provided as mg of drug per kg weight of the test animal.

FIG. 39 is a graph showing the in vivo PTH response to NPS R,S-467 in a test animal (a rat). The dosage is provided as mg of drug per kg weight of the test animal.

FIG. 40 is a graph showing in vivo serum Ca^{2+} response over the course of 24 hours to 25 mg/kg NPS R,S-467 in a test animal (a rat). The dosage is provided as mg of drug per kg weight of the test animal.

FIG. 41 is a graph showing the in vitro response of $[\text{Ca}^{2+}]_i$ in cultured bovine parathyroid cells to different enantiomers of NPS 467. EE refers to the R enantiomer. LE and to the S enantiomer.

FIG. 42 is a graph showing the in vivo response of ionized serum Ca^{2+} in rats to different enantiomers of NPS 467. DE and E refer to the R enantiomer. LE and L refer to the S enantiomer. Native refers to the racemic mixture.

FIG. 43a depicts a reaction scheme for the preparation of fendiline or fendiline analogues or derivatives depicted in FIG. 36. FIG. 43b depicts a reaction scheme for the synthesis of NPS 467.

FIG. 44 depicts a dose-response curve showing that NPS R-467 (NPS-467E) lowers serum ionized calcium in rats when administered orally.

FIG. 45 is a restriction map of soPcaR 1.

FIG. 46 is a restriction map of the plasmid containing BoPCaR 1, deposited with the ATCC under accession number 75416.

FIGS. 47a–d show the nucleotide sequence corresponding to the ~5 Kb fragment of BoPCaR 1 and the encoded-for amino acid sequence (SEQ. ID. NO. 1).

FIGS. 48a–48d show the nucleotide sequence corresponding to the ~5 Kb insert from pHuPCaR 5.2 and the encoded-for amino acid sequence (SEQ. ID. NO. 2).

FIGS. 49a–49c show the nucleotide sequence corresponding to the ~4 Kb insert from pHuCaR 4.0 and the encoded-for amino acid sequence (SEQ. ID. NO. 3).

22

FIGS. 50a–50d show the nucleotide sequence corresponding to the ~4 Kb insert of pRakCaR 3A and the encoded-for amino acid sequence (SEQ. ID. NO. 4).

FIG. 51 depicts the ability of NPS R-467 and NPS R-568 to potentiate the response of a calcium receptor to submaximal concentrations of extracellular Ca^{2+} , and shift the extracellular Ca^{2+} concentration-response curve to the left.

FIG. 52 depicts a reaction scheme for compound 17X.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca^{2+} and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.

Applicant is the first to describe a Ca^{2+} receptor protein in parathyroid cells, and to pharmacologically differentiate such Ca^{2+} receptors in other cells, such as C-cells and osteoclasts. Applicant is also the first to describe methods by which molecules active at these Ca^{2+} receptors can be identified and used as lead molecules in the discovery, development, design, modification and/or construction of useful calcimimetics or calcilytics which are active at Ca^{2+} receptors.

Publications concerned with the calcium activity, calcium receptor and/or calcium receptor modulating compounds include the following: Brown et al., *Nature* 366: 574, 1993; Nemeth et al., PCT/US93/01642, International Publication Number WO 94/18959; Nemeth et al., PCT/US92/07175, International Publication Number WO 93/04373; Shoback and Chen, *J. Bone Mineral Res.* 9: 293 (1994); and Racke et al., *FEBS Lett.* 333: 132, (1993). These publications are not admitted to be prior art to the claimed invention.

I. CALCIUM RECEPTOR-MODULATING AGENTS

Calcium receptor-modulating agents can mimic or block an effect of extracellular Ca^{2+} on cell having a calcium receptor. Generic and specific structures of calcium receptor-modulating agents are provided in the Summary supra, and in FIGS. 1 and 36. Preferred calcium receptor-modulating agents are calcimimetics and calcilytics. The ability of molecules to mimic or block an activity of Ca^{2+} at calcium receptors can be determined using procedures described below. The same type of procedures can be used to measure the ability of a molecule to mimic or block an activity of other inorganic ions at their respective inorganic ion receptors by assaying for specific inorganic ion receptor activities. Examples of these procedures, and their examples provided herein, are not limiting, in the invention, but merely illustrate methods which are readily used or adapted by those of ordinary skill in the art.

A. Calcium Receptor

Calcium receptors are present on different cell types and can have different activities in different cell types. The

6,011,068

23

pharmacological effects of the following cells, in response to calcium, is consistent with the presence of a calcium receptor: parathyroid cell, bone osteoclast, juxtaglomerular kidney cell, proximal tubule kidney cell, distal tubule kidney cell, central nervous system cell, peripheral nervous system cell, cell of the thick ascending limb of Henle's loop and/or collecting duct, keratinocyte in the epidermis, parafollicular cell in the thyroid (C-cell), intestinal cell, trophoblast in the placenta, platelet, vascular smooth muscle cell, cardiac atrial cell, gastrin-secreting cell, glucagon-secreting cell, kidney mesangial cell, mammary cell, beta cell, fat/adipose cell, immune cell, GI tract cell, skin cell, adrenal cell, pituitary cell, hypothalamic cell and cell of the subfornical organ. In addition, the presence of calcium receptors on parathyroid cell, central nervous system cell, peripheral nervous system cell, cell of the thick ascending limb of Henle's loop and/or collecting duct in the kidney, parafollicular cell in the thyroid (C-cell), intestinal cell, GI tract cell, pituitary cell, hypothalamic cell and cell of the subfornical organ, has been confirmed by physical data.

The calcium receptor on these cell types may be different. It is also possible that a cell can have more than one type of calcium receptor. Comparison of calcium receptor activities and amino acid sequences from different cells indicate that distinct calcium receptor types exist. For example, calcium receptors can respond to a variety of di- and trivalent cations. The parathyroid calcium receptor responds to calcium and Gd^{3+} , while osteoclasts respond to divalent cations such as calcium, but do not respond to Gd^{3+} . Thus, the parathyroid calcium receptor is pharmacologically distinct from the calcium receptor on the osteoclast.

On the other hand, the nucleic acid sequences encoding calcium receptors present in parathyroid cells and C-cells indicate that these receptors have a very similar amino acid structure. Nevertheless, calcimimetic compounds exhibit differential pharmacology and regulate different activities at parathyroid cells and C-cells. Thus, pharmacological properties of calcium receptors may vary significantly depending upon the cell type or organ in which they are expressed even though the calcium receptors may have similar or even identical structures.

Calcium receptors, in general, have a low affinity for extracellular Ca^{2+} (apparent K_d generally greater than about 0.5 mM). Calcium receptors may include a free or bound effector mechanism as defined by Cooper, Bloom and Roth, "The Biochemical Basis of Neuropharmacology", Ch. 4, and are thus distinct from intracellular calcium receptors, e.g., calmodulin and the troponins.

Calcium receptors respond to changes in extracellular calcium levels. The exact changes depend on the particular receptor and cell line containing the receptor. For example, the *in vitro* effect of calcium on the calcium receptor in a parathyroid cell includes the following:

1. An increase in internal calcium. The increase is due to the influx of external calcium and/or to mobilization of internal calcium. Characteristics of the increase in internal calcium include the following:
 - (a) A rapid (time to peak < 5 seconds) and transient increase in $[Ca^{2+}]_i$ that is refractory to inhibition by $1 \mu M La^{3+}$ or $1 \mu M Gd^{3+}$ and is abolished by pretreatment with ionomycin (in the absence of extracellular Ca^{2+});
 - (b) The increase is not inhibited by dihydropyridines;
 - (c) The transient increase is abolished by pretreatment for 10 minutes with 10 mM sodium fluoride;
 - (d) The transient increase is diminished by pretreatment with an activator of protein kinase C (PKC), such as

24

phorbol myristate acetate (PMA), mezerein or (-)-indolactam V. The overall effect of the protein kinase C activator is to shift the concentration-response curve of calcium to the right without affecting the maximal response; and

(e) Pretreatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect the increase.

2. A rapid (< 30 seconds) increase in the formation of inositol-1,4,5-triphosphate or diacylglycerol. Pretreatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect this increase;
3. The inhibition of dopamine- and isoproterenol-stimulated cyclic AMP formation. This effect is blocked by pretreatment with pertussis toxin (100 ng/ml for > 4 hours); and
4. The inhibition of PTH secretion. Pretreatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect the inhibition in PTH secretion.

Using techniques known in the art, the effect of calcium on other calcium receptors in different cells can be readily determined. Such effects may be similar in regard to the increase in internal calcium observed in parathyroid cells. However, the effect is expected to differ in other aspects, such as causing or inhibiting the release of a hormone other than parathyroid hormone.

B. Calcimimetics

The ability of molecules to mimic or block the activity of Ca^{2+} at calcium receptors can be determined using the assays described in the present application. For example, calcimimetics possess one or more and preferably all of the following activities when tested on parathyroid cells *in vitro*:

1. The molecule causes a rapid (time to peak < 5 seconds) and transient increase in $[Ca^{2+}]_i$ that is refractory to inhibition by $1 \mu M La^{3+}$ or $1 \mu M Gd^{3+}$. The increase in $[Ca^{2+}]_i$ persists in the absence of extracellular Ca^{2+} , but is abolished by pretreatment with ionomycin (in the absence of extracellular Ca^{2+});
2. The molecule potentiates increases in $[Ca^{2+}]_i$ elicited by submaximal concentrations of extracellular Ca^{2+} ;
3. The increase in $[Ca^{2+}]_i$ elicited by extracellular Ca^{2+} is not inhibited by dihydropyridines;
4. The transient increase in $[Ca^{2+}]_i$ caused by the molecule is abolished by pretreatment for 10 minutes with 10 mM sodium fluoride;
5. The transient increase in $[Ca^{2+}]_i$ caused by the molecule is diminished by pretreatment with an activator of protein kinase C (PKC), such as phorbol myristate acetate (PMA), mezerein or (-)-indolactam V. The overall effect of the protein kinase C activator is to shift the concentration-response curve of the molecule to the right without affecting the maximal response;
6. The molecule causes a rapid (< 30 seconds) increase in the formation of inositol-1,4,5-triphosphate and/or diacylglycerol;
7. The molecule inhibits dopamine- or isoproterenol-stimulated cyclic AMP formation;
8. The molecule inhibits PTH secretion;
9. Pretreatment with pertussis toxin (100 ng/ml for > 4 hours) blocks the inhibitory effect of the molecule on cyclic AMP formation, but does not effect increases in $[Ca^{2+}]_i$, inositol-1,4,5-triphosphate, or diacylglycerol, nor decreases in PTH secretion;
10. The molecule elicits increases in Cl^- current in *Xenopus* oocytes injected with poly(A)⁺-enriched

6,011,068

25

mRNA from bovine or human parathyroid cells, but is without effect in *Xenopus* oocytes injected with water, or liver mRNA; and

11. Similarly, using a cloned calcium receptor from a parathyroid cell, the molecule will elicit a response in *Xenopus* oocytes injected with the specific cDNA or mRNA encoding the receptor.

Parallel definitions of molecules mimicking Ca^{2+} activity on other calcium-responsive cells, preferably at a calcium receptor, are evident from the examples provided herein. Preferably, the agent has one or more, more preferably all of the following activities: evokes a transient increase in internal calcium, having a duration of less than 30 seconds (preferably by mobilizing internal calcium); evokes a rapid increase in $[\text{Ca}^{2+}]_i$, occurring within thirty seconds; evokes a sustained increase (greater than thirty seconds) in $[\text{Ca}^{2+}]_i$ (preferably by causing an influx of external calcium); evokes an increase in inositol-1,4,5-triphosphate or diacylglycerol levels, preferably within less than 60 seconds; and inhibits dopamine- or isoproterenol-stimulated cyclic AMP formation.

The transient increase in $[\text{Ca}^{2+}]_i$ is preferably abolished by pretreatment of the cell for ten minutes with 10 mM sodium fluoride, or the transient increase is diminished by brief pretreatment (not more than ten minutes) of the cell with an activator of protein kinase C, preferably, phorbol myristate acetate (PMA), mezerein or (-) indolactam V.

C. Calcilytics

The ability of a molecule to block or decrease the activity of extracellular calcium at a cell surface calcium receptor can be determined using standard techniques based on the present disclosure. For example, molecules which block or decrease the effect of extracellular calcium, when used in reference to a parathyroid cell, possess one or more, and preferably all of the following characteristics when tested on parathyroid cells *in vitro*:

1. The molecule blocks, either partially or completely, the ability of increased concentrations of extracellular Ca^{2+} to:
 - (a) increase $[\text{Ca}^{2+}]_i$,
 - (b) mobilize intracellular Ca^{2+} ,
 - (c) increase the formation of inositol-1,4,5-triphosphate,
 - (d) decrease dopamine- or isoproterenol-stimulated cyclic AMP formation, and
 - (e) inhibit PTH secretion;
2. The molecule blocks increases in Cl^- current in *Xenopus* oocytes injected with poly(A)⁺-mRNA from bovine or human parathyroid cells elicited by extracellular Ca^{2+} or calcimimetic compounds, but not in *Xenopus* oocytes injected with water or liver mRNA; and
3. Similarly, using a cloned calcium receptor from a parathyroid cell, the molecule will block a response in *Xenopus* oocytes injected with the specific cDNA, mRNA or cRNA encoding the calcium receptor, elicited by extracellular Ca^{2+} or a calcimimetic compound.

Parallel definitions of molecules blocking Ca^{2+} activity on other calcium responsive cells, preferably at a calcium receptor, are evident from the examples provided herein.

D. Designing Calcium Receptor-Modulating Agents

Generally, calcium receptor-modulating agents are identified by screening molecules which are modelled after a molecule shown to have a particular activity (i.e., a lead

26

molecule). Derivative molecules are readily designed by standard procedures and tested using the procedures described herein.

Rational design of calcium receptor-modulating agents involves studying a molecule known to be calcimimetic or calcilytic and then modifying the structure of the known molecule. For example, polyamines are potentially calcimimetic since spermine mimics the action of Ca^{2+} in several *in vitro* systems. Results show that spermine does indeed cause changes in $[\text{Ca}^{2+}]_i$ and PTH secretion reminiscent of those elicited by extracellular di- and trivalent cations (see below). Conversely, Ga^{3+} antagonizes the effects of Gd^{3+} on the bovine parathyroid calcium receptor(s). The experiments outlined below are therefore aimed at demonstrating that this phenomenology, obtained with spermine, involves the same mechanisms used by extracellular Ca^{2+} . To do this, the effects of spermine on a variety of physiological and biochemical parameters which characterize activation of the calcium receptor were assessed. Those molecules having similar types of effects, and preferably at a greater magnitude, are useful in this invention and can be discovered by selecting or making molecules having a structure similar to spermine. Once another useful molecule is discovered this selection process can be readily repeated. The same type of analysis can be performed using different lead molecules shown to have desired activity.

For clarity, a specific series of screening protocols to identify molecules active at a parathyroid cell calcium receptor is described below. Equivalent assays can be used for molecules active at other calcium receptors or other inorganic ion receptors, or which otherwise mimic or antagonize cellular functions regulated by extracellular $[\text{Ca}^{2+}]_i$ at a calcium receptor. These assays exemplify the procedures which are useful to find molecules, including calcimimetic molecules, of this invention. Equivalent procedures can be used to find ionolytic molecules, including calcilytic molecules, by screening for those molecules most antagonistic to the actions of the ion, including extracellular Ca^{2+} . *In vitro* assays can be used to characterize the selectivity, saturability, and reversibility of these calcimimetics and calcilytics by standard techniques.

1. Screening Procedures

Various screening procedures can be carried out to assess the ability of a compound to act as a calcilytic or calcimimetic by measuring its ability to have one or more activities of a calcilytic or calcimimetic. In the case of parathyroid cells, such activities include the effects on intracellular calcium, inositol phosphates, cyclic AMP and PTH.

Measuring $[\text{Ca}^{2+}]_i$ with fura-2 provides a very rapid means of screening new organic molecules for activity. In a single afternoon, 10-15 compounds (or molecule types) can be examined and their ability to mobilize or inhibit mobilization of intracellular Ca^{2+} can be assessed by a single experimenter. The sensitivity of observed increases in $[\text{Ca}^{2+}]_i$ to depression by PMA can also be assessed.

For example, bovine parathyroid cells loaded with fura-2 are initially suspended in buffer containing 0.5 mM CaCl_2 . A test substance is added to the cuvette in a small volume (5-15 μl) and changes in the fluorescence signal are measured. Cumulative increases in the concentration of the test substance are made in the cuvette until some predetermined concentration is achieved or no further changes in fluorescence are noted. If no changes in fluorescence are noted, the molecule is considered inactive and no further testing is performed.

6,011,068

27

In the initial studies, e.g., with polyamine-type molecules, molecules were tested at concentrations as high as 5 or 10 mM. As more potent molecules became known, the ceiling concentration was lowered. For example, newer molecules are tested at concentrations no greater than 500 μ M. If no changes in fluorescence are noted at this concentration, the molecule can be considered inactive.

Molecules causing increases in $[Ca^{2+}]_i$ are subjected to additional testing. Two characteristics of a molecule which can be considered in screening a calcimimetic molecule are the mobilization of intracellular Ca^{2+} and sensitivity to PKC activators. Molecules causing the mobilization of intracellular Ca^{2+} in a PMA-sensitive manner have invariably been found to be calcimimetic molecules and to inhibit PTH secretion. Sensitivity to PKC activators is measured in cells where PKC has not undergone treatment resulting in persistent activation. Chronic pretreatment with low concentrations of PMA (about 30–100 nM treatment for about 24 hours) results in persistent activation of PKC and allows for the inhibition of PTH secretion by extracellular Ca^{2+} without any accompanying increase in $[Ca]_i$.

A single preparation of cells can provide data on $[Ca^{2+}]_i$, cyclic AMP levels, IP_3 and PTH secretion. A typical procedure is to load cells with fura-2 and then divide the cell suspension in two; most of the cells are used for measurement of $[Ca^{2+}]_i$ and the remainder are incubated with molecules to assess their effects on cyclic AMP and PTH secretion. Because of the sensitivity of the radioimmunoassays for cyclic AMP and PTH, both variables can be determined in a single incubation tube containing 0.3 ml cell suspension (about 500,000 cells).

Measurements of inositol phosphates are a time-consuming aspect of the screening. However, ion-exchange columns eluted with chloride (rather than formate) provide a very rapid means of screening for IP_3 formation, since rotary evaporation (which takes around 30 hours) is not required. This method allows processing of nearly 100 samples in a single afternoon by a single experimenter. Those molecules that prove interesting, as assessed by measurements of $[Ca^{2+}]_i$, cyclic AMP, IP_3 , and PTH, can be subjected to a more rigorous analysis by examining formation of various inositol phosphates and assessing their isomeric form by HPLC.

Additional testing can, if needed, be performed to confirm the ability of a molecule to act as a calcimimetic prior to its use to inhibit PTH in human cells or test animals. Typically, all the various tests for calcimimetic or calcilytic activity are not performed. Rather, if a molecule causes the mobilization of intracellular Ca^{2+} in a PMA-sensitive manner, it is advanced to screening on human parathyroid cells. For example, measurements of $[Ca^{2+}]_i$ are performed to determine the EC_{50} , and to measure the ability of the molecule to inhibit PTH secretion in human parathyroid cells which have been obtained from patients undergoing surgery for primary or secondary hyperparathyroidism. The lower the EC_{50} or IC_{50} , the more potent the molecule as a calcimimetic or calcilytic.

Calcimimetic and calcilytic molecules affecting PTH secretion are then preferably assessed for selectivity, for example, by also examining the effects of such compounds on $[Ca^{2+}]_i$ or calcitonin secretion in calcitonin-secreting C-cells such as the rat MTC 6–23 cells.

The following is illustrative of methods useful in these screening procedures. Examples of typical results for various test calcimimetic or calcilytic molecules are provided in FIGS. 2–34.

28

(a) Parathyroid Cell Preparation

This section describes procedures used to obtain and treat parathyroid cells from calves and humans. Parathyroid glands were obtained from freshly slaughtered calves (12–15 weeks old) at a local abattoir and transported to the laboratory in ice-cold parathyroid cell buffer (PCB) which contains (mM) NaCl, 126; KCl, 4; $MgCl_2$, 1; Na-HEPES, 20; pH 7.4; glucose, 5.6, and variable amounts of $CaCl_2$, e.g., 1.25 mM. Human parathyroid glands, were obtained from patients undergoing surgical removal of parathyroid tissue for primary or uremic hyperparathyroidism (uremic HPT), and were treated similarly to bovine tissue.

Glands were trimmed of excess fat and connective tissue and then minced with fine scissors into cubes approximately 2–3 mm on a side. Dissociated parathyroid cells were prepared by collagenase digestion and then purified by centrifugation in Percoll buffer. The resultant parathyroid cell preparation was essentially devoid of red blood cells, adipocytes, and capillary tissue as assessed by phase contrast microscopy and Sudan black B staining. Dissociated and purified parathyroid cells were present as small clusters containing 5 to 20 cells. Cellular viability, as indexed by exclusion of trypan blue or ethidium bromide, was routinely 95%.

Although cells can be used for experimental purposes at this point, physiological responses (e.g., suppressibility of PTH secretion and resting levels of $[Ca^{2+}]_i$) should be determined after culturing the cells overnight. Primary culture also has the advantage that cells can be labeled with isotopes to near isotopic equilibrium, as is necessary for studies involving measurements of inositol phosphate metabolism.

After purification on Percoll gradients, cells were washed several times in a 1:1 mixture of Ham's F12-Dulbecco's modified Eagle's medium (GIBCO) supplemented with 50 μ g/ml streptomycin, 100 U/ml penicillin, 5 μ g/ml gentamicin and ITS⁺. ITS⁺ is a premixed solution containing insulin, transferrin, selenium, and bovine serum albumin (BSA)-linolenic acid (Collaborative Research, Bedford, Mass.). The cells were then transferred to plastic flasks (75 or 150 cm^2 ; Falcon) and incubated overnight at 37° C. in a humid atmosphere of 5% CO_2 . No serum is added to these overnight cultures, since its presence allows the cells to attach to the plastic, undergo proliferation, and dedifferentiate. Cells cultured under the above conditions were readily removed from the flasks by decanting, and show the same viability as freshly prepared cells.

(b) Measurement of Cytosolic Ca^{2+} in Parathyroid Cells

This section describes procedures used to measure cytosolic Ca^{2+} in parathyroid cells (The "Cytolic Ca^{2+} Cell Assay"). Purified parathyroid cells were resuspended in 1.25 mM $CaCl_2$ -2% BSA-PCB containing 1 μ M fura-2-acetoxymethylester and incubated at 37° C. for 20 minutes. The cells were then pelleted, resuspended in the same buffer, but lacking the ester, and incubated a further 15 minutes at 37° C. The cells were subsequently washed twice with PCB containing 0.5 mM $CaCl_2$ and 0.5% BSA and maintained at room temperature (about 20° C.). Immediately before use, the cells were diluted five-fold with prewarmed 0.5 mM $CaCl_2$ -PCB to obtain a final BSA concentration of 0.1%. The concentration of cells in the cuvette used for fluorescence recording was $1-2 \times 10^6$ /ml.

The fluorescence of indicator-loaded cells was measured at 37° C. in a spectrofluorimeter (Biomedical Instrumentation Group, University of Pennsylvania, Philadelphia, Pa.) equipped with a thermostated cuvette holder and magnetic stirrer using excitation and emission wavelengths of 340 and

6,011,068

29

510 nm, respectively. This fluorescence indicates the level of cytosolic Ca^{2+} . Fluorescence signals were calibrated using digitonin (50 $\mu\text{g}/\text{ml}$, final) to obtain maximum fluorescence (F_{max}), and EGTA (10 mM, pH 8.3, final) to obtain minimal fluorescence (F_{min}), and a dissociation constant of 224 nM. Leakage of dye is dependent on temperature and most occurs within the first 2 minutes after warming the cells in the cuvette. Dye leakage increases only very slowly thereafter. To correct the calibration for dye leakage, cells were placed in the cuvette and stirred at 37° C. for 2–3 minutes. The cell suspension was then removed, the cells pelleted, and the supernatant returned to a clean cuvette. The supernatant was then treated with digitonin and EGTA to estimate dye leakage, which is typically 10–15% of the total Ca^{2+} -dependent fluorescent signal. This estimate was subtracted from the apparent F_{min} .

(c) Measurement of Cytosolic Ca^{2+} in C-cells

This section describes procedures used to measure cytosolic Ca^{2+} in cells. Neoplastic C-cells derived from a rat medullary thyroid carcinoma (rMTC 6–23) were obtained from American Type Culture Collection (ATCC No. 1607) and cultured as monolayers in Dulbecco's Modified Eagle's medium (DMEM) plus 150 horse serum in the absence of antibiotics. For measurements of $[\text{Ca}^{2+}]_i$, the cells were harvested with 0.02% EDTA/0.05% trypsin, washed twice with PCB containing 1.25 mM CaCl_2 and 0.5% BSA, and loaded with fura-2 as described in section I.D.2(b), supra. Measurements of $[\text{Ca}^{2+}]_i$ were performed as described above with appropriate corrections for dye leakage.

(d) Measurement of $[\text{Ca}^{2+}]_i$ in Rat Osteoclasts

This section describes techniques used to measure $[\text{Ca}^{2+}]_i$ in rat osteoclasts. Osteoclasts were obtained from 1–2 day old Sprague-Dawley rats using aseptic conditions. The rat pups were sacrificed by decapitation, the hind legs removed, and the femora rapidly freed of soft tissue and placed in prewarmed F-12/DMEM media (DMEM containing 10% fetal calf serum and antibiotics (penicillin-streptomycin-gentamicin; 100 U/ml-100 $\mu\text{g}/\text{ml}$ -100 $\mu\text{g}/\text{ml}$)). The bones from two pups were cut lengthwise and placed in 1 ml culture medium. Bone cells were obtained by gentle trituration of the bone fragments with a plastic pipet and diluted with culture medium. The bone fragments were allowed to settle and equal portions (about 1 ml) of the medium transferred to a 6-well culture plate containing 25-mm glass coverslips. The cells were allowed to settle for 1 hour at 37° C. in a humidified 5% CO_2 -air atmosphere. The coverslips were then washed 3 times with fresh media to remove nonadherent cells. Measurements of $[\text{Ca}^{2+}]_i$ in osteoclasts were performed within 6–8 hours of removing nonadherent cells.

Cells attached to the coverslip were loaded with indo-1 by incubation with 5 μM indo-1 acetoxymethylester/0.01% Pluronic F28 for 30 minutes at 37° C. in F-12/DMEM lacking serum and containing instead 0.5% BSA. The coverslips were subsequently washed and incubated an additional 15 minutes at 37° C. in F-12/DMEM lacking the acetoxymester before being transferred to a superfusion chamber mounted on the stage of a Nikon Diaphot inverted microscope equipped for microfluorimetry. Osteoclasts were easily identified by their large size and presence of multiple nuclei. The cells were superfused with buffer (typically PCB containing 0.1% BSA and 1 mM Ca^{2+}) at 1 ml/min with or without test substance. The fluorescence emitted by excitation at 340 nm was directed through the video port of the microscope onto a 440 nm dichroic mirror and fluorescence intensity at 495 and 405 nm collected by photomultiplier tubes. The outputs from the photomultiplier tubes were

30

amplified, digitized, and stored in an 80386 PC. Ratios of fluorescence intensity were used to estimate $[\text{Ca}^{2+}]_i$.

(e) Measuring $[\text{Ca}^{2+}]_i$ in Oocytes

Additional studies used *Xenopus* oocytes injected with mRNA from bovine or human parathyroid cells and measured Cl^- current as an indirect means of monitoring increases in $[\text{Ca}^{2+}]_i$. The following is an example of such studies used to test the effect of neomycin.

Oocytes were injected with poly(A)⁺-enriched mRNA from human parathyroid tissue (hyperplastic glands from a case of secondary HPT). After 3 days, the oocytes were tested for their response to neomycin. Neomycin B evoked oscillatory increases in the Cl^- current which ceased upon superfusion with drug-free saline (see FIG. 20). Responses to neomycin B were observed at concentrations between 100 μM and 10 mM.

To ensure that the response evoked by neomycin B was contingent upon injection of parathyroid mRNA, the effect of neomycin B on currents in water-injected oocytes was determined. In each of five oocytes examined, neomycin B (10 mM) failed to cause any change in the current.

About 40% of oocytes are known to respond to carbachol, an effect mediated by an endogenous muscarinic receptor. In five oocytes examined one showed inward currents in response to carbachol and this is shown in the lower trace of FIG. 20. Thus, in cells expressing a muscarinic receptor coupled to increases in $[\text{Ca}^{2+}]_i$ and Cl^- current, neomycin B fails to evoke a response. This shows that the response to neomycin B depends on expression of a specific protein encoded by parathyroid cell mRNA. It strongly suggests that in intact cells, neomycin B acts directly on the calcium receptor to alter parathyroid cell function.

(f) Measurement of PTH Secretion

In most experiments, cells loaded with fura-2 were also used in studies of PTH secretion. Loading parathyroid cells with fura-2 does not change their PTH secretory response to extracellular Ca^{2+} .

PTH secretion was measured by first suspending cells in PCB containing 0.5 mM CaCl_2 and 0.1% BSA. Incubations were performed in plastic tubes (Falcon 2058) containing 0.3 ml of the cell suspension with or without small volumes of CaCl_2 and/or organic polycations. After incubation at 37° C. for various times (typically 30 minutes), the tubes were placed on ice and the cells pelleted at 2° C. Samples of the supernatant were brought to pH 4.5 with acetic acid and stored at -70° C. This protocol was used for both bovine and human parathyroid cells.

For bovine cells, the amount of PTH in sample supernatants was determined by a homologous radioimmunoassay using GW-1 antibody or its equivalent at a final dilution of 1/45,000. ¹²⁵I-PTH (65–84; INCSTAR, Stillwater, Minn.) was used as tracer and fractions separated by dextran-activated charcoal. Counting of samples and data reduction were performed on a Packard Cobra 5005 gamma counter.

For human cells, a commercially available radioimmunoassay kit (INS-PTH; Nichols Institute, Los Angeles, Calif.) which recognizes intact and N-terminal human PTH was used because GW-1 antibody recognizes human PTH poorly.

(g) Measurement of cyclic AMP

This section describes measuring cyclic AMP levels. Cells were incubated as above for PTH secretion studies and at the end of the incubation, a 0.15-ml sample was taken and transferred to 0.85 ml of hot (70° C.) water and heated at this temperature for 5–10 minutes. The tubes were subsequently frozen and thawed several times and the cellular debris sedimented by centrifugation. Portions of the supernatant

6,011,068

31

were acetylated and cyclic AMP concentrations determined by radioimmunoassay.

(b) Measurement of Inositol Phosphate Formation

This section describes procedures measuring inositol phosphate formation. Membrane phospholipids were labeled by incubating parathyroid cells with 4 $\mu\text{Ci/ml}$ ^3H -myo-inositol for 20–24 hours. Cells were then washed and resuspended in PCB containing 0.5 mM CaCl_2 and 0.1% BSA. Incubations were performed in microfuge tubes in the absence or presence of various concentrations of organic polycation for different times. Reactions were terminated by the addition of 1 ml chloroform-methanol-12 N HCl (200:100:1; v/v/v). Aqueous phytic acid hydrolysate (200 μl ; 25 μg phosphate/tube). The tubes were centrifuged and 600 μl of the aqueous phase was diluted into 10 ml water.

Inositol phosphates were separated by ion-exchange chromatography using AG1-X8 in either the chloride- or formate-form. When only IP_3 levels were to be determined, the chloride-form was used, whereas the formate form was used to resolve the major inositol phosphates (IP_3 , IP_2 , and IP_1). For determination of just IP_3 , the diluted sample was applied to the chloride-form column and the column was washed with 10 ml 30 mM HCl followed by 6 ml 90 mM HCl and the IP_3 was eluted with 3 ml 500 mM HCl. The last eluate was diluted and counted. For determination of all major inositol phosphates, the diluted sample was applied to the formate-form column and IP_1 , IP_2 , and IP_3 eluted sequentially by increasing concentrations of formate buffer. The eluted samples from the formate columns were rotary evaporated, the residues brought up in cocktail, and counted.

The isomeric forms of IP_3 were evaluated by HPLC. The reactions were terminated by the addition of 1 ml 0.45M perchloric acid and stored on ice for 10 minutes. Following centrifugation, the supernatant was adjusted to pH 7–8 with NaHCO_3 . The extract was then applied to a Partisil SAX anion-exchange column and eluted with a linear gradient of ammonium formate. The various fractions were then desalted with Dowex followed by rotary evaporation prior to liquid scintillation counting in a Packard Tri-carb 1500 LSC.

For all inositol phosphate separation methods, appropriate controls using authentic standards were used to determine if organic polycations interfered with the separation. If so, the samples were treated with cation-exchange resin to remove the offending molecule prior to separation of inositol phosphates.

2. Use of Lead Molecules

By systematically measuring the ability of a lead molecule to mimic or antagonize the effect of extracellular Ca^{2+} , the importance of different functional groups for calcimimetics and calcilytics were identified. Of the molecules tested, some are suitable as drug candidates while others are not necessarily suitable as drug candidates. The suitability of a molecule as a drug candidate depends on factors such as efficacy and toxicity. Such factors can be evaluated using standard techniques. Thus, lead molecules can be used to demonstrate that the hypothesis underlying calcium receptor-based therapies is correct and to determine the structural features that enable the calcium receptor-modulating agents to act on the calcium receptor and, thereby, to obtain other molecules useful in this invention.

Examples of molecules useful as calcimimetics include branched or cyclic polyamines, positively charged polyamino acids, and arylalkylamines. In addition, other positively charged organic molecules, including naturally occurring molecules and their analogues, are useful calcimimetics. These naturally occurring molecules and their

32

analogues preferably have positive charge-to-mass ratios that correlate with those ratios for the molecules exemplified herein. (Examples include material isolated from marine species, arthropod venoms, terrestrial plants and fermentation broths derived from bacteria and fungi.) It is contemplated that one group of preferred naturally occurring molecules and analogues useful as calcimimetics will have a ratio of positive charge: molecular weight (in daltons) from about 1:40 to 1:200, preferably from about 1:40 to 1:100.

FIG. 36 provides additional examples of molecules expected to act as either calcilytics or calcimimetics based upon their structure. In general these molecules were synthesized based on the lead molecule, fendiline, and tested to determine their respective EC_{50} or IC_{50} values. Studies of stereoisomers, such as NPS 447 (R-fendiline) and NPS 448 (S-fendiline), have revealed stereospecific effects of molecular structure. The most active compounds tested to date are designated NPS R-467, NPS R-568, compound 8J, compound 8U, compound 9R, compound 11X, compound 12U, compound 12V, compound 12Z, compound 14U, compound 17M, compound 17P and compound 17X (see Table 8 infra). These compounds all have EC_{50} values of less than 5 μM at the parathyroid cell calcium receptor.

The examples described herein demonstrate the general design of molecules useful as ionomimetics and ionolytics, preferably, calcimimetics and calcilytics. The examples also describe screening procedures to obtain additional molecules, such as the screening of natural product libraries. Using these procedures, those of ordinary skill in the art can identify other useful ionomimetics and ionolytics, preferably calcimimetics and calcilytics.

(a) Functional Groups

This section describes useful functional groups for conferring increased mimetic or lytic activity and analytical procedures which can be used to identify different functional groups from lead molecules. Analysis of lead molecules have identified useful functional groups such as aromatic groups, stereospecificity (R-isomer) and preferred charge-to-molecule weight ratios. The described analytic steps and analogous analyses can be conducted on other lead molecules to obtain calcium receptor-modulating agents of increasing activity.

A factor examined earlier on was the charge-to-size ratio of a calcium receptor-modulating agent. Initial results of testing the correlation between net positive charge and potency in mobilizing intracellular Ca^{2+} in parathyroid cells revealed that protamine (+21; EC_{50} =40 nM) was more effective than neomycin B (+6; EC_{50} =20 μM in human parathyroid cells and 40 μM in bovine parathyroid cells), which was more effective than spermine (+4; EC_{50} =150 μM).

These results raised the question of whether positive charge alone determines potency, or if there are other structural features contributing to activity on the calcium receptor. This was important to determine at the outset because of its impact on the view that the calcium receptor can be targeted with effective and specific therapeutic molecules. Thus, a variety of other organic polycations related to neomycin B and spermine were studied to determine the relationship between the net positive charge of a molecule and its potency to mobilize intracellular Ca^{2+} .

The first series of molecules studied were the aminoglycosides. The ability of these molecules to mobilize intracellular Ca^{2+} was determined in bovine parathyroid cells. The rank order of potency for eliciting cytosolic Ca^{2+} transients was neomycin B (EC_{50} =20 or 40 μM)>gentamicin (150 μM)>beknamycin (200 μM)>streptomycin (600 μM).

6,011,068

33

Kanamycin and lincomycin were without effect when tested at a concentration of 500 μM . The net positive charge on these aminoglycosides at pH 7.3 is neomycin B (+6) > gentamicin (+5) = bekanamycin (+5) > kanamycin (average +4.5) > streptomycin (+3) > lincomycin (+1). Thus, within the aminoglycoside series there is some correlation between net positive charge and calcium receptor-modulating activity. However, the correlation is not absolute as illustrated by kanamycin, which would be predicted to be more potent than streptomycin, having no activity.

Testing of various polyamines revealed additional and more marked discrepancies between net positive charge and potency. Three structural classes of polyamines were examined: (1) straight-chain, (2) branched-chain, and (3) cyclic. The structures of the polyamines tested are provided in FIG. 1. Amongst the straight-chain polyamines, spermine (+4; EC_{50} =150 μM) was more potent than pentaethylenhexamine (+6; EC_{50} =500 μM) and tetraethylenepentamine (+5; EC_{50} =2.5 mM), even though the latter molecules have a greater net positive charge.

Branched-chain polyamines having different numbers of secondary and primary amino groups and, thus, varying in net positive charge were synthesized and tested. Two of these molecules, NPS 381 and NPS 382, were examined for effects on $[\text{Ca}^{2+}]_i$ in bovine parathyroid cells. NPS 382 (+8; EC_{50} =50 μM) was about twice as potent as NPS 381 (+10; EC_{50} =100 μM), even though it contains two fewer positive charges.

A similar discrepancy between positive charge and potency was noted in experiments with cyclic polyamines. For example, hexacyclen (+6; EC_{50} =20 μM) was more potent than NPS 383 (+8; EC_{50} =150 μM). The results obtained with these polyamines show that positive charge is not the sole factor contributing to potency.

Additional studies provided insights into other structural features of molecules that impart activity on the parathyroid cell calcium receptor. One of the structurally important features is the intramolecular distance between the nitrogens (which carry the positive charge). Spermine is 50-fold more potent than triethylenetetramine (EC_{50} =8 mM) in evoking increases in $[\text{Ca}^{2+}]_i$ in bovine parathyroid cells, yet both molecules carry a net positive charge of +4. The only difference in structure between these two polyamines is the number of methylenes separating the nitrogens: in spermine it is 3-4-3 whereas in triethylenetetramine it is 2-2-2. This seemingly minor change in the spacing between nitrogens has profound implications for potency and suggests that the conformational relationships of nitrogens within the molecule are important.

Studies with hexacyclen and pentaethylenhexamine further demonstrated the importance of the conformational relationship. The former molecule is simply the cyclic analog of the latter and contains the same number of methylenes between all nitrogens, yet the presence of the ring structure increases potency 25-fold. These results indicate that positive charge per se is not the critical factor determining the activity of an organic molecule on the calcium receptor.

Another series of experiments revealed the importance of aromatic groups in determining activity on the calcium receptor. The initial results were obtained using two arylalkyl polyamines isolated from the venom of the spider *Argiope lobata*. These molecules, argiotoxin 636 and argiotoxin 659, have identical polycationic portions linked to different aromatic groups (FIG. 1e). Argiotoxin 659 evoked transient increases in $[\text{Ca}^{2+}]_i$ in bovine parathyroid cells when tested at concentrations of 100 to 300 μM . In

34

contrast, argiotoxin 636 had no effect when tested at similar concentrations (FIG. 24). The only difference in structure between these two arylalkyl polyamines is in the aromatic portion of the molecules: argiotoxin 659 contains a 4-hydroxyindole moiety whereas argiotoxin 636 contains a 2,4-dihydroxyphenyl group. The net positive charge on these two arylalkyl polyamines is the same (+4), so their different potencies results from the different aromatic groups. This findings further demonstrates that net positive charge alone does not determine potency and that aromatic groups contribute significantly to the ability of molecules to activate the calcium receptor.

Substitutions on aromatic rings also effect calcium receptor-modulating activity. Agatoxin 489 (NPS 017) and Agatoxin 505 (NPS 015) both cause the mobilization of intracellular Ca^{2+} in parathyroid cells with EC_{50} 's of 6 and 22 μM , respectively. The only difference between the structures of these molecules is a hydroxyl group on the indole moiety (FIG. 1f).

Thus, the structural features to be varied systematically from lead molecules described herein include the following: (1) net positive charge; (2) number of methylenes separating nitrogens; (3) cyclic versions of molecules, for example polyamines with and without changes in methylene spacing and net positive charge; and (4) the structure and location of aromatic groups.

A variety of arylalkyl polyamines can be isolated from the venoms of wasps and spiders. Additionally, analogous synthetic molecules can be prepared by the coupling of commercially available aromatic moieties to the argiotoxin polyamine moiety. The argiotoxin polyamine moiety can be readily coupled to any aromatic moiety containing a carboxylic acid.

One of ordinary skill in the art can readily obtain and systematically screen the hydroxy and methoxy derivatives of phenylacetic acid and benzoic acid as well as the hydroxyindoleacetic acid series using the techniques described herein. Analogues containing heteroaromatic functionalities can also be prepared and assessed for activity. Comparisons of potency and efficacy among molecules having different functional groups will reveal the optimal structure and location of the aromatic group at a constant positive charge.

(b) Testing of Natural Products

Testing of natural products and product libraries can be carried out to identify functional groups and to test molecules having particular functional groups. Screening of natural products selected on the basis of the structural information can be readily performed using the structure-function relationships established by the testing of lead molecules. For example, molecules can be selected on the basis of well-established chemotaxonomic principles using appropriate data bases, such as Napralert, to obtain pools of molecules having desired functional groups. For example, macrocyclic polyamine alkaloids derived from papilionoid legumes related to *Albizia*, such as *Pithecolobium*, and other plant-derived molecules can be screened.

The results obtained with budmunchiamine A illustrate the predictive power of the structure-activity studies and the novel structural information to be gained by testing natural products. One of the structural variations on the polyamine motif that seems to increase potency is the presence of the cyclic version of the straight-chain parent molecule. Budmunchiamine A, isolated from the plant *Albizia amara*, is a cyclic derivative of spermine (FIG. 1a) The addition of budmunchiamine A to bovine parathyroid cells caused a rapid and transient increase in $[\text{Ca}^{2+}]_i$, that persisted in the

6,011,068

35

absence of extracellular Ca^{2+} and was blunted by pretreatment with PMA. It therefore causes the mobilization of intracellular Ca^{2+} in parathyroid cells, probably by acting on the calcium receptor. It is about equipotent with spermine (EC_{50} about 200 μM), yet carries one less positive charge (+3) than does spermine.

3. Polyamines

Preferred polyamines useful as calcimimetics in this invention may be either branched or cyclic. Branched or cyclic polyamines potentially have higher calcimimetic activity than their straight-chain analogues. That is, branched or cyclic polyamines tend to have a lower EC_{50} than their corresponding linear polyamines with the same effective charge at physiological pH (see Table 1).

TABLE 1

Molecule	Net (+) Charge	EC_{50} (μM)
Neomycin	+6	20 or 40
Hexacyclen	+6	20
NPS 382	+8	50
NPS 381	+10	100
NPS 383	+8	150
Gentamicin	+5	150
Spermine	+4	150
Bekanamycin	+5	200
Argitoxin-659	+4	300
Pentaethylenhexamine (PEHA)	+6	500
Streptomycin	+3	600
Spermidine	+3	2000
Tetraethylenepentamine (TEPA)	+5	2500
1,12-diaminododecane (DADD)	+2	3000
Triethylenetramine (TETA)	+4	8000

"Branched polyamines" as used herein refers to a chain molecule consisting of short alkyl bridges or alkyl groups joined together by amino linkages, and also containing points at which the chain branches. These "branch points" can be located at either a carbon atom or a nitrogen atom, preferably at a nitrogen atom. A nitrogen atom branch point is typically a tertiary amine, but it may also be quaternary. A branched polyamine may have 1 to 20 branch points, preferably 1 to 10 branch points.

Generally, the alkyl bridges and alkyl branches in a branched polyamine are from 1 to 50 carbon atoms in length, preferably 1-15, more preferably from 2 to 6 carbon atoms. The alkyl branches may also be interrupted by one or more heteroatoms (nitrogen, oxygen or sulfur) or substituted with functional groups such as: halo, including fluoro, chloro, bromo, or iodo; hydroxy; nitro; acyloxy ($\text{R}'\text{COO}-$), acylamido ($\text{R}'\text{CONH}-$), or alkoxy ($-OR'$), where R' may contain from 1 to 4 carbon atoms. The alkyl branches may also be substituted with groups that are positively charged at physiological pH, such as amino or guanidino. These functional substituents may add or change physical properties such as solubility to increase activity, delivery or bioavailability of the molecules.

The branched polyamines may have three or more chain and branch termination points. These termination points may be methyl groups or amino groups, preferably amino groups.

A preferred group of branched polyamines have the formula:



where k is an integer from 1 to 10;

36

each j is the same or different and is an integer from 2 to 20;

each R_i is the same or different and is selected from the group consisting of hydrogen and $-(\text{CH}_2)_l-\text{NH}_2$, where j is as defined above; and

at least one R_i is not hydrogen.

Particularly preferred branched polyamines of this invention are the molecules $\text{N}^1, \text{N}^1, \text{N}^5, \text{N}^{10}, \text{N}^{14}, \text{N}^{14}$ -hexakis-(3-aminopropyl) spermine and $\text{N}^1, \text{N}^1, \text{N}^5, \text{N}^{14}, \text{N}^{14}$ -tetrakis-(3-aminopropyl)spermine referred to as NPS 381 and NPS 382, respectively, in FIGS. 1a and 1f.

"Cyclic polyamines" refers to heterocycles containing two or more heteroatoms (nitrogen, oxygen or sulfur), at least two of which are nitrogen atoms. The heterocycles are generally from about 6 to about 20 atoms in circumference, preferably from about 10 to about 18 atoms in circumference. The nitrogen heteroatoms are separated by 2 to 10 carbon atoms. The heterocycles may also be substituted at the nitrogen sites with aminoalkyl or aminoaryl groups ($\text{NH}_2\text{R}-$), wherein R is aminoaryl or a lower alkyl of 2 to 6 carbon atoms. Particularly preferred cyclic polyamines of this invention are shown in FIGS. 1f and 1a as hexacyclen (1,4,7,10,13,16-hexaaza-cyclooctadecane) and NPS 383.

4. Polyamino Acids

"Polyamino acids" refers to polypeptides containing two or more amino acid residues which are positively charged at physiological pH. Positively charged amino acids include histidine, lysine and arginine. The polyamino acids can vary in length from 2 to 800 amino acids, more preferably from 20 to 300 amino acids and may consist of a single repeating amino acid residue or may have the variety of a naturally occurring protein or enzyme. Preferred polyamino acids are polyarginine, polylysine, and poly(argininyl-tyrosine), having 20-300 residues, and protamine or a protamine analog.

The amino acid residues present in the polyamino acids may be any of the twenty naturally occurring amino acids, or other alternative residues. Alternative residues include, for example, the ω -amino acids of the formula $\text{H}_2\text{N}(\text{CH}_2)_n\text{COOH}$, where n is from 2 to 6, and other nonpolar amino acids, such as sarcosine, *t*-butyl alanine, *t*-butyl glycine, *N*-methyl isoleucine, norleucine, phenyl glycine, citrulline, methionine sulfoxide, cyclohexyl alanine, and hydroxyproline. Ornithine is an example of an alternative positively charged amino acid residue. The polyamino acids of this invention may also be chemically derivatized by known methods.

5. Arylalkyl Polyamines

"Arylalkyl polyamines" refers to a class of positively charged natural products derived from arthropod venoms. Preferred arylalkyl polyamines are philanthotoxin-433, argitoxin-636, argitoxin-659, agatoxin 505, agatoxin 489 (FIG. 1), and analogous synthetic molecules modeled after these natural products.

6. Arylalkyl Amines

Preferred molecules of the present invention are arylalkyl amines having structure I; more preferably having structure III described supra, wherein R_2 is an aryl group, preferably a carbocyclic aryl group such as phenyl or a bicyclic carbocyclic aryl groups such as naphthyl, preferably 1-naphthyl. Especially preferred are *R*-isomers.


Two examples of arylalkyl amines are NPS 467 and NPS 568. NPS 467 and NPS 568 are analogues. NPS 568 is more

6,011,068

39

40

-continued



More Preferably R = C₁-C₃,
Most Preferably R = Me

X=nothing; for example when C (Carbon, see Z=) are sp² or sp³, or for example when Y=O(Oxygen). Possible combinations are not limited to these examples. 30

m=1 through 7 inclusive (independent).

Z and N together form a piperidiny, piperaziny or pyrroliny ring

X=—H

X=—F, —(Cl, —Br, or —I)

X=—OR

X=—NR₂ (R's selected independently)

X=—SR, S(O)R, S(O)₂R,

X=—CN

X=—NO₂

X=—C(O)R—OC(O)R, —C(O)OR—NRC(O)R, C(O)NR₂, (R's selected independently) 40

R=—H, —CF₃, —CF₂H, —CFH₂, —CH₂CF₃, —C₁-C₁₀ (sp, sp², or sp³ carbons, selected independently) alkyl (linear, branched, cyclic system, fused cyclic or bicyclic systems, selected independently) or phenyl. 45

Ar=any aromatic, heteroaromatic, or heterocyclic system, preferably phenyl, 1-naphthyl, 2-naphthyl, biphenyl, tetrahydronaphthyl, indanyl, indenyl, fluorenyl, 9,10-dihydranthracenyl, 9,10-dihydrophenanthrenyl, pyrrolyl, furanyl, 1,2,3-triazolyl, 1,2,4-diazolyl, tetrazolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, thiofuranyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,4-triazinyl, 1,3,5-tiazinyl, tetrahydrofuranyl, pyrrolidinyl, imidazoliny, thiazolidinyl, decahydroquinolinyl, decahydroisoquinolinyl, piperidinyl, piperziny, morpholinyl, thiomorpholinyl, benzofuranyl, dihydrobenzofuranyl, dihydrobenzopyranyl, benzimidazolyl, indazoly, tetrahydroquinolinyl, tetrahydroisoquinoline, quinollinyl, isoquinolinyl, benzotriazolyl, carbazolyl, indoly, indolinyl, phenoxazinyl, phenothiazinyl, a-carbolinyl, -carbolinyl, acenaphthenyl, or acenaphthylenyl. 50

Y=—NR, —O, —S, —S(O), —S(O)₂, —C*R, —C*(O), —OC*(O), —C*(O)O, —NRC*(O), C*(O)NR, (*sp² carbon), —CR₂, —CRX, or —CX₂. 55

7. Additional Components

Calcium receptor-modulating agents may be substituted with additional components. The additional components are used to provide additional functionality to the molecules, apart from the molecules ability to act as a calcimimetic or calcilytic. These additional components include targeting components and functionalities such as labels which enhance a molecule's ability to be used in the different applications, such as for screening for agonists or antagonists of extracellular Ca²⁺ in a competitive or non-competitive assay format. 35

For example, an immunoglobulin or a ligand specific for parathyroid cells or a calcium receptor can be used as a target-specific component. The immunoglobulin can be a polyclonal or monoclonal antibody and may comprise whole antibodies or immunologically reactive fragments of these antibodies such as F_(ab), F_(ab), or (F_{ab})₂. 40

A wide variety of labeling moieties can be used, including radioisotopes, chromophores, and fluorescent labels. Radioisotope labeling in particular can be readily detected in vivo. Radioisotopes may be coupled by coordination as cations in the porphyrin system. Useful cations include technetium, gallium, and indium. In the compositions, the positively charged molecule can be linked to or associated with a label. 45

II. SYNTHESIS OF CALCIUM RECEPTOR-MODULATING AGENTS

Different ionomimetics and ionolytics can be synthesized by using procedures known in the art and described herein. Ionomimetics and ionolytics can also be synthesized as described by Bradford C VanWagenen, Steven R Duff, William A. Nelson and Thomas E. D'Ambra in U.S. patent application Ser. No. 276,214 issued as U.S. Pat. No. 5,504, 253 entitled "Amine Preparation" hereby incorporated by reference herein. 50

6,011,068

41

A. Synthesis of Polyamines

The synthetic methods used to produce polyamines described in this section are modelled after methods used to construct argiopines 636 and 659 and other arylalkyl polyamines derived from spider venoms. Polyamines can be synthesized starting with, for example, diaminoalkanes and simple polyamines such as spermidine or spermine. Strategies for the synthesis and the modification of polyamines involve using a variety of amine-protecting groups (e.g., phthalimido, BOC, CBZ, benzyl, and nitrile) which can be selectively removed to construct functionalized molecules.

Chain extensions, of the starting material, by 2-4 methylenes were typically accomplished by alkylation with the corresponding N-(bromoalkyl)phthalimide. A 1:1.2 mixture of amine to the bromoalkylphthalimide was refluxed in acetonitrile in the presence of 50% KF on Celite. Chain extensions were also accomplished by alkylation of a given amine with acrylonitrile or ethylacrylate. Reaction progress was monitored by thin-layer chromatography (TLC) and intermediates purified on silica gel using combinations of dichloromethane, methanol, and isopropylamine. Final products were purified by cation exchange (HEMA-SB) and RP-HPLC (Vydac C-18). Purity and structure verification were accomplished by ¹H- and ¹³C-NMR spectroscopy and high-resolution mass spectrometry (EI, CI and/or FAB).


Amine-protecting groups, phthalimido, BOC, CBZ, benzyl, and nitrile, were added and later selectively removed to construct functionalized molecules. BOC protecting groups were added by treating a primary or secondary amine (1° or 2°) with di-tert-butyl dicarbonate in dichloromethane. Benzyl protecting groups were applied in one of two ways: (1) condensation of a 1° amine with benzaldehyde followed by sodium borohydride reduction or (2) alkylation of a 2° amine with benzylbromide in the presence of KF.

Deprotection of the different groups was carried out using different procedures. Deprotection of the phthalimido functionality was accomplished by reduction with hydrazine in refluxing methanol. Deprotection of the BOC functionality was accomplished in anhydrous TFA or concentrated HCl in acetonitrile. Deprotection of benzyl, nitrile, and CBZ protecting functionalities was accomplished by reduction in glacial acetic acid under 55 psi hydrogen in the presence of a catalytic amount of palladium hydroxide on carbon. Nitrile functionalities in the presence of benzyl and CBZ groups were selectively reduced under hydrogen in the presence of sponge Raney nickel.

Amide linkages were typically prepared by reacting an amine (1° or 2°) with an N-hydroxysuccinimide or p-nitrophenylester of a given acid. This was accomplished directly, in the case of adding cyclic groups, by treating the amine with dicyclohexylcarbodiimide under dilute conditions.


Specifically, branched polyamines are typically prepared from simple diaminoalkanes of the formula NH₂-(CH₂)_n-NH₂, or simple polyamines such as spermidine or spermine. One of the two primary (terminal) amines is protected or "masked" with a protecting group such as BOC (t-butyloxycarbonyl), phthalimido, benzyl, 2-ethylnitrile (the Michael condensation production product of an amine and acrylonitrile), or amide. A typical reaction is the addition of a DOC protecting group by treatment with di-t-butyl-dicarbonate (BOC anhydride):

42




The monoprotected product is separated from the unprotected and diprotected products by simple chromatographic or distillation techniques.

The remaining free amine in the monoprotected product is then selectively alkylated (or acylated) with an alkylating (or acylating) agent. To ensure mono-alkylation, the free amine is partially protected by condensation with benzaldehyde followed by sodium borohydride reduction to form the N-benzyl derivative:



The N-benzyl derivative is then reacted with the alkylating agent. A typical alkylating agent is in an N-(bromoalkyl) phthalimide, which reacts as follows:




For example, N-(bromobutyl)phthalimide is used to extend or branch the chain with four methylene units. Alternatively, reaction with acrylonitrile followed by reduction of the cyano group will extend the chain by three methylenes and an amino group.

The protecting groups of the resulting chain-extended molecule can then be selectively cleaved to yield a new free amine. For example, trifluoroacetic acid is used to remove a BOC group; catalytic hydrogenation is used to reduce a nitrile functionality and remove a benzyl group; and hydrazine is used to remove phthalimido groups as follows:


6,011,068

43




44
This ultimately yields an arylalkyl polyamine. The BOC group can then be selectively removed with trifluoroacetic acid to expose the other amino terminus which can be extended as above.

Certain branched polyamines may be formed by simultaneously alkylating or acylating the free primary and secondary amines in a polyamine formed as above. For example, treatment of spermine with excess acrylonitrile followed by catalytic reduction yields the following:



The new free amine may be alkylated (or acylated) further as above to increase the length of the polyamine. This process is repeated until the desired chain length and number of branches is obtained. In the final step, deprotection of the product results in the desired polyamine. However, further modifications may be effected at the protected end prior to deprotection. For example, prior to BOC-deprotection, the polyamine is acylated with the N-hydroxysuccinimide ester of 3,4-dimethoxyphenylacetic acid to yield a diprotected polyamine:



Cyclic polyamines may be prepared as above with starting materials such as hexacylen (Aldrich Chem.).

B. Polyamino Acid Synthesis

Polyamino acids can be made using standard techniques such as being translated using recombinant nucleic acid techniques or being synthesized using standard solid-phase techniques. Solid-phase synthesis is commenced from the carboxy-terminal end of the peptide using an α -amino protected amino acid. BOC protective groups can be used for all amino groups even through other protective groups are suitable. For example, BOC-lys-OH can be esterified to chloromethylated polystyrene resin supports. The polystyrene resin support is preferably a copolymer of styrene with about 0.5 to 2% divinylbenzene as a cross-linking agent which causes the polystyrene polymer to be completely insoluble in certain organic solvents. See Stewart et al., *Solid-Phase Peptide Synthesis* (1969), W. H. Freeman Co., San Francisco; and Merrifield, *J. Am. Chem. Soc.* (1963) 85:2149-2154. These and other methods of peptide synthesis are also exemplified by U.S. Pat. Nos. 3,862,925; 3,842,067; 3,972,859; and 4,105,602.

The polypeptide synthesis may use manual techniques or be automated. For example, synthesis can be carried out

6,011,068

45

using an Applied Biosystems 403A Peptide Synthesizer (Foster City, California) or a Biosearch SAM II automatic peptide synthesizer (Biosearch, Inc., San Rafael, Calif.), following the instructions provided in the instruction manual supplied by the manufacturer.

C. Arylalkyl Polyamines

Arylalkyl polyamines such as those shown in FIG. 1 can be obtained from natural sources isolated by known techniques, or synthesized as described in Jasys et al., *Tetrahedron Lett.* 29:6223-6226, (1988); Nason et al., *Tetrahedron Lett.* 30:2337-2340, (1989); and Schafer et al., "Polyamine Toxins from Spiders and Wasps," *The Alkaloids*, vol. 45, p. 1-125, 1994.

D. Arylalkylamines

This section describes general protocol to prepare arylalkylamines such as fendiline or fendiline analogues as shown in FIG. 36. In a 10-ml round-bottom flask equipped with a magnetic stir bar and rubber septum, 1.0 mmole 3,3'-diphenylpropylamine (or primary alkylamine such as substituted or unsubstituted phenylpropylamine) in 2 ml ethanol was treated with 1.0 mmole acetophenone (or substituted acetophenone). Two millimoles $MgSO_4$ and 1.0 mmole $NaCNBH_3$ were then added and the solution was stirred under a nitrogen atmosphere at room temperature (about 20° C.) for 24 hours. The reaction was poured into 50 ml ether and washed 3 times with 1 N NaOH and once with brine. The ether layer was dried with anhydrous K_2CO_3 and reduced in vacuo. The product was then purified by column chromatography or HPLC incorporating a silica stationary phase with combinations of CH_2Cl_2 -methanol-isopropylamine (typically 3% methanol and 0.1% isopropylamine in methylene chloride).

A preferred procedure for preparing fendiline or fendiline analogues (such as those depicted in FIG. 36) uses titanium (IV) isopropoxide and was modified from methods described in *J. Org. Chem.* 55:2552 (1990). For the synthesis of Compound 2M, titanium tetrachloride (method described in *Tetrahedron Lett.* 31:5547 (1990)) was used in place of titanium (IV) isopropoxide.

A reaction scheme is depicted in FIG. 43a. In FIG. 43a, R, R' and R'' depict appropriately substituted hydrocarbon and aromatic moieties groups. Referring to FIG. 43a in a 4-ml vial, 1 mmole of amine (1) (typically a primary amine) and 1 mmole ketone or aldehyde (2) (generally an appropriately substituted acetophenone) are mixed, then treated with 1.25 mmoles titanium(IV) isopropoxide (3) and allowed to stand with occasional stirring at room temperature for about 30 minutes. Alternatively, a secondary amine may be used in place of (1). Reactions giving heavy precipitates or solids can be heated to their melting point to allow for mixing during the course of the reaction.

The reaction mixture is then treated with 1 ml ethanol containing 1 mmole sodium cyanoborohydride (4) and the resulting mixture is allowed to stand at room temperature with occasional stirring for about 16 hours. After this time the reaction is quenched by the addition of about 500 μ l water. The reaction mixture is then diluted to about 4 ml total volume with ethyl ether and then centrifuged. The upper organic phase is removed and reduced on a rotavapor. The resulting product (6) is partially purified by chromatography through a short silica column (or alternatively by using preparative TLC on silica) using a combination of dichloromethane-methanol-isopropylamine (typically 95:5 0.1), and then purified by HPLC (normal-phase using

46

silica with dichloromethane-methanol-isopropylamine or reversed phase, C-18 with 0.1% TFA with acetonitrile or methanol).

Chiral resolution may be accomplished using methods such as those described in Example 22, *infra*.

III. INORGANIC ION RECEPTORS, DERIVATIVES, AND FRAGMENTS

The invention also relates to a superfamily of inorganic ion receptor proteins including derivatives thereof, and inorganic ion receptor fragments. Members of the superfamily are related to each other by similarity of amino acid sequence and structure. Receptor proteins, such as the calcium receptor, have intracellular domains, extracellular domains, transmembrane domains, and multiple-transmembrane domains. Preferably, the novel superfamily of inorganic ion receptors have an amino acid sequence similarity of at least 15% to the human calcium receptor (SEQ. ID. NOs. 6 and 7) and respond to inorganic ions.

Calcium receptors appear to be functionally related to a class of receptors which utilize so-called "G" proteins to couple ligand binding to intracellular signals. Such "G-coupled" receptors may elicit increases in intracellular cyclic AMP due to the stimulation of adenylyl cyclase by a receptor activated "G_s" protein, or else may elicit a decrease in cyclic AMP due to inhibition of adenylyl cyclase by a receptor activated "G_i" protein. Other receptor activated G proteins elicit changes in inositol triphosphate levels resulting in release of Ca^{2+} from intracellular stores. This latter mechanism is particularly pertinent to calcium receptors.

A. Inorganic Ion Receptors

Inorganic ion receptors have an amino acid sequence encoding a functioning inorganic ion receptor. Inorganic ion receptors include proteins having the amino acid sequence of the receptor protein normally found in a cell and derivatives thereof. Inorganic ion receptors are distinguished by their ability to detect and respond to changes in the levels of inorganic ions by evoking a change in cellular function. Changes in cellular function may involve changes in secondary messenger levels such those mediated by G protein coupled to the receptor or changes in ionic transmembrane ion flux. Inorganic ions include cations such as calcium, magnesium, potassium, sodium, or hydrogen ions and anions such as phosphate or chloride ions. Cd^{2+} -sensing receptors are described by Herbert in U.S. application entitled "Cloned Human Cadmium(II)-Sensing Receptor and Uses thereof," hereby incorporated by reference herein.

Regardless of the nature of the physiological ligand or activator of an inorganic ion receptor, inorganic ion receptors can be "promiscuous" in that they can be activated by non-physiological stimuli. These non-physiological stimuli may be useful, for example, to identify another inorganic ion receptor or to facilitate the isolation of the gene encoding it. An example of an inorganic ion receptor responding to a non-physiological stimuli is the ability of osteoclast calcium receptor to respond not only to Ca^{2+} , but also to Mn^{2+} , Co^{2+} and Ni^{2+} . The cations Mn^{2+} and Co^{2+} also serve to distinguish the osteoclast calcium receptor from the parathyroid calcium receptor.

Another example of an inorganic ion receptor responding to a non-physiological stimuli is the ability of the parathyroid calcium receptor to respond to low concentrations of La^{3+} and Gd^{3+} which are highly unlikely to be encountered under normal circumstances. Nevertheless, Gd^{3+} has been used successfully as an activator for the calcium receptor

6,011,068

47

and facilitated the cloning of this receptor by expression in *Xenopus* oocytes (see Example 25).

Additionally, receptors belonging to the superfamily of inorganic ion receptors may also be activated by stimuli other than ligand binding. For example, some members are activated by physical forces such as stretch forces acting on membranes of cells expressing inorganic ion receptors.

B. Inorganic Ion Receptor Derivatives

Derivatives of a particular receptor have similar amino acid sequences and retain, to some extent, one or more activities of the related receptor. Derivatives have at least 15% sequence similarity, preferably 70%, more preferably 90%, even more preferably 95% sequence similarity to the related receptor. "Sequence similarity" refers to "homology" observed between amino acid sequences in two different polypeptides, irrespective of polypeptide origin.

The ability of the derivative to retain some activity can be measured using techniques described herein, for example, those described in Section I supra. Derivatives include modifications occurring during or after translation, for example, by phosphorylation, glycosylation, crosslinking, acylation, proteolytic cleavage, linkage to an antibody molecule, membrane molecule or other ligand (see Ferguson et al., 1988, *Annu. Rev. Biochem.* 57:285-320).

Specific types of derivatives also include amino acid alterations such as deletions, substitutions, additions, and amino acid modifications. A "deletion" refers to the absence of one or more amino acid residue(s) in the related polypeptide. An "addition" refers to the presence of one or more amino acid residue(s) in the related polypeptide. Additions and deletions to a polypeptide may be at the amino terminus, the carboxy terminus, and/or internal. Amino acid "modification" refers to the alteration of a naturally occurring amino acid to produce a non-naturally occurring amino acid. A "substitution" refers to the replacement of one or more amino acid residue(s) by another amino acid residue(s) in the polypeptide. Derivatives can contain different combinations of alterations including more than one alteration and different types of alterations.

While the effect of an amino acid change varies depending upon factors such as phosphorylation, glycosylation, intra-chain linkages, tertiary structure, and the role of the amino acid in the active site or a possible allosteric site, it is generally preferred that the substituted amino acid is from the same group as the amino acid being replaced. To some extent the following groups contain amino acids which are interchangeable: the basic amino acids lysine, arginine, and histidine; the acidic amino acids aspartic and glutamic acids; the neutral polar amino acids serine, threonine, cysteine, glutamine, asparagine and, to a lesser extent, methionine; the nonpolar aliphatic amino acids glycine, alanine, valine, isoleucine, and leucine (however, because of size, glycine and alanine are more closely related and valine, isoleucine and leucine are more closely related); and the aromatic amino acids phenylalanine, tryptophan, and tyrosine. In addition, although classified in different categories, alanine, glycine, and serine seem to be interchangeable to some extent, and cysteine additionally fits into this group, or may be classified with the polar neutral amino acids.

While proline is a nonpolar neutral amino acid, its replacement represents difficulties because of its effects on conformation. Thus, substitutions by or for proline are not preferred, except when the same or similar conformational results can be obtained. The conformation conferring properties of proline residues may be obtained if one or more of these is substituted by hydroxyproline (Hyp).

48

Examples of modified amino acids include the following: altered neutral nonpolar amino acids such as ω -amino acids of the formula $H_2N(CH_2)_nCOOH$ where n is 2-6, sarcosine (Sar), t-butylalanine (t-BuAla), t-butylglycine (t-BuGly), N-methyl isoleucine (N-Melle), and norleucine (Nleu); altered neutral aromatic amino acids such as phenylglycine; altered polar, but neutral amino acids such as citrulline (Cit) and methionine sulfoxide (MSO); altered neutral and non-polar amino acids such as cyclohexyl alanine (Cha); altered acidic amino acids such as cysteic acid (Cya); and altered basic amino acids such as ornithine (orn).

Preferred derivatives have one or more amino acid alteration(s) which do not significantly affect the receptor activity of the related receptor protein. In regions of the calcium receptor protein not necessary for receptor activity amino acids may be deleted, added or substituted with less risk of affecting activity. In regions required for receptor activity, amino acid alterations are less preferred as there is a greater risk of affecting receptor activity. Such alterations should be conservative alterations. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent.

Conserved regions tend to be more important for protein activity than non-conserved regions. Standard procedures can be used to determine the conserved and non-conserved regions important of receptor activity using in vitro mutagenesis techniques or deletion analyses and measuring receptor activity as described by the present disclosure.

Derivatives can be produced using standard chemical techniques and recombinant nucleic acid techniques. Modifications to a specific polypeptide may be deliberate, as through site-directed mutagenesis and amino acid substitution during solid-phase synthesis, or may be accidental such as through mutations in hosts which produce the polypeptide. Polypeptides including derivatives can be obtained using standard techniques such as those described herein, and by Sambrook et al., *Molecular Cloning*, Cold Spring Harbor Laboratory Press (1989). For example, Chapter 15 of Sambrook describes procedures for site-directed mutagenesis of cloned DNA.

C. Receptor Fragments

Receptor fragments are portions of inorganic ion receptors. Receptor fragments preferably bind to one or more binding agents which bind to a full-length receptor. Binding agents include ionomimetics, ionolytics, and antibodies which bind to the receptor. Fragments have different uses such as to select other molecules able to bind to a receptor.

Fragments can be generated using standard techniques such as expression of cloned partial sequences of receptor DNA and proteolytic cleavage of a receptor protein. Proteins are specifically cleaved by proteolytic enzymes, such as trypsin, chymotrypsin or pepsin. Each of these enzymes is specific for the type of peptide bond it attacks. Trypsin catalyzes the hydrolysis of peptide bonds whose carbonyl group is from a basic amino acid, usually arginine or lysine. Pepsin and chymotrypsin catalyze the hydrolysis of peptide bonds from aromatic amino acids, particularly tryptophan, tyrosine and phenylalanine.

Alternate sets of cleaved protein fragments are generated by preventing cleavage at a site which is susceptible to a proteolytic enzyme. For example, reaction of the ϵ -amino group of lysine with ethyltrifluoroacetate in mildly basic solution yields a blocked amino acid residue whose adjacent peptide bond is no longer susceptible to hydrolysis by

6,011,068

49

trypsin. Goldberger et al., *Biochemistry* 1:401 (1962). Treatment of such a polypeptide with trypsin thus cleaves only at the arginyl residues.

Polypeptides also can be modified to create peptide linkages that are susceptible to proteolytic enzyme-catalyzed hydrolysis. For example, alkylation of cysteine residues with β -haloethylamines yields peptide linkages that are hydrolyzed by trypsin. Lindley, *Nature*, 178: 647 (1956).

In addition, chemical reagents that cleave polypeptide chains at specific residues can be used. Witkop, *Adv. Protein Chem.* 16: 221 (1961). For example, cyanogen bromide cleaves polypeptides at methionine residues. Gross & Witkip, *J. Am. Chem. Soc.* 83: 1510 (1961).

Thus, by treating an inorganic ion receptor, such as, for example, a human calcium receptor or fragments thereof, with various combinations of modifiers, proteolytic enzymes and/or chemical reagents, numerous discrete overlapping peptides of varying sizes are generated. These peptide fragments can be isolated and purified from such digests by chromatographic methods. Alternatively, fragments can be synthesized using an appropriate solid-state synthetic procedure.

Fragments may be selected to have desirable biological activities. For example, a fragment may include just a ligand binding site. Such fragments are readily identified by those of ordinary skill in the art using routine methods to detect specific binding to the fragment. For example, in the case of a calcium receptor, nucleic acid encoding a receptor fragment can be expressed to produce the polypeptide fragment which is then contacted with a receptor ligand under appropriate association conditions to determine whether the ligand binds to the fragment. Such fragments are useful in screening assays for agonists and antagonists of calcium, and for therapeutic effects where it is useful to remove calcium from serum, or other bodily tissues.

Other useful fragments include those having only the external portion, membrane-spanning portion, or intracellular portion of the receptor. These portions are readily identified by comparison of the amino acid sequence of the receptor with those of known receptors, or by other standard methodology. These fragments are useful for forming chimeric receptors with fragments of other receptors to create a receptor with an intracellular portion which performs a desired function within that cell, and an extracellular portion which causes that cell to respond to the presence of ions, or those agonists or antagonists described herein. Chimeric receptor genes when appropriately formulated are useful in genetic therapies for a variety of diseases involving dysfunction of receptors or where modulation of receptor function provides a desirable effect in the patient.

Additionally, chimeric receptors can be constructed such that the intracellular domain is coupled to a desired enzymatic process which can be readily detected by calorimetric, radiometric, luminometric, spectrophotometric or fluorimetric assays and is activated by interaction of the extracellular portion with its native ligand (e.g., calcium) or agonist and/or antagonists of the invention. Cells expressing such chimeric receptors can be used to facilitate screening of inorganic ion receptor agonists and antagonists.

IV. NUCLEIC ACIDS ENCODING ION-RECEPTORS

The invention also features nucleotide sequences encoding inorganic ion receptors and receptor fragments. Nucleotide sequences encoding inorganic ion receptors may be obtained from organisms through a variety of procedures,

50

such as through the use of hybridization probes, antibodies binding a receptor, gene walking, and/or expression assays.

A nucleic acid encoding a particular receptor provides for additional tools to obtain more receptors, for example by providing for hybridization assay probes and antibodies. Furthermore, sequence information from two or more receptors can be analyzed to determine localized sequence conservation which is useful for obtaining still additional clones encoding other members of the superfamily. Conserved sequences also may be derived from an analysis of the overall structure of BoPCaR 1, as it conventionally includes an extracellular domain, transmembrane domain and intracellular domain.

"Conserved nucleic acid regions" refers to two or more nucleic acids encoding an inorganic ion receptor, preferably a calcium receptor, to which a particular nucleic acid sequence can hybridize to under lower stringency conditions. Examples of lower stringency conditions suitable for screening for nucleic acid encoding inorganic ion receptors are provided in the examples below and in Abe et al. *J. Biol. Chem.*, 19:13361 (1992) (hereby incorporated by reference herein). Preferably, conserved regions differ by no more than 7 out of 20 nucleotides.

In preferred embodiments the purified nucleic acid encodes an extracellular domain, but is substantially free of transmembrane and intracellular domains; the purified nucleic acid encodes an intracellular domain, but is substantially free of transmembrane and extracellular domains; the purified nucleic acid encodes a transmembrane domain, but is substantially free of an extracellular or intracellular domain; the purified nucleic acid encodes a multiple-transmembrane domain (e.g., a seven-transmembrane domain), but is substantially free of C-terminal intracellular and N-terminal extracellular regions; the purified nucleic acid encodes an extracellular domain which is transcriptionally coupled to nucleic acid encoding a transmembrane, multiple-transmembrane, and/or intracellular domain of a non-inorganic ion receptor or a different inorganic ion receptor and results in a fusion protein; the purified nucleic acid encodes an extracellular domain of a non-inorganic ion receptor or a different inorganic ion receptor which is transcriptionally coupled to nucleic acid encoding a transmembrane, multiple-transmembrane, and/or intracellular domain of an inorganic ion receptor and results in a fusion protein.

In addition, isolated nucleic acid sequences of the invention may be engineered so as to modify processing or expression of receptor sequences. For example, the coding sequence may be combined with an exogenous promoter sequence and/or a ribosome binding site. Another example, is that codons may be modified such that while they encode an identical amino acid, that codon may be a preferred codon in the chosen expression system.

Additionally, a given coding sequence can be mutated in vitro or in vivo, to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification. Standard recombinant techniques for mutagenesis such as in vitro site-directed mutagenesis (Hutchinson et al., *J. Biol. Chem.* 253:6551, (1978), Sambrook et al., chapter 15, supra), use of TAB® linkers (Pharmacia), and PCR-directed mutagenesis can be used to create such mutations.

Cloning the calcium receptor from different cells will allow the presence of homologous proteins in other cells to be directly assessed. A family of structurally homologous calcium receptor proteins can thus be obtained. Such recep-

6,011,068

51

tors will allow understanding of how these cells detect extracellular Ca^{2+} and enable evaluation of the mechanism (s) as a site of action for the therapeutics described herein effective in the treatment of for example, HPT, osteoporosis, and hypertension, and novel therapies for other bone and mineral-related diseases.

A. Assays To Detect Receptors

Various assays can be used to detect the presence of an inorganic ion receptor such as calcium receptor and fragments thereof. Such assays include detecting the presence of receptor protein, or receptor activity, expressed by nucleic acid encoding the receptor. Examples of assays for measuring calcium receptor activity are described below. Equivalent assays for other inorganic ion receptors such as Na^+ , K^+ , and phosphate are known in the art.

1. Measurement of Receptor Activity

The ability of nucleic acid to encode a functioning calcium receptor can be conveniently measured using a *Xenopus* expression assay to detect increases in intracellular Ca^{2+} due to receptor activation. Increases in intracellular Ca^{2+} can be measured by different techniques such as by measuring current through the endogenous Ca^{2+} -activated Cl^- channel; loading oocytes with $^{45}\text{Ca}^{2+}$ and measuring mobilization of $^{45}\text{Ca}^{2+}$ from intracellular stores; and using fluorescent Ca^{2+} indicators. Expression assays can also be used to measure the calcimimetic and calcilytic activity of agents using *Xenopus* egg containing nucleic acid expressing a functioning calcium receptor.

Receptors are activated by using receptor ligands, such as neomycin, Gd^{3+} , Ca^{2+} , Mg^{2+} or other calcimimetic compound. The ability of receptors to be activated by calcimimetics can be measured in a *Xenopus* expression assay. For example, molecules can be tested for their ability to elicit increases in intracellular Ca^{2+} in *Xenopus* oocytes containing nucleic acid expressing a functioning calcium receptor indirectly by measuring current through the endogenous Ca^{2+} -activated Cl^- channel. The amplification of the response afforded by this signal transduction pathway enables the detection of receptor proteins encoded by mRNA at very low levels. This allows the detection of receptor-specific cDNA clones without the need for high-affinity ligands, specific antisera, or protein or nucleic acid sequence information.

For example, for each mRNA fraction, 10–20 oocytes are injected with 50 ng of RNA at a concentration of 1 ng/nl in water. Injected oocytes are maintained at 18° C. for 48–72 hours, after which they are assessed for expression of the calcium receptor using measurements of Cl^- current. For each group of injected oocytes, the number positive for expression of the receptor, as well as the magnitude of the Ca^{2+} -dependent Cl^- current measured, is determined. As negative controls, oocytes are injected with rat liver poly (A)⁺-enriched mRNA, yeast RNA, or water.

2. Measuring the Presence of a Receptor

The presence of a receptor protein or polypeptide fragment can be carried out using agents which bind to the receptor. The binding agent should have a group which readily indicates its presence, such as a radiolabel, or group which can be easily detected, such as an antibody.

Antibodies can be used to screen expression libraries, such as cDNA libraries in λ gt11 to determine the presence of clones expressing antigenically reactive protein. Screening

52

can be carried out using standard techniques. Sambrook et al., *Molecular Cloning*, chapter 18, Cold Spring Harbor Laboratory Press (1989). Clones testing positive can be purified and then sequenced to determine whether they encode a calcium receptor.

Similarly phage display libraries can be used to clone and analyze calcium receptors in place of monoclonal antibodies. In these libraries, antibody-variable regions or random peptides are shotgun cloned into phage expression vectors such that the antibody regions or peptides are displayed on the surface of the phage particle. Phage(s) which display antibody regions or peptides capable of high specific binding to calcium receptors will bind to cells which display these receptors (e.g., parathyroid cells, C-cells, osteoclasts, etc.). Hundreds of millions of such phage can be panned against these cell types preferentially selecting those phage which can bind to these cells (which includes those phage binding to calcium receptors). In this manner, the complexity of the library can be vastly reduced. Iterative repetition of this process results in a pool of phage which bind to the cell type used. Subsequently, screens for monoclonal antibodies can be used to isolate phage displaying a calcium receptor-binding antibody or peptide regions, and these phage can be used to isolate the calcium receptor for purposes of structural identification and cloning. Kits to prepare such phage-display libraries are commercially available (e.g., Stratacyte, or Cambridge Antibody Technology Limited).

Recombinant phage endowed with such calcium receptor-binding properties can also be used in lieu of monoclonal antibodies in the various analyses of calcium receptors. Such phage can also be used in high-throughput binding-competition screens to identify organic compounds capable of functional binding to calcium receptors which can serve as structural leads for the development of human therapeutics acting at the calcium receptor.

In another alternative, affinity cross-linking of radioligands to their receptors can be used to isolate the receptor protein as described by Pilch & Czech, *1 Receptor Biochem. Methodol.* 161, 1984. Covalent attachment of a radioligand allows extensive washing to remove non-specific binding. For example, a high-affinity molecule, e.g., a random copolymer of arginine and tyrosine (MW=22K; arg:tyr ratio=4:1) which mobilizes intracellular Ca^{2+} with an EC_{50} of about 100 nM or less, is iodinated with ^{125}I , and cross-linked. Protamines, because of their much smaller size, may be preferable in cross-linking studies and can be reductively, alkylated as described by Dottavio-Martin & Ravel, *87 Analyt. Biochem.* 562, 1978.

Nonspecific labelling is kept to a minimum by cross-linking in the presence of unlabeled polycations and di- and trivalent cations. At high concentrations of these molecules, nonspecific interactions of the label with the cell surface might be reduced.

B. Expression Assay

This section describes techniques to clone bovine and human parathyroid cell calcium receptor cDNAs by functional expression in *Xenopus* oocytes. Adult female *Xenopus laevis* were obtained from *Xenopus* I (Ann Arbor, MI) and maintained according to standard procedures. Lobes of ovary were excised from hypothermically anesthetized toads. Clusters of oocytes were transferred into modified Barth's saline (MBS). Individual oocytes were obtained by incubation in MBS containing 2 mg/ml collagenase (Sigma, Type 1A) for 2 hours at 21° C. and stage V–VI oocytes were selected for injection.

6,011,068

53

Glass capillary tubes (1 mm diameter) were pulled to a fine tip and manually broken to achieve a tip diameter of about 15 μ meters. A droplet of mRNA (1 ng/ml in diethylpyrocyanate (DEPC)-treated water) was placed onto PARAFILM™ and drawn into the capillary tube by suction. The capillary tube was then connected to a picospritzer (WPI Instruments) and the volume of the air-pulsed droplets adjusted to deliver 50 ng of mRNA (typically 50 nl) A 35-mm culture dish with a patch of nylon stocking fixed to the bottom was used to secure the oocytes during injection of mRNA into the vegetal pole. The injected oocytes were placed into a 35-mm culture dish containing MBS, 100 μ g/ml penicillin and 100 μ g/ml streptomycin and incubated at 18° C. for 3 days.

Following incubation, an oocyte was placed into a 100- μ l plastic chamber and superfused with MBS at a flow rate of 0.5 ml/min using a peristaltic pump. Test molecules or inorganic polycations were added by rapidly moving the tubing into different buffers. Recording and current-passing electrodes were constructed from thin-wall capillary tubing pulled to a resistance of 1–3 Mohms and filled with 3M KCl. Oocytes were impaled (in the animal pole) with both electrodes under microscopic observation and connected to an Axon Instruments Axoclamp 2A voltage-clamp amplifier which was used to set the holding potential (–70 to –80 mV) and to measure the currents that were passed to maintain the holding potential. Currents were recorded directly onto a strip chart recorder.

For mRNA preparation, tissue was obtained from calves or patients with secondary HPT undergoing surgical removal of the parathyroid glands. Whole pieces of gland were used to prepare mRNA that directs the expression of the calcium receptor in *Xenopus* oocytes. Total cellular RNA was obtained by acid guanidinium thiocyanate/phenol extraction of homogenized glands. Oligo-dT cellulose chromatography was used to select poly(A)⁺-mRNA by standard procedures.

Size fractionation of mRNA was carried out by centrifugation through glycerol gradients. The mRNA was denatured with 20 mM methylmercuric hydroxide and loaded (50–100 μ g at a concentration of 1 mg/ml) onto a linear 15–30% glycerol gradient prepared in Beckman TLSSS tubes. Following centrifugation at 34,000 rpm for 16 hours, 0.3 ml gradient fractions were collected and diluted in an equal volume of water containing 5 mM beta-mercaptoethanol. The mRNA was then recovered by two cycles of ethanol precipitation.

The mRNA (50–100 μ g of poly(A)⁺) can also be separated on a 1.2% agarose/6.0M urea preparative gel, along with a range of RNA size markers. Following visualization of the mRNA by ethidium bromide staining, gel slices containing RNA approximately 1 kb to 2 kb in size are excised. The mRNA is recovered from the agarose gel slices using RNAid binding matrix (according to the supplier's standard protocol; Stratagene, Inc.) and recovered mRNA fractions eluted into DEPC-treated water.

Amounts of recovered mRNA were quantified by UV absorbance measurement. The size range of mRNA contained within each fraction of the glycerol gradient was determined by formaldehyde/agarose gel electrophoresis using a small quantity (0.5 μ g) of each sample.

The integrity of the mRNA was assessed by *in vitro* translation. Reticulocyte lysates (commercially available kits; BRL) were used to translate 0.05–0.5 μ g of each mRNA fraction. The resulting ³⁵S-labelled proteins were analyzed by SDS-PAGE. Intact mRNA was capable of directing the synthesis of proteins of a complete size range, corresponding roughly to the sizes of the individual mRNA fractions.

54

A cDNA library was then constructed in the vector λ ZAPII, using a modifications of the techniques described by Gubler and Hoffman. RNA fractions were tested for their ability to induce Cl⁻ current. Fractions giving the best response in the oocyte assay were used as starting material for cDNA synthesis.

First-strand cDNA synthesis was primed with an oligo-dT/NotI primer-linker. Second-strand synthesis was performed using the RNase H/DNA Polymerase I self-priming method. Double-stranded cDNA was blunted with T4 DNA polymerase and EcoRI adaptors blunt-end ligated to the cDNA with T4 ligase. Following NotI digestion to cleave the linker, full-length cDNA was size-selected by exclusion chromatography on Sephacryl 500 HA. First-strand cDNA was radiolabeled with α -³²P-dATP, and all synthesis and recovery steps monitored by following the incorporation of radioactivity. Full-length cDNA recovered from the sizing column was ligated to EcoRI/NotI digested λ ZAPII arms. The ligation mix was test packaged with commercially available high-efficiency packaging extract (Stratagene, Inc.) and plated on the appropriate host strain (XL1-blue). The percentage of recombinant phage was determined by the ratio of white-to-blue plaques when the library was plated on IPTG and X-gal.

The average insert size was determined from ten randomly selected clones. Phage DNA "mini-preps" were digested with EcoRI and NotI to release the insert, and the size determined by agarose gel electrophoresis. The library consisted of >90% recombinant phage, and the insert size ranged from 1.5 to 4.2 kb. The recombinant ligation was packaged in large scale to generate 800,000 primary clones. The packaging mix was titered and plated at 50,000 plaques per 15 cm plate. Each pool of 50,000 clones was eluted in SM buffer and stored individually.

Plate lysate stocks of each of the clone pools were used for small-scale phage DNA preparation. Phage particles were concentrated by polyethylene glycol precipitation, and phage DNA purified by proteinase K digestion followed by phenol-chloroform extraction. Twenty micrograms of DNA were digested with NotI, and used as template for *in vitro* transcription of sense-strand RNA. *In vitro* transcription was carried out according to standard protocols, utilizing T7 RNA polymerase and 5' cap analog m⁷GpppG in a 50 μ l total reaction volume. Following Dnase I/Proteinase K digestion and phenol-chloroform extraction, the RNA was concentrated by ethanol precipitation and used for oocyte injection.

Oocytes were injected with synthetic mRNA (cRNA) from each of the 16 library subpools constituting 50,000 independent clones each. After incubation for 3 to 4 days, oocytes were assayed for the ability of 10 mM neomycin to elicit a Ca²⁺-dependent Cl⁻ current. A pool designated "pool 6" gave a positive signal and thus contains a cDNA clone encoding a functional calcium receptor.

Pool 6 phage was replated at about 20,000 plaques per plate and 12 plates harvested. DNA was prepared from each of these subpools and cRNA synthesized. Again, oocytes were injected with cRNA and assayed 3–4 days later for the ability of 10 mM neomycin to elicit a Ca²⁺-dependent Cl⁻ current. A subpool, pool 6–3, was positive and this pool was subjected to a further round of plating, reducing the complexity of pools to around 5,000 clones per pool. Pools were again assayed by preparation of cRNA and injection in oocytes. A subpool, pool 6–3.4, was positive.

To further purify the positive clone in pool 6–3.4, phage DNA from this pool was rescued as plasmid DNA by superinfection with the helper phage, ExAssist (Stratagene).

6,011,068

55

Transfection of rescued plasmids into bacterial strain DH5 α resulted in transformed bacterial colonies on ampicillin plates. These were harvested in pools of 900 clones each. Plasmid DNA was then prepared from each subpool and cRNA synthesized and assayed in the usual manner. Subpool 6-3.4.4 was positive.

Bacteria containing the plasmid subpool 6-3.4.4 were subsequently plated in subpools of about 50 clones each. Continuation of this process is expected to result in a single clone encoding a functional calcium receptor.

3. Calcium-Trapping Assay

This section describes a "calcium-trapping assay" for the detection of COS 7 cells expressing G protein-coupled receptors. In this assay COS 7 cell monolayers are transfected with cDNA clones from a bovine parathyroid cDNA library (e.g., subfractions or pools from a library prepared in pCDNA1) and are assayed for their ability to trap radioactive $^{45}\text{Ca}^{2+}$ in response to treatment with an agonist for the calcium receptor. The monolayers undergo emulsion autoradiography and cells that have trapped $^{45}\text{Ca}^{2+}$ are identified by the presence of photographic grain clusters under dark-field microscopy. Library pools that produce a positive signal are then sequentially subdivided until a single cDNA that produces the signal is identified.

D. Hybrid-Depletion Assay

A hybrid depletion assay can be used to obtain mRNA encoding inorganic ion receptors. In this approach, clones are selected on the basis of their ability to deplete a specific mRNA species from the total mRNA population. A clone encoding a single subunit is identified by its ability to prevent the formation of the active multi-subunit complex. By exhaustive screening it is possible to identify clones encoding all of the necessary subunits.

Thus, the hybrid-depletion screening strategy can result in the isolation of clones that do not contain a complete protein coding region. Positive clones isolated by this screening strategy are sequenced to determine their protein coding capacity. Northern blot analysis of human parathyroid gland RNA permits the determination of the size of the complete mRNA corresponding to specific clones. If positive clones do not appear to be full length, the cloned cDNA will be used as a hybridization probe to screen a parathyroid gland cDNA library for complete cDNAs.

For example, human parathyroid cells express a beta-adrenergic receptor coupled to adenylate cyclase. This receptor can be expressed in oocytes, where it is capable of agonist-induced activation of the endogenous adenylate cyclase. During the hybrid-depletion screening for Ca^{2+} receptor clones, oocytes injected with hybrid-depleted mRNA are assayed for isoproterenol-induced adenylate cyclase activation. A positive response in this assay serves to indicate that any observed inhibition of Ca^{2+} receptor response is specific, and not due to a general inhibition of G protein receptor functions.

E. Cloning Using Hybridization Probes and Primers

The presently preferred method for isolating inorganic ion receptor nucleic acid is based upon hybridization screening. Region-specific primers or probes derived from nucleic acid encoding a calcium receptor can be used to prime DNA synthesis and PCR amplification, as well as to identify colonies containing cloned DNA encoding a member of the inorganic ion receptor family using known methods (e.g., Innis et al., *PCR Protocols*, Academic Press, San Diego, Calif. (1990)).

56

1. PCR Cloning

Primer hybridization specificity to target nucleic acid encoding an inorganic ion receptor can be adjusted by varying the hybridization conditions. When annealing at higher stringency conditions of 50-60° C., sequences which are greater than about 76% homologous to the primer will be amplified. By employing lower stringency conditions, annealing at 35-37° C., sequences which are greater than about 40-50% homologous to the primer will be amplified.

Analysis of the calcium receptor indicates that it is a G protein-coupled receptor having seven conserved transmembrane domains. One particularly useful approach is to employ degenerate primers homologous to the conserved transmembrane domain coding regions and to amplify DNA regions encoding these sequences using polymerase chain reaction (PCR). Thus, such oligonucleotide primers are mixed with genomic DNA or cDNA to RNA isolated from the tissue of choice and PCR carried out. Some experimentation may be required to specifically amplify novel G protein-coupled receptor sequences from the tissue of choice since these are not necessarily identical to already known G protein-coupled receptors, but this is well understood by those of ordinary skill in the art (see, for example, Buck, L. and Axel, R. (1991) *Cell*, 65:175-187).

2. Hybridization Assay Probes

Hybridization assay probes can be designed based on sequence information obtained from cloned calcium receptors and amino acid sequences encoding such receptors. Hybridization assay probes can be designed to detect the presence of a particular nucleic acid target sequence perfectly complementary to the probe and target sequences of lesser complementarity by varying the hybridization conditions and probe design.

DNA probes targeted to inorganic ion receptors can be designed and used under different hybridization conditions to control the degree of specificity needed for hybridization to a target sequence. Factors affecting probe design, such as length, G and C content, possible self-complementarity, and wash conditions, are known in the art. (See, for example, Sambrook et al., *Molecular Cloning*, Cold Spring Harbor Laboratory Press (1989).) Sambrook et al., *Molecular Cloning*, also discusses the design and use of degenerative probes based on sequence polypeptide information.

As a general guideline, high stringency conditions (hybridization at 50-65°C, 5 \times SSPC, 50% formamide, wash at 50-65° C., 0.5 \times SSPC) can be used to obtain hybridization between nucleic acid sequences having regions which are greater than about 90% complementary. Low stringency conditions (hybridization at 35-37° C., 5 \times SSPC, 40-45% formamide, wash at 42° C. SSPC) can be used so that sequences having regions which are greater than 35-45% complementarity will hybridize to the probe.

Any tissue encoding an inorganic ion receptor can be used as a source for genomic DNA. However, with respect to RNA, the most preferred source is tissues which express elevated levels of the desired inorganic ion receptor family member.

F. Targeting Gene Walking

Targeted gene walking (TGW) is a modification of a standard polymerase chain reaction (PCR) that allows amplification of unknown DNA sequences adjacent to short segments of known sequence. Parker et al., *Nucl. Acids Res.*, 19: 3055 (1991). Unlike conventional PCR techniques that

6,011,068

57

amplify DNA sequences between two known primer sites, TGW can amplify DNA adjacent to one such site. Thus, TGW can serve as a replacement for conventional cloning and library screening methods for isolating sequences upstream or downstream from known sequences. The procedure can be used to isolate genes from any starting DNA template for which a limited amount of sequence information is known.

For example, first, several standard PCR reactions are run in parallel using one "targeted primer" and different "walking primers." The targeted primer is a sequence-specific primer exactly complementary to a known sequence on the DNA molecule of interest, and is directed towards unknown adjacent sequences. The walking primers are non-specific sequences not complementary to DNA near the target primer. The walking primers can be any oligonucleotides unrelated to the target primer sequence.

In the first series of PCR, products are produced only when a walking primer anneals to a DNA strand contiguous with and complementary to the strand to which the targeted primer has hybridized. The PCR products of interest are preferably within the 5 kilobase size range. Amplification products are produced with as many as 60% mismatched nucleotides within the walking primer relative to DNA template. Perfect base-pairing is required only for the first two 3' nucleotides of the walking primer, but partial homology is tolerated otherwise. Annealing temperature is a key variable in determining the number of PCR products, as identified by agarose gel electrophoresis.

Second, an oligomer extension assay is performed using an "internal detection primer." This primer represents known sequences between the previous two primers, contiguous with the targeted primer. The internal detection primer is kinased with ³²P-gamma-ATP, then used in a single PCR cycle with DNA from the first PCR as template. This extension identifies products in the first PCR contiguous with the targeted primer. These new products are identified by agarose gel electrophoresis and autoradiography. Any products that do not hybridize to the internal detection primer represent non-contiguous amplification products produced by any subset of the primers.

Last, bands identified in the oligomer extension assay are excised from the gel, and reamplified by standard PCR using target primer and the walking primer that produced the band initially. This new PCR band is then sequenced directly to provide previously unknown sequence information.

To extend information in the opposite direction, complements are made of the targeted and internal detection primers, and their order is reversed in the protocol. The pieces of information obtained from going in both directions are combined.

V. ANTIBODIES

Inorganic ion receptors, derivatives, and fragments thereof retaining antigenic determinants can be used to generate antibodies recognizing an inorganic ion receptor. Both polyclonal and monoclonal antibodies can be generated. Because derivatives have a different amino acid sequence than the inorganic ion receptor, the derivative may not have all the antigenic determinants of the inorganic ion receptor which it is related to and may have some different antigenic determinants. Preferably, the inorganic ion receptor is a calcium receptor.

Antibodies can be produced and used to purify proteins using standard techniques such as those described by Harlow and Lane in *Antibodies, a Laboratory Manual*, Cold

58

Spring Harbor Laboratory, 1988. Sources of immunogens for antibody production include purified inorganic ion receptors, purified inorganic ion receptor fragments, and whole cells expressing an inorganic ion receptor. Preferably, the immunogen is a purified calcium receptor, purified calcium receptor fragment, or whole cells expressing a purified calcium receptor. An example for obtaining antibodies to a calcium receptor from bovine parathyroid is described below.

For example, whole bovine parathyroid gland cells as the immunogen. Purified, dispersed cells are obtained, and live or fixed cell preparations are injected intraperitoneally into the appropriate mouse strain, according to established procedures. Standard protocols are followed for immunization schedules and for the production of hybridomas. A two-step screening procedure is used to identify hybridomas secreting monoclonal antibodies that recognize the calcium receptor.

The initial screen identifies monoclonal antibodies recognizing parathyroid cell surface antigens. Immunohistochemical techniques are then used to screen hybridoma supernatants for the presence of mouse antibodies that bind to the surface of parathyroid cells. The second screen can be performed on fixed sections of parathyroid gland tissue, or on dispersed cells in primary culture.

This procedure identifies hybridomas producing monoclonal antibodies to a variety of cell-surface determinants, and monoclonals specific for the calcium receptor would be expected to comprise only a small subset of these. To identify monoclonal antibodies that bind to the calcium receptor, hybridoma supernatants that test positive in the initial screen are assayed for their ability to block the response of cultured parathyroid cells to calcium receptor agonists. Some antibodies that bind to the extracellular domain of the receptor are expected to inhibit or activate ligand binding or to otherwise interfere with or affect receptor activation.

Monoclonal antibodies positive in both screens are characterized through Western blotting, immunoprecipitation and immunohistochemistry. This permits the determination of the size of the antigen that is recognized and its tissue distribution. The appropriate monoclonal antibody is then used for purification of the calcium receptor protein by immunoaffinity chromatography, following standard techniques.

Polyclonal antibodies recognizing an ion receptor may be obtained by immunizing rabbits or other mammals with isolated ion receptor polypeptides. Polypeptides used for immunization can comprise the entire receptor polypeptide or fragments thereof.

Ion receptor polypeptides may be isolated from tissues or cells normally expressing the ion receptor of choice, or from cells constructed for the purpose of recombinant expression of such polypeptides.

VI. HIGHLIGHTED USES

This section highlights and expands on some of the uses of the ionomimetic and/or ionolytic molecules, receptor polypeptides, nucleic acids encoding receptor polypeptides and antibodies recognizing receptor polypeptides. Additional uses are discussed in other parts of the application and are apparent to one of ordinary skill in the art reading the application.

A. Treatment of Diseases

Diseases or disorders which can be treated by modulating calcium receptor activity are known in the art. For example,

6,011,068

59

diseases or disorders which can be treated by modulating calcium receptor activity can be identified based on the functional responses of cells regulated by calcium receptor activity. Functional responses of cells regulated by calcium receptor are known in the art, including PTH secretion by parathyroid cells, calcitonin secretion by C-cells, and bone resorption by osteoclasts.

Such functional responses are associated with different diseases or disorders. For example, hyperparathyroidism results in elevated levels of PTH in the plasma. Decreasing the plasma levels of PTH offers an effective means of treating hyperparathyroidism. Likewise, increasing plasma levels of calcitonin is associated with an inhibition of bone resorption. Inhibiting bone resorption is an effective treatment for osteoporosis. Thus, modulation of calcium receptor activity can be used to treat diseases such as hyperparathyroidism, and osteoporosis.

Those compounds modulating inorganic ion receptor activity, preferably calcium receptor activity, can be used to confer beneficial effects to patients suffering from a variety of diseases or disorders. For example, osteoporosis is an age-related disorder characterized by loss of bone mass and increased risk of bone fracture. Compounds can be used to block osteoclastic bone resorption either directly (e.g., an osteoclast ionomimetic compound) or indirectly by increasing endogenous calcitonin levels (e.g., a C-cell calcimimetic). Alternatively, a calcilytic active on the parathyroid cell calcium receptor will increase circulating levels of parathyroid hormone, stimulating bone formation. All three of these approaches will result in beneficial effects to patients suffering from osteoporosis.

In addition, it is known that intermittent low dosing with PTH results in an anabolic effect on bone mass and appropriate bone remodeling. Thus, compounds and dosing regimens evoking transient increases in parathyroid hormone (e.g., intermittent dosing with a parathyroid cell ionolytic) can increase bone mass in patients suffering from osteoporosis.

Additional diseases or disorders can be identified by identifying additional cellular functional responses, associated with a disease or disorder, which are regulated by calcium receptor activity. Diseases or disorder which can be treated by modulating other inorganic ion receptors can be identified in an analogous manner.

Patient treatment can be carried out using different molecules described herein including: (1) inorganic ion receptor-modulating agents, preferably calcium receptor-modulation agents; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; and (4) antibodies, and fragments thereof targeted to inorganic ion receptor proteins, preferably a calcium receptor.

1. Inorganic Ion Receptor-Modulating Agents

The inorganic ion receptor-modulating agents of the present invention can exert an effect on an inorganic ion receptor causing one or more cellular effects ultimately producing a therapeutic effect. Different types of diseases or disorders can be treated by modulating inorganic ion receptor activity, preferably calcium receptor activity, such as those having one or more of the following: (1) those characterized by abnormal inorganic ion homeostasis, preferably, calcium homeostasis; (2) those characterized by an abnormal amount of an extracellular or intracellular

60

messenger whose production can be affected by inorganic ion receptor activity, preferably calcium receptor activity; and (3) other diseases or disorders in which modulation of inorganic ion receptor activity, preferably calcium receptor activity, will exert a beneficial effect, for example, in diseases or disorders where the production of an intracellular or extracellular messenger stimulated by receptor activity compensates for an abnormal amount of a different messenger.

Calcium receptor-modulating agents of the present invention can exert an effect on calcium receptor causing one or more cellular effects ultimately producing a therapeutic effect. Different diseases can be treated by the present invention by targeting cells having a calcium receptor. For example, primary hyperparathyroidism (HPT) is characterized by hypercalcemia and abnormal elevated levels of circulating PTH. A defect associated with the major type of HPT is a diminished sensitivity of parathyroid cells to negative feedback regulation by extracellular Ca^{2+} . Thus, in tissue from patients with primary HPT, the "set-point" for extracellular Ca^{2+} is shifted to the right so that higher than normal concentrations of extracellular Ca^{2+} are required to depress PTH secretion. Moreover, in primary HPT, even high concentrations of extracellular Ca^{2+} often depress PTH secretion only partially. In secondary (uremic) HPT, a similar increase in the set-point for extracellular Ca^{2+} is observed even though the degree to which Ca^{2+} suppresses PTH secretion is normal. The changes in PTH secretion are paralleled by changes in $[\text{Ca}^{2+}]_i$: the set-point for extracellular Ca^{2+} -induced increases in $[\text{Ca}^{2+}]_i$ is shifted to the right and the magnitude of such increases is reduced.

Molecules that mimic the action of extracellular Ca^{2+} are beneficial in the long-term management of both primary and secondary HPT. Such molecules provide the added impetus required to suppress PTH secretion which the hypercalcemic condition alone cannot achieve and, thereby, help to relieve the hypercalcemic condition. Molecules with greater efficacy than extracellular Ca^{2+} may overcome the apparent nonsuppressible component of PTH secretion which is particularly troublesome in the major form of primary HPT caused by adenoma of the parathyroid gland. Alternatively or additionally, such molecules can depress synthesis of PTH, as prolonged hypercalcemia has been shown to depress the levels of preproPTH mRNA in bovine and human adenomatous parathyroid tissue. Prolonged hypercalcemia also depresses parathyroid cell proliferation *in vitro*, so calcimimetics can also be effective in limiting the parathyroid cell hyperplasia characteristic of secondary HPT.

Cells other than parathyroid cells can respond directly to physiological changes in the concentration of extracellular Ca^{2+} . For example, calcitonin secretion from parafollicular cells in the thyroid (C-cells) is regulated by changes in the concentration of extracellular Ca^{2+} .

Isolated osteoclasts respond to increases in the concentration of extracellular Ca^{2+} with corresponding increases in $[\text{Ca}^{2+}]_i$ that arise partly from the mobilization of intracellular Ca^{2+} . Increases in $[\text{Ca}^{2+}]_i$ in osteoclasts are associated with the inhibition of bone resorption. Release of alkaline phosphatase from bone-forming osteoblasts is directly stimulated by calcium.

Renin secretion from juxtaglomerular cells in the kidney, like PTH secretion, is depressed by increased concentrations of extracellular Ca^{2+} . Extracellular Ca^{2+} causes the mobilization of intracellular Ca^{2+} in these cells. Other kidney cells respond to calcium as follows: elevated Ca^{2+} inhibits formation of $1,25(\text{OH})_2$ -vitamin D by proximal tubule cells,

6,011,068

61

stimulates production of calcium-binding protein in distal tubule cells, and inhibits tubular reabsorption of Ca^{2+} and Mg^{2+} and the action of vasopressin on the thick ascending limb of Henle's loop (MTAL), reduces vasopressin action in the cortical collecting duct cells, and affects vascular smooth muscle cells in blood vessels of the renal glomerulus.

Calcium also promotes the differentiation of intestinal goblet cells, mammary cells, and skin cells; inhibits atrial natriuretic peptide secretion from cardiac atria; reduces cAMP accumulation in platelets; alters gastrin and glucagon secretion; acts on vascular smooth muscle cells to modify cell secretion of vasoactive factors; and affects cells of the central nervous system and peripheral nervous system.

Thus, there are sufficient indications to suggest that Ca^{2+} , in addition to its ubiquitous role as an intracellular signal, also functions as an extracellular signal to regulate the responses of certain specialized cells. Molecules of this invention can be used in the treatment of diseases or disorders associated with disrupted Ca^{2+} responses in these cells.

Specific diseases and disorders which might be treated or prevented, based upon the affected cells, also include those of the central nervous system such as seizures, stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage such as in cardiac arrest or neonatal distress, epilepsy, neurodegenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease, dementia, muscle tension, depression, anxiety, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia, neuroleptic malignant syndrome, and Tourette's syndrome; diseases involving excess water reabsorption by the kidney such as syndrome of inappropriate ADH secretion (SIADH), cirrhosis, congestive heart failure, and nephrosis; hypertension; preventing and/or decreasing renal toxicity from cationic antibiotics (e.g., aminoglycoside antibiotics); gut motility disorders such as diarrhea, and spastic colon; GI ulcer diseases; GI diseases with excessive calcium absorption such as sarcoidosis; and autoimmune diseases and organ transplant rejection.

While calcium receptor-modulating agents of the present invention will typically be used in therapy for human patients, they may also be used to treat similar or identical diseases in other warm-blooded animal species such as other primates, farm animals such as swine, cattle, and poultry; and sports animals and pets such as horses, dogs and cats.

B. Toxin Binding Agents

The invention further provides receptor-binding agents including antibodies and/or fragments thereof which can be conjugated to a toxin moiety, or expressed along with a toxin moiety as a recombinant fusion protein. The toxin moiety will bind to and enter a target cell using the interaction of the binding agent and the corresponding target cell surface receptor. The toxin moiety results in targeted cell death. Thus, cells having calcium receptors characteristic of a disease or disorder, such as cancers, can be targeted by the present invention.

Suitable toxin moieties bound to a binding agent include proteins such as pokeweed anti-viral protein, abrin, diphtheria exotoxin, or *Pseudomonas* exotoxin; ricin, and a high energy-emitting radionuclide such as cobalt-60. Other examples of possible toxin moieties are known in the art. See, for example, "Conjugate Vaccines", *Contributions to Microbiology and Immunology*, J. M. Cruse and R. E. Lewis, Jr. (eds.), Carger Press, New York, (1989). The chosen toxin moiety should be pharmaceutically acceptable.

62

The conjugation of the binding agent to another moiety (e.g., bacterial toxin) can be accomplished by linking the two molecules using standard techniques so long as both molecules retain their respective activity. Possible linkages can be obtained by different chemical mechanisms, for example, covalent binding, affinity binding, intercalation, coordinate binding and complexation. Preferably, covalent binding is used. Covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules.

Many bivalent or polyvalent linking agents are useful in coupling protein molecules, such as an antibody, to other molecules. Representative coupling agents include organic compounds such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehydes, diazobenzenes and hexamethylene diamines. (See Killen and Lindstrom 1984, "Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by toxin-acetylcholine receptor conjugates." *J. Immunol.* 133: 1335-2549; Jansen, F. K., H. E. Blythman, D. Carriere, P. Casella, O. Gros, P. Gros, J. C. Laurent, F. Paolucci, B. Pau, P. Poncelet, G. Richer, H. Vidal, and G. A. Voisin. 1982. "Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity." *Immunological Rev.* 62: 185-216; and Vitetta et al., supra).

C. In Vitro Diagnostics

The different molecules of the present invention can be used to facilitate diagnosis of calcium-related diseases. Diagnosis can be carried in vitro or in viva. For example, the molecules of the present invention can be used to assay for defects in calcium receptors and the ability of a cell to properly respond to extracellular calcium. Cells can be obtained from patients using standard medical techniques.

Ionomimetics and ionolytics, such as calcimimetics and calcilytics can be used to assay the responsiveness of a cell or tissue to extracellular calcium. For example, a tissue or a cell type such as an osteoclast can be obtained from a patient and treated with a calcimimetic. The cell's failure to respond to the calcimimetic indicates a defect in calcium receptor activity.

Nucleic acids encoding calcium receptors can be used to help determine whether a particular cellular defect is due to a defective calcium receptor or at a different point in calcium homeostasis. For example, after a cell defective in calcium homeostasis is identified, a nucleic acid encoding a functional calcium receptor can be inserted into the cell. The ability of the calcium receptor to return calcium homeostasis to normal indicates the defect is due to a calcium receptor.

Nucleic acid probes can be used to identify defects in calcium receptors occurring at the genetic level. For example, hybridization probes complementary to nucleic acid encoding a receptor can be used to clone the receptor. The cloned receptor can be inserted into a cell, such as an oocyte, and its responsiveness to a calcimimetic or calcilytic determined. Another example of using hybridization assay probes to detect defects involves using the probes to detect mRNA levels or the presence of nucleic acid sequences associated with a particular disease. A decreased mRNA level would be consistent with a decreased amount of expressed receptor.

Antibodies and fragments thereof able to recognize a calcium receptor antigen can be used to help determine calcium receptor number, integrity, structure, and to localize cells expressing calcium receptors in the body. For example, antibodies targeted to calcium receptors can be used to

6,011,068

63

determine the number of receptors on a cell; antibodies able to distinguish defective from normal receptors can be used to determine the presence of defective receptors; antibodies targeted to a calcium receptor can be used to determine if a disease or surgical procedure results in the spread of normal or abnormal cells expressing calcium receptors; and antibodies targeted to a calcium receptor can be used to localize cells having abnormal calcium receptor number or structure to direct subsequent treatment.

D. Administration

The different molecules described by the present invention can be used to treat different diseases or disorders by modulating inorganic ion receptor activity, preferably calcium receptor activity. The molecules of the invention can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pa.

Suitable dosage forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such dosage forms should allow the agent to reach a target cell whether the target cell is present in a multicellular host or in culture. For example, pharmacological agents or compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and dosage form which retard the agent or composition from exerting its effect.

Agents can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and complexes thereof. Pharmaceutically acceptable salts are non-toxic salts at the concentration at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical characteristic of the agent without preventing it from exerting its physiological effect. Useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate administering higher concentrations of the drug.

Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. (See e.g., supra. PCT/US92/03736.) Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.

Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free base form of a compound is dissolved in a suitable solvent, such as an aqueous or aqueous-alcohol solution, containing the appropriate acid and then isolated by evaporating the solution. In another example, a salt is prepared by reacting the free base and acid in an organic solvent.

Carriers or excipients can also be used to facilitate administration of the compound. Examples of carriers and excipients include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. The compositions or pharmaceutical composition can be

64

administered by different routes including intravenously, intraperitoneal, subcutaneous, and intramuscular, orally, topically, or transmucosally.

For systemic administration, oral administration is preferred. Alternatively, injection may be used, e.g., intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the molecules of the invention are formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the molecules may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.

Systemic administration can also be by transmucosal or transdermal means, or the molecules can be administered orally. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through nasal sprays, for example, or using suppositories. For oral administration, the molecules are formulated into conventional oral administration dosage forms such as capsules, tablets, and liquid preparations.

For topical administration, the molecules of the invention are formulated into ointments, salves, gels, or creams, as is generally known in the art.

As shown in the examples provided herein, the amounts of various compounds of this invention to be administered can be determined by standard procedures. Generally, a therapeutically effective amount is between about 1 nmole and 3 μ mole of the molecule, preferably 0.1 nmole and 1 μ mole depending on its EC_{50} or IC_{50} and on the age and size of the patient, and the disease or disorder associated with the patient. Generally, it is an amount between about 0.1 and 50 mg/kg, preferably 0.01 and 20 mg/kg of the animal to be treated.

E. Gene and Oligonucleotide Therapy

Gene and oligonucleotide therapy include the use of nucleic acid encoding a functioning inorganic ion receptor, preferably a calcium receptor, and the use of inhibitory oligonucleotides. Inhibitory oligonucleotides include antisense nucleic acids and ribozymes. Gene and oligonucleotide therapy can be performed ex vivo on cells which are then transplanted into a patient, or can be performed by direct administration of the nucleic acid or nucleic acid-protein complex into the patient.

1. Antisense Oligonucleotides and Ribozymes

Antisense oligonucleotides and ribozymes are targeted to nucleic acid encoding an inorganic ion receptor, preferably a calcium receptor, and inhibit protein expression from the targeted nucleic acid. Numerous mechanisms have been proposed to explain the effects of antisense nucleic acids. For example, see Helene, C. and Toulme, J. *Biochimica et Biophysica Acta* 1049:99 (1990), and Uhlmann, E. and Peyman, A. *Chemical Reviews* 90:543 (1990). Proposed mechanisms include hybridization of an antisense oligonucleotide to nascent mRNA causing premature transcription termination and interfering with mRNA processing by hybridizing to a pre-mRNA intron/exon junction. These and several other proposed mechanisms for inhibiting nucleic acid activity by antisense oligonucleotides are based upon the ability of antisense nucleic acid to hybridize to a target

6,011,068

65

nucleic acid sequence. Preferably, anti-sense nucleic acids are 15 to 30 bases in length.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozyme action involves sequence specific interaction of the ribozyme to complementary target RNA, followed by an endonucleolytic cleavage. Different ribozyme cutting motifs such as hammer-head can be engineered to specifically and efficiently catalyze endonucleolytic cleavage of specific RNA sequences encoding.

Specific ribozyme cleavage sites include GUA, GUU and GUC. Once cleavage sites are identified, short RNA sequences of between 15 and 20 ribonucleotides targeted to the region of the targeted RNA containing the cleavage site may be evaluated for predicted structural features to determine ribozyme suitability. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays. See, Draper PCT WO 93/23569, hereby incorporated by reference herein.

Anti-sense oligonucleotides and ribozymes may be prepared by methods known in the art for the synthesis of RNA and DNA molecules. Standard techniques for chemically synthesizing nucleic acids include solid phase phosphoramidite chemical synthesis. Specific nucleic acids can also be produced enzymatically using a host transformed with a plasmid encoding for the desired nucleic acid.

Various modifications to the nucleic acid may be introduced to increase intracellular stability and half-life. Possible modifications include modifications to the phosphodiester backbone such as the use of phosphorothioate or methylphosphonate linkages.

Antisense oligonucleotides and ribozymes can be administered to a patient using different techniques such as by naked nucleic acid, nucleic acid compositions (for example, encapsulated by a liposome) and by retroviral vectors. Miller, *Nature* 357; 455-460, hereby incorporated by reference herein. Antisense oligonucleotides and ribozymes can also be introduced into a cell using nucleic acid encoding the antisense nucleic acid or ribozyme.

2. Gene Therapy

Gene therapy can be achieved by transferring a gene encoding an inorganic ion receptor, preferably a calcium receptor, into a patient in a manner allowing expression of the receptor protein. Recombinant nucleic acid molecules encoding receptor protein sequences can be introduced into a cell in vivo or ex vivo. In vivo transfection techniques include the use of liposomes and retroviral vectors. Miller, *Nature* 357; 455-460, hereby incorporated by reference herein. Ex vivo transfection increases the number of available transfection techniques, but also adds additional complications due to removal and subsequent insertion of cells into a patient.

F. Transgenic Animals

The present invention also concerns the construction and use of transgenic animals, and transformed cells encoding inorganic ion receptors, preferably human calcium receptors. Transgenic animals and transformed cells can be used to study the effects on cell function of receptor excess or depletion. Experimental model systems may be used to study the effects in cell or tissue cultures, in whole animals, or in particular cells or tissues within whole animals or tissue culture systems. The effects can be studied over specified time intervals (including during embryogenesis)

66

The present invention provides for experimental model systems for studying the physiological role of the receptors. Model systems can be created having varying degrees of receptor expression. For example, the nucleic acid encoding a receptor may be inserted into cells which naturally express the receptors such that the gene is expressed at much higher levels. Alternatively, a recombinant gene may be used to inactivate the endogenous gene by homologous recombination, and thereby create an inorganic ion receptor deficient cell, tissue, or animal.

Inactivation of a gene can be caused, for example, by using a recombinant gene engineered to contain an insertional mutation (e.g., the neo gene). The recombinant gene is inserted into the genome of a recipient cell, tissue or animal, and inactivates transcription of the receptor. Such a construct may be introduced into a cell, such as an embryonic stem cell, by techniques such as transfection, transduction, and injection. Stem cells lacking an intact receptor sequence may generate transgenic animals deficient in the receptor.

Preferred test models are transgenic animals. A transgenic animal has cells containing DNA which has been artificially inserted into a cell and inserted into the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats.

A variety of methods are available for producing transgenic animals. For example, DNA can be injected into the pronucleus of a fertilized egg before fusion of the male and female pronuclei, or injected into the nucleus of an embryonic cell (e.g., the nucleus of a two-cell embryo) following the initiation of cell division (Brinster et al., *Proc. Nat. Acad. Sci. USA* 82: 4438-4442 (1985)). By way of another example, embryos can be infected with viruses, especially retroviruses, modified to carry inorganic ion receptor nucleotide sequences.

Pluripotent stem cells derived from the inner cell mass of the embryo and stabilized in culture can be manipulated in culture to incorporate nucleotide sequences of the invention. A transgenic animal can be produced from such stem cells through implantation into a blastocyst that is implanted into a foster mother and allowed to come to term. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, Mass.), Taconic (Germantown, N.Y.), and Harlan Sprague Dawley (Indianapolis, Ind.).

Methods for the culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection also are well known to those of ordinary skill in the art. See, for example, *Teratocarcinomas and Embryonic Stem Cells, A Practical Approach*, E. J. Robertson, ed., IRL Press (1987).

Procedures for embryo manipulations are well known in the art. The procedures for manipulation of the rodent embryo and for microinjection of DNA into the pronucleus of the zygote are well known to those of ordinary skill in the art (Hogan et al., supra). Microinjection procedures for fish, amphibian eggs and birds are detailed in Houdebine and Chourout, *Experientia* 47: 897-905 (1991). Other procedures for introduction of DNA into tissues of animals are described in U.S. Pat. No. 4,945,050 (Sandford et al., Jul. 30, 1990).

Transfection and isolation of desired clones can be carried out using standard techniques (e.g., E. J. Robertson, supra).

6,011,068

67

For example, random gene integration can be carried out by co-transfecting the nucleic acid with a gene encoding antibiotic resistance. Alternatively, for example, the gene encoding antibiotic resistance is physically linked to a nucleic acid sequence encoding an inorganic ion receptor.

DNA molecules introduced into ES cells can also be integrated into the chromosome through the process of homologous recombination. Capecchi, *Science* 244: 1288-1292 (1989). Methods for positive selection of the recombination event (e.g., neomycin resistance) and dual positive-negative selection (e.g., neomycin resistance and gancyclovir resistance) and the subsequent identification of the desired clones by PCR have been described by Capecchi, supra and Joyner et al., *Nature* 338:153-156 (1989), the teachings of which are incorporated herein.

The final phase of the procedure is to inject targeted ES cells into blastocysts and to transfer the blastocysts into pseudopregnant females. The resulting chimeric animals are bred and the offspring are analyzed by Southern blotting to identify individuals that carry the transgene.

An example describing the preparation of a transgenic mouse is as follows. Female mice are induced to superovulate and placed with males. The mated females are sacrificed by CO₂ asphyxiation or cervical dislocation and embryos are recovered from excised oviducts. Surrounding cumulus cells are removed. Pronuclear embryos are then washed and stored until the time of injection.

Randomly cycling adult female mice paired with vasectomized males serve as recipients for implanted embryos. Recipient females are mated at the same time as donor females and embryos are transferred surgically to recipient females.

The procedure for generating transgenic rats is similar to that of mice. See Hammer et al., *Cell* 63:1099-1112 (1990). Procedures for the production of transgenic non-rodent mammals and other animals are known in art. See, for example, Houdebine and Chourrout, supra; Pursel et al., *Science* 244:1281-1288 (1989); and Simms et al., *Bio/Technology* 6:179-183 (1988).

G. Transfected Cells Lines

Nucleic acid expressing a functional inorganic ion receptor can be used to create transfected cells lines which functionally express a specific inorganic ion receptor. Such cell lines have a variety of uses such as being used for high-throughput screening for molecules able to modulate inorganic ion receptor activity, preferably calcium receptor activity; and being used to assay binding to an inorganic ion receptor, preferably a calcium receptor.

A variety of cell lines are capable of coupling exogenously expressed receptors to endogenous functional responses. A number of these cell lines (e.g., NIH-3T3, HeLa, NG115, CHO, HEK 293 and COS7) can be tested to confirm that they lack an endogenous calcium receptor. Those lines lacking a response to external Ca²⁺ can be used to establish stably transfected cell lines expressing the cloned calcium receptor.

Production of these stable transfectants is accomplished by transfection of an appropriate cell line with a eukaryotic expression vector, such as pMSG, in which the coding sequence for the calcium receptor cDNA has been cloned into the multiple cloning site. These expression vectors contain a promoter region, such as the mouse mammary tumor virus promoter (MMTV), that drive high-level transcription of cDNAs in a variety of mammalian cells. In addition, these vectors contain genes for the selection of

68

cells that stably express the cDNA of interest. The selectable marker in the PMSG vector encodes an enzyme, xanthine-guanine phosphoribosyl transferase (XGPRT), that confers resistance to a metabolic inhibitor that is added to the culture to kill the nontransfected cells. A variety of expression vectors and selection schemes are usually assessed to determine the optimal conditions for the production of calcium receptor-expressing cell lines for use in high-throughput screening assays.

The most effective method for transfection of eukaryotic cell lines with plasmid DNA varies with the given cell type. The calcium receptor expression construct will be introduced into cultured cells by the appropriate technique, either Ca²⁺ phosphate precipitation, DEAE-dextran transfection, lipofection or electroporation.

Cells that have stably incorporated the transfected DNA will be identified by their resistance to selection media, as described above, and clonal cell lines will be produced by expansion of resistant colonies. The expression of the calcium receptor cDNA by these cell lines will be assessed by solution hybridization and Northern blot analysis. Functional expression of the receptor protein will be determined by measuring the mobilization of intracellular Ca²⁺ in response to externally applied calcium receptor agonists.

The following examples illustrate the invention, but do not limit its scope.

EXAMPLES

In the studies described herein, a variety of organic molecules were found to mobilize intracellular Ca²⁺ and depress PTH secretion in parathyroid cells. These molecules are structurally diverse, but most have a net positive charge at physiological pH. The cationic nature of the organic molecules plays an important role, but is not the sole factor determining activity.

Example 1

Screening Calcimimetic Molecules on Bovine Parathyroid cells

Dissociated bovine parathyroid cells were purified on gradients of Percoll and cultured overnight in serum-free medium. The cells were subsequently loaded with fura-2 and the concentration of free intracellular Ca²⁺ measured fluorimetrically. Changes in [Ca²⁺]_i were used to screen for molecules active at the calcium receptor. To be considered a calcimimetic in this example, a molecule was required to show the normal effects caused by increasing extracellular Ca²⁺ and triggered by the activation of the calcium receptor. That is,

- 1) The molecule must elicit an increase in [Ca²⁺]_i; the increase in [Ca²⁺]_i may persist in the absence of extracellular Ca²⁺ and/or the molecule may potentiate increases in [Ca²⁺]_i elicited by extracellular Ca²⁺.
- 2) The molecule must cause a decrease in isoproterenol-stimulated cyclic AMP formation which is blocked by pertussis toxin;
- 3) The molecule must inhibit PTH secretion over the same range of concentrations that cause the increase in [Ca²⁺]_i; and
- 4) The concentration-response curves for increases in [Ca²⁺]_i and PTH secretion by the molecule must be shifted to the right by a PKC activator, such as phorbol myristate acetate (PMA).

Several structurally different classes of molecules were tested: polyamines, aminoglycoside antibiotics, protamine, and polymers of lysine or arginine. The structures of these

6,011,068

69

molecules are depicted in FIG. 1. Included in FIG. 1 are the net positive charge of the molecules and their EC_{50} 's for evoking the mobilization of intracellular Ca^{2+} in bovine parathyroid cells.

In general, the greater the net positive charge on the molecule, the greater its potency in causing the mobilization of intracellular Ca^{2+} . However, some striking exceptions to this apparent general rule have been found as discussed below.

As can be seen from the figures, spermine, neomycin B, and protamine evoked rapid and transient increases in $[Ca^{2+}]_i$ in fura-2-loaded bovine parathyroid cells (FIGS. 6, 7, 11). They did not, however, cause sustained, steady-state increases in $[Ca^{2+}]_i$ in bovine parathyroid cells (FIG. 6, 11), although they did in human parathyroid cells (FIG. 19). In this respect, they resembled the cytosolic Ca^{2+} response elicited by extracellular Mg^{2+} , which causes the mobilization of intracellular Ca^{2+} unaccompanied by an influx of extracellular Ca^{2+} in bovine cells (FIG. 11b). Transient increases in $[Ca^{2+}]_i$ elicited by spermine, neomycin B, or protamine were not blocked by low concentrations (1 μM) of La^{3+} or Gd^{3+} (FIG. 11f,g). Cytosolic Ca^{2+} transients elicited by the molecular polycations persisted in the absence of extracellular Ca^{2+} , but were blocked when cellular stores of Ca^{2+} were depleted by pretreatment with ionomycin (FIGS. 7, 11h and 11i). All of these molecules therefore cause the mobilization of intracellular Ca^{2+} in parathyroid cells.

It was additionally shown that the molecular polycations mobilized the same pool of intracellular Ca^{2+} as that used by extracellular Ca^{2+} . Thus, increasing the concentration of extracellular Ca^{2+} progressively inhibited the transient increases in $[Ca^{2+}]_i$ evoked by spermine (FIG. 6). Conversely, a maximally effective concentration of spermine or neomycin B (FIG. 12) blocked transient, but not steady-state increases in $[Ca^{2+}]_i$ evoked by extracellular Ca^{2+} .

Significantly, spermine, neomycin B, and protamine inhibited PTH secretion to the same extent as extracellular Ca^{2+} . These inhibitory effects on secretion were obtained at concentrations that caused the mobilization of intracellular Ca^{2+} (FIGS. 8, 13). These findings are relevant to understanding the mechanisms contributing to the regulation of PTH secretion by extracellular Ca^{2+} . Because a variety of inorganic polycations all inhibit secretion, yet only extracellular Ca^{2+} causes sustained, steady-state increases in $[Ca^{2+}]_i$, such increases in $[Ca^{2+}]_i$ cannot be importantly involved in the regulation of secretion. Mobilization of intracellular Ca^{2+} , rather than the influx of extracellular Ca^{2+} , is the essential mechanism associated with the inhibition of PTH secretion. This is important because it defines the sufficient mechanism to be affected if a molecule is to affect PTH secretion; molecules stimulating selectively the influx of extracellular Ca^{2+} will be relatively ineffective in suppressing PTH secretion. In contrast, molecules causing solely the mobilization of intracellular Ca^{2+} should be just as efficacious as extracellular Ca^{2+} in suppressing PTH secretion.

Like the mobilization of intracellular Ca^{2+} elicited by extracellular Ca^{2+} , that elicited by molecular polycations was depressed by PMA. A representative experiment showing the preferential inhibitory effects of PMA on cytosolic Ca^{2+} transients elicited by spermine is shown in FIG. 14. Cytosolic Ca^{2+} transients evoked by ATP were unaffected, even when a submaximal concentration of ATP was used. The effect of PMA on cytosolic Ca^{2+} transients elicited by the molecular polycations paralleled its effect on responses to extracellular Ca^{2+} ; in both cases, there was a shift to the

70

right in the concentration-response curve (FIG. 15). The depressive effects of PMA on $[Ca^{2+}]_i$ were accompanied by potentiating effects on secretion which were overcome at higher concentrations of the organic polycations (FIG. 16).

The mobilization of intracellular Ca^{2+} elicited by molecular polycations was associated with increases in the formation of inositol phosphates. For example, protamine caused a rapid (within 30 seconds) increase in the formation of IP_3 , which was accompanied by a rise in levels of IP_1 . Both these effects were dependent on the concentration of extracellular protamine (FIG. 17). Moreover, pretreatment with PMA blunted the formation of inositol phosphates elicited by molecular polycations. Representative results obtained with spermine are presented in FIG. 18.

Spermine, neomycin B, and protamine depressed isoproterenol-induced increases in cyclic AMP. Like the inhibitory effects of extracellular Ca^{2+} on cyclic AMP formation, those caused by molecular polycations were blocked by pretreatment with pertussis toxin (Table 2).

TABLE 2

	cyclic AMP (% of control)	
	control	+PTx
0.5 mM Ca^{2+}	100	106 ± 8
2.0 mM Ca^{2+}	19 ± 4	94 ± 2
0.5 mM Ca^{2+} , 200 μM spermine	23 ± 5	93 ± 6
0.5 mM Ca^{2+} , 30 μM neomycin B	28 ± 8	87 ± 6
0.5 mM Ca^{2+} , 2 $\mu g/ml$ protamine	20 ± 4	89 ± 9

Pertussis toxin (PTx) blocks the inhibitory effects of extracellular Ca^{2+} and molecular polycations on cyclic AMP formation. Bovine parathyroid cells were cultured for 16 hours with or without 100 ng/ml pertussis toxin. The cells were subsequently washed and incubated for 15 min with 10 μM isoproterenol with or without the indicated concentrations of extracellular Ca^{2+} or molecular polycations. Total cyclic AMP (cells+supernatant) was determined by RIA and the results are expressed as a percentage of the levels obtained in 0.5 mM Ca^{2+} (112 ± 17 pmole/ 10^6 cells). Each value is the mean \pm SEM of three experiments.

In human parathyroid cells, extracellular Mg^{2+} elicited a sustained, steady-state increase in $[Ca^{2+}]_i$ in addition to a rapid transient increase (FIG. 10). As in bovine parathyroid cells responding to extracellular Ca^{2+} , the steady-state increase in $[Ca^{2+}]_i$ evoked by Mg^{2+} in human parathyroid cells results from Ca^{2+} influx through voltage-insensitive channels (FIG. 10a). This effect of Mg^{2+} on steady-state $[Ca^{2+}]_i$ in human parathyroid cells is seen in both adenomatous and hyperplastic tissue.

Neomycin B and spermine were tested for effects on $[Ca^{2+}]_i$ in human parathyroid cells prepared from adenomatous tissue. Representative results with neomycin B are shown in FIG. 19. Neomycin B caused not only a transient, but additionally a steady-state increase in $[Ca^{2+}]_i$ in human parathyroid cells (FIG. 19a). Thus, in human cells, the pattern of change in $[Ca^{2+}]_i$ evoked by extracellular Ca^{2+} , Mg^{2+} or neomycin B is very similar.

Cytosolic Ca^{2+} transients elicited by neomycin B persisted in the presence of La^{3+} (1 μM) and absence of extracellular Ca^{2+} . Neomycin B therefore causes the mobilization of intracellular Ca^{2+} in human parathyroid cells. Neomycin B inhibited PTH secretion from human parathyroid cells at concentrations that caused the mobilization of intracellular Ca^{2+} (FIG. 13). There were, however, some differences in the responses of human and bovine parathy-

6,011,068

71

roid cells to neomycin B. The EC_{50} of neomycin B for the mobilization of intracellular Ca^{2+} was $40 \mu M$ in bovine and $20 \mu M$ in human parathyroid cells (cf. FIGS. 13 and 15), whereas the potency of spermine was similar in bovine and human parathyroid cells ($EC_{50}=150 \mu M$). Thus, although

bovine cells can be used for initial studies to screen test molecules for activity, it is important to perform follow-up studies using human parathyroid cells. To assess the effects of molecular polycations on C-cells, a neoplastic cell line, derived from a rat medullary thyroid carcinoma (rMTC 6-23 cells) was used. Both spermine (10 mM) and neomycin B (5 mM) were without effect on basal $[Ca^{2+}]_i$ in these cells. Nor did either molecule affect the response to the subsequent addition of extracellular Ca^{2+} . Representative results documenting the lack of effect of neomycin B are shown in FIG. 21. Neomycin B (1 mM) or spermine (1 or 5 mM) failed to evoke any increase in $[Ca^{2+}]_i$ in osteoclasts (FIG. 23). In the trace shown, there appeared to be some potentiation of the response to a subsequent increase in the concentration of extracellular Ca^{2+} , although this was not a consistent finding. In two other cells, spermine (5 mM) was again without effect on basal $[Ca^{2+}]_i$ and caused a small inhibition (about 15%) of the extracellular Ca^{2+} -induced increase in $[Ca^{2+}]_i$. In a third cell, neomycin B (5 mM) was without effect on basal $[Ca^{2+}]_i$ and did not affect increases in $[Ca^{2+}]_i$ elicited by extracellular Ca^{2+} . The overall picture that develops from these studies is that spermine and neomycin B are without effect on basal or stimulated levels of cytosolic Ca^{2+} in osteoclasts.

The failure of the molecular polycations to affect the Ca^{2+} -sensing mechanisms of C-cells or osteoclasts demonstrates the ability to discover or design novel lead molecules that act specifically on the parathyroid cell calcium receptor or otherwise modulate one or more functions of the parathyroid cell's normal response to $[Ca^{2+}]_i$.

Screening of various other molecules is described in detail below and the results summarized in Table 1.

Example 2

Polyamine Screening

Straight-chain polyamines (spermine, spermidine, TETA, TEPA, and PEHA) and two derivatives thereof (NPS 381 and NPS 382) were screened as in Example 1. These molecules were all found to mobilize intracellular Ca^{2+} in bovine parathyroid cells. Their order of potency is as follows, with the net positive charge listed in parentheses:

TABLE 3

Molecule	EC_{50} (in μM)
NPS 382 (+8)	50
NPS 381 (+10)	100
spermine (+4)	150
PEHA (+6)	500
spermidine (+3)	2000
TEPA (+5)	2500
TETA (+4)	8000

Putrescine (+2) and cadaverine (+2) were inactive at a concentration of 2 mM.

Another straight-chain polyamine, DADD, behaved somewhat differently from the other polyamines and is described in Table 1.

Example 3

Cyclic Polyamine Screening

Two cyclic polyamines, hexacyclen and NPS 383, were screened as in Example 1. Hexacyclen (+6, $EC_{50}=20 \mu M$) is

72

7-fold more potent than NPS 383 (+8, $EC_{50}=150 \mu M$). The converse would be expected based solely on net positive charge as the structural characteristic for calcium receptor activity.

Example 4

Aminoglycoside Antibiotic Screening

Six antibiotics were screened as in Example 1. The resulting EC_{50} 's for the mobilization of intracellular Ca^{2+} , in rank order of potency, were:

TABLE 4

Antibiotic	EC_{50} (in μM)
neomycin (+6)	10
gentamicin (+5)	150
beknamycin (+5)	200
streptomycin (+3)	600

Kanamycin (+4.5) and lincomycin (+1) were without effect at a concentration of $500 \mu M$. Within the aminoglycoside series, there is a correlation between net positive charge and potency. However, neomycin is considerably more potent than various polyamines (NPS 381, NPS 382, NPS 383, PEHA) that have an equal or greater positive charge. Since aminoglycoside antibiotics of this type have renal toxicity which may be related to interaction with calcium receptors in the kidney, such screening could be used to screen for toxicity in the development of new aminoglycoside antibiotics.

Example 5

Peptide and Polyamino Acid Screening

Protamine and polymers of lysine or arginine varying in peptide length were screened for their ability to mobilize intracellular Ca^{2+} as in Example 1. The resulting EC_{50} 's for the mobilization of intracellular Ca^{2+} , in rank order of potency, were:

TABLE 5

Peptide (MW in kD)	EC_{50} (in nM)
polyArg (100)	4
polyArg (40)	15
polyLys (27)	30
protamine (4.8)	75
polyArgTyr (22)	200
polyLys (14)	1000
polyLys (3.8)	3000

The net positive charge of these polymers increases as the MW increases. Thus, as for the aminoglycosides, there is a direct correlation between net charge and potency among this series of polyamino acids. Protamine is essentially polyArg with a net positive charge of +21.

Example 6

Arylalkyl Polyamine Screening

Molecules selected from the class of arylalkyl polyamines derived from the venoms of wasps and spiders were screened as in Example 1.

Philanthotoxin-433 (+3) was without effect at a concentration of $500 \mu M$. It is similar in structure to the argitoxins described below.

Argitoxin-636 ($400 \mu M$) did not elicit increases in $[Ca^{2+}]_i$, but it did potentiate cytosolic Ca^{2+} responses to the subsequent addition of extracellular Ca^{2+} . This is a feature common to all molecules that activate the calcium receptor

6,011,068

73

and is also seen with a variety of extracellular divalent cations. This is considered in more detail in Example 7.

In contrast to argitoxin-636, argitoxin-659 elicited increases in $[Ca^{2+}]_i$ with an EC_{50} of 300 μM . Argitoxin-659 differs from argitoxin-636 in having a 4-hydroxyindole moiety rather than a 2,4-dihydroxyphenyl group. This is the only structural difference between these two molecules. Thus, the difference in potency lies in the nature of the aromatic group, not in the polyamine chain which carries the positive charge.

Example 7

Screening of Ca^{2+} Channel Blockers

Ca^{2+} channel blockers, i.e., those molecules which block influx of extracellular Ca^{2+} through voltage-sensitive Ca^{2+} channels, were screened as in Example 1. There are three structural classes of Ca^{2+} channel blockers: (1) dihydropyridines, (2) phenylalkylamines, and (3) benzothiazepines.

None of the dihydropyridines tested (nifedipine, nitrendipine, BAY K 8644, and (-) 202-791 and (+) 202-791) had any effect on basal $[Ca^{2+}]_i$ or increases in $[Ca^{2+}]_i$ evoked by extracellular Ca^{2+} when they were tested at 1 μM . Previous studies showed that parathyroid cells lack voltage-sensitive Ca^{2+} channels, but do have voltage-insensitive Ca^{2+} channels that are regulated by the calcium receptor.

The phenylalkylamines examined were verapamil, D-600 (a methoxy derivative of verapamil), TMB-8, and an analog of TMB-8, NPS 384. The first three molecules were tested at a concentration of 100 μM . The phenylalkylamines behaved differently from other molecules examined. They evoked no change in $[Ca^{2+}]_i$ when added to cells bathed in buffer containing a low concentration of extracellular Ca^{2+} (0.5 mM). However, verapamil, D-600, and TMB-8 potentiated the mobilization of intracellular Ca^{2+} elicited by extracellular divalent cations and they additionally blocked the influx of extracellular Ca^{2+} . At intermediate levels of extracellular Ca^{2+} (1-1.5 mM), these molecules were capable of evoking a small, but robust increase in $[Ca^{2+}]_i$ that arose from the mobilization of intracellular Ca^{2+} .

The phenylalkylamines act differently than organic polycations like neomycin. The data suggest that verapamil, D-600 and TMB-8 are partial agonists or allosteric activators at the calcium receptor, in contrast to the other molecules examined which are full agonists.

Molecule NPS 384, at a concentration of 300 μM , did not evoke an increase in $[Ca^{2+}]_i$ but it blocked influx of extracellular Ca^{2+} . Testing at higher concentrations may reveal an ability of this molecule to cause the mobilization of intracellular Ca^{2+} .

While the ability of these molecules to block influx is intriguing and not entirely unexpected, it is the ability of these molecules to evoke transient increases in $[Ca^{2+}]_i$ (arising from intracellular Ca^{2+} mobilization) that is important. Considerable experience with measurements of $[Ca^{2+}]_i$ in parathyroid cells shows that transient increases in $[Ca^{2+}]_i$ almost invariably result from the mobilization of intracellular Ca^{2+} and therefore reflects activation of the calcium receptor.

The benzothiazepine examined, diltiazem, was similar in all respects to verapamil and D-600 and was also effective at 100 μM .

With the exception of the phenylalkylamines, all the active molecules tested above evoke increases in $[Ca^{2+}]_i$ having a magnitude similar to that evoked by a maximally effective concentration of extracellular Ca^{2+} . This shows that these molecules are equally efficacious as extracellular

74

divalent cations. This contrasts with the activity of phenylalkylamines, which seem to act only as partial agonists.

Amongst the phenylalkylamines, some interesting structure-activity relationships emerge. Significant is the different potencies of molecules like TMB-8 and NPS 384. TMB-8 potentiated transient increases in $[Ca^{2+}]_i$ at 100 μM whereas NPS 384 fails to do so even at 300 μM , yet these molecules carry the same net positive charge. It follows that some other structural feature, unrelated to net charge, imparts greater potency to TMB-8.

Example 8

Molecule Screening on Human Parathyroid Cells

Spermine and neomycin were tested for effects on $[Ca^{2+}]_i$ in human parathyroid cells obtained from glands removed by surgery and prepared as in Example 1. In human parathyroid cells, spermine was found to cause only a small increase in $[Ca^{2+}]_i$ when tested at a concentration of 300 μM .

Neomycin, on the other hand, evoked a large increase in $[Ca^{2+}]_i$ in human parathyroid cells when tested at a concentration of 20 μM . The magnitude of the response elicited by neomycin was equal to that evoked by a maximally effective concentration of extracellular Ca^{2+} .

Example 9

Molecule Screening on Xenopus Oocytes

Oocytes injected with mRNA from human parathyroid cells express the calcium receptor and mobilize intracellular Ca^{2+} in response to a variety of extracellular inorganic di- and trivalent cations. Using this screen allows one to test for an action directly on the calcium receptor. Oocytes expressing the calcium receptor also responded to several molecules active on intact parathyroid cells when screened as follows. Hexacyclen caused the mobilization of intracellular Ca^{2+} at a concentration of 135 μM . Neomycin (100 μM) and NPS 382 (5 mM) were also effective. This offers rather compelling evidence showing that these molecules act on the calcium receptor or on some other protein intimately associated with its function.

For example, we have been able to detect calcium receptor expression in oocytes by measuring $^{45}Ca^{2+}$ mobilization. In these experiments, oocytes were injected with bovine parathyroid mRNA or water and, after 72 hours, exposed to serum or 10 mM neomycin. Prior to being stimulated, oocytes were loaded with $^{45}Ca^{2+}$. Stimulation with serum for 20 min resulted in intracellular $^{45}Ca^{2+}$ release representing a 45% increase compared to mock challenge with buffer. Challenge with 10 mM neomycin for 20 min resulted in a 76% increase in $^{45}Ca^{2+}$ release. The assay is sensitive enough for use in cloning the calcium receptor, and has the advantage of a higher throughput than the electrophysiological measurement of Ca^{2+} -activated Cl^- current.

In another example, human osteoclastoma tissue was obtained from bone biopsy tissue. Oocytes injected with mRNA isolated from this tissue were challenged with 30 mM Ca^{2+} . Controls did not respond while 8 of 12 oocytes injected with osteoclastoma mRNA responded appropriately (FIG. 34). These experiments provide the first evidence that the Ca^{2+} response of osteoclasts to extracellular Ca^{2+} is in fact genetically encoded. The results also indicate that the osteoclast calcium receptor may be cloned by expression in *Xenopus* oocytes.

Example 10

Molecule Screening on Rat Osteoclasts

The different sensitivities of parathyroid cells and rat osteoclasts to extracellular Ca^{2+} suggest that their calcium

6,011,068

75

receptors are different. While parathyroid cells respond to extracellular Ca^{2+} concentrations between 0.5 and 3 mM, osteoclasts respond only when the level of extracellular Ca^{2+} increases beyond 5 mM. This rather high concentration of Ca^{2+} is nonetheless physiological for osteoclasts; as they resorb bone, the local concentration of extracellular Ca^{2+} may reach levels as high as 30 mM.

Molecule screening with rat osteoclasts was performed as follows. Osteoclasts were obtained from the long bones of neonatal rats. $[\text{Ca}^{2+}]_i$ was measured in single cells using the fluorimetric indicator indo-1. Spermine, spermidine, neomycin, and verapamil were tested, and none of these caused any large increase in $[\text{Ca}^{2+}]_i$ in osteoclasts (although small responses were detected).

At a concentration of 1 mM, spermidine caused a small increase in $[\text{Ca}^{2+}]_i$ (about 10% of that evoked by a maximal concentration of extracellular Ca^{2+}). Neither neomycin (10 mM) nor spermine (10 or 20 mM) caused increases in $[\text{Ca}^{2+}]_i$ in rat osteoclasts. Neomycin (10 mM) did not block the increase in $[\text{Ca}^{2+}]_i$ elicited by the subsequent addition of 25 mM extracellular Ca^{2+} . Pretreatment with spermine (20 mM), however, did depress the response to extracellular Ca^{2+} . Verapamil (100 μM) caused no detectable increase in $[\text{Ca}^{2+}]_i$, but it did block the response to extracellular Ca^{2+} .

Comparisons between osteoclasts and parathyroid cells show that molecules active on the latter are relatively ineffective in osteoclasts. This demonstrates that drugs that target a specific calcium receptor without affecting those receptor types present on other Ca^{2+} -sensing cells are readily developed. Similarly, drugs active at two or more such calcium receptors may also be developed.

Screening for Calcimimetic and Calcilytic Activity on the Osteoclast Calcium Receptor

Compounds possessing activity on the osteoclast calcium receptor can be discovered by measuring $[\text{Ca}^{2+}]_i$ in single rat osteoclasts as described above. An improved assay enables moderate-to-high levels of compound throughput. This new method is based on the use of rabbit osteoclasts which can be obtained in high yield (10^5 per animal) and purity (95% of the cells are osteoclasts). The purity of the rabbit osteoclast preparation allows measurements of $[\text{Ca}^{2+}]_i$ to be performed on populations of cells. Because the recorded fluorescence signal is an averaged population response, intercellular variability is minimized and the precision of the assay is greatly increased. This, in turn, enables more compounds to be screened for activity.

Rabbit osteoclasts are prepared from 6-day old bunnies. The animals are sacrificed by decapitation and the long bones removed and placed into osteoclast medium (OC medium: alpha-minimum essential medium containing 5% fetal bovine serum and penicillin/streptomycin). The bones are cut into sections with a scalpel and placed in 2 ml of OC media in a 50-ml conical centrifuge tube. The bone sections are minced with scissors until a fairly homogeneous suspension of bone particles is obtained. The suspension is then diluted with 25 ml of OC media and the preparation swirled gently ("vortexed") for 30 seconds. The bone particles are allowed to settle for 2 minutes after which the supernatant is removed and added to a 50-ml centrifuge tube. The bone particles are resuspended in OC media, swirled, sedimented and harvested as just described. The supernatants from the two harvests are combined and centrifuged and the resulting cellular pellet resuspended in Percoll. The suspension is then centrifuged and the white viscous band just below the meniscus is removed and washed with OC media. The Percoll centrifugation step results in a significant improvement in purity and allows osteoclasts to be plated at high

76

densities, suitable for measuring $[\text{Ca}^{2+}]_i$ in populations of cells. The cells are plated onto glass cover slips appropriate for measuring $[\text{Ca}^{2+}]_i$, according to one of the methods described below. If necessary, the purity of the preparation can be improved. In this case, the cells are cultured overnight and then rinsed with Ca^{2+} - and Mg^{2+} -free buffer. The cell monolayer is then immersed in Ca^{2+} - and Mg^{2+} -free buffer containing 0.02% EDTA and 0.001% pronase for 5 minutes. This buffer is then removed and replaced with OC media and the cells allowed to recover for 1 to 2 hours before loading the cells with fluorimetric indicator and measuring $[\text{Ca}^{2+}]_i$ as described below.

In one embodiment, this technique allows the measurement of $[\text{Ca}^{2+}]_i$ in populations of osteoclasts using fluorescence microscopy. The purified osteoclasts are allowed to attach to 25-mm diameter glass cover slips and then loaded with indo-1. The cover slips are secured into a superfusion chamber and placed onto the stage of a fluorescence microscope. The use of a low-power objective (x4) allows a field containing 10 to 15 osteoclasts to be visualized. In one variation, the fluorescence of each cell in the field can be recorded simultaneously and stored separately for later analysis. Changes in $[\text{Ca}^{2+}]_i$ of each cell can be estimated and the average response of all cells in the field calculated. In another variation, the fluorescence from the entire field of cells can be recorded and processed immediately. In either variation, the final data are in the form of an average response from the cells present in the microscopic field. Because of this, intercellular variability is minimized and precision of the assay greatly increased. This method enables 10–20 compounds per week to be screened for activity on the osteoclast calcium receptor.

In a more preferred embodiment, this technique allows the measurement of $[\text{Ca}^{2+}]_i$ in populations of osteoclasts using a conventional fluorimeter. The purified osteoclasts are allowed to attach to rectangular glass cover slips. In one variation, a standard quartz cuvette (1 cm^2) is used and the glass coverslips are 2x1.35 cm. In another variation, a microcuvette is used (0.5 cm^2) and the glass coverslips are 1x0.75 cm. In either case the cells are loaded with fura-2 or some other suitable fluorimetric indicator for measuring $[\text{Ca}^{2+}]_i$. The fluorescence of indicator-loaded cells is recorded as described above for bovine parathyroid cells. This method allows a higher throughput than fluorescence microscopy and enables 20–50 compounds per week to be evaluated for activity on the osteoclast calcium receptor.

In a most preferred embodiment, the technique can be used to measure $[\text{Ca}^{2+}]_i$ in osteoclasts in a 96-well plate. The purified osteoclasts are plated at high density into each well of a 96-well plate and subsequently loaded with a suitable fluorimetric indicator. The fluorescence of each well is recorded using a custom-designed fluorimeter attached to a Hamilton 220 robotic liquid handler. This method is fully automated and is capable of reading 1,000 compound per week per device.

Example 11

Calcium Receptor Selectivity

This example demonstrates that calcium receptors present on different cells exist as distinct subtypes which can be differentially affected by a particular drug. The parathyroid cell calcium receptor senses levels of extracellular Ca^{2+} around 1.5 mM whereas the calcium receptor on the osteoclast responds to levels around 10 mM (FIG. 22). Neomycin or spermine, which activate the parathyroid cell calcium receptor, fail to affect the calcium receptors on C-cells or osteoclasts (FIGS. 21 and 23).

These data constitute the first evidence for pharmacologically distinct subtypes of calcium receptors and these data

6,011,068

77

are being used to design and develop drugs that act selectively on a particular type of calcium receptor. Indeed, testing of lead molecules demonstrate such cell-specific effects. For example, Mg^{2+} , which increases $[Ca^{2+}]_i$ in bovine parathyroid cells ($EC_{50}=5$ mM), is without effect on $[Ca^{2+}]_i$ in osteoclasts even when tested at concentrations as high as 30 mM. Conversely, R-fendiline, which activates the parathyroid cell calcium receptor, is effective in activating the osteoclast calcium receptor only at concentrations 10-fold higher. Finally, agatoxin 489, although not very potent in activating the C-cell calcium receptor ($EC_{50}=150$ μM), is a quite potent activator of the parathyroid cell calcium receptor ($EC_{50}=3$ μM). The lead molecules presently under development will affect selectively the activity of a specific type of Ca^{2+} -sensing cell in vivo.

Drugs with less specificity might not necessarily be therapeutically undesirable. Thus, depressing osteoclast activity and stimulating calcitonin secretion are two different approaches to inhibiting bone resorption. Drugs that target the calcium receptors on both of these cells might be very effective therapies for osteoporosis. Because PTH is also involved in regulating bone metabolism, drugs acting on the parathyroid cell calcium receptor may also be useful in the treatment and/or prevention of osteoporosis.

Results of some test molecules are shown below. In Table 6, the comparative activity of calcimimetic molecules is shown. Bovine parathyroid cells and C-cells (rMTC 6-23 cells) were loaded with fura-2, and rat osteoclasts with indo-1 and the potency of the indicated molecules to mobilize intracellular Ca^{2+} determined by constructing cumulative concentration-response curves. Molecules listed as "inactive" did not alter $[Ca^{2+}]_i$ when tested at a concentration of 1 mM.

TABLE 6

COMPOUND	EC_{50} (μM)		
	PARATHYROID	OSTEOCLAST	C-CELL
NPS R-568	0.60	200	1.9
NPS S-568	30	—	—
NPS R-467	2	>100	2.2
NPS S-467	>30	—	—
NPS 017	6	inactive	150
R-Fendiline	9	150	—
Fendiline*	15	200	>100
NPS 015	22	—	inactive
NPS 019	40	>300	5
R-Prenylamine	7	150	6
1H*	30	250	—
Spermine	150	inactive	inactive
Neomycin	40	inactive	inactive

*racemic mixture;

"inactive" is defined as causing no increase in cytosolic Ca^{2+} at a concentration of 1-5 mM.

Example 12

Lead Molecules for Parathyroid Calcium Receptor

Structure-activity studies using polyamines and arylalkyl polyamines led to the testing of molecules structurally akin to fendiline. Fendiline is a potent activator of the parathyroid cell calcium receptor. This molecule is notable because it possess only one positive charge, yet is much more potent than many polybasic molecules. Brief (2 min) pretreatment with PMA shifts the concentration-response curve for fendiline to the right. This indicates that fendiline acts through the same mechanism used by extracellular Ca^{2+} to activate the calcium receptor on parathyroid cells.

Fendiline evokes the mobilization of intracellular Ca^{2+} in *Xenopus* oocytes expressing the parathyroid cell calcium

78

receptor, which demonstrates a direct action on the calcium receptor (FIG. 33). Moreover, fendiline contains a chiral carbon, and therefore exists in two isomeric forms. Both isomers have been synthesized and examined for activity. The R-isomer, R-fendiline, is 12 times more potent than the S-isomer, S-fendiline. This is the first demonstration that a calcium receptor can recognize an organic molecule in a stereospecific manner.

Because R-fendiline is a structurally simple molecule with selective and potent effects on the parathyroid cell calcium receptor, structure-activity studies around this lead molecule are simple. The aim of these studies is to generate an array of related molecules with various characteristics from which the final development candidate can be selected. This effort has already revealed some of the structural domains of R-fendiline that contribute to activity and potency. For example, the novel compound 1D is an analog of R-fendiline that is smaller ($MW<240$), yet nearly as potent as the parent molecule, whereas several other analogues are relatively inactive. The most interesting molecules from this analog project can be put into in vivo testing for effects on PTH secretion and serum Ca^{2+} levels (see Examples 15, 16, 17, 18 and 23).

meta-Methoxyfendiline is another compound as potent as NPS 467 in causing the mobilization of intracellular Ca^{2+} in parathyroid cells. meta-Methoxyfendiline is a racemic mixture and it is anticipated that the resolution of meta-methoxyfendiline into its enantiomers will result in an isomer that is more potent than the racemic mixture.

The novel compound NPS 467 is an even smaller molecule than R-fendiline, yet the former is about 3-fold more potent than the latter in causing increases in $[Ca^{2+}]_i$ in parathyroid cells. Like fendiline, NPS 467 is a racemic mixture. Resolution of NPS 467 into its enantiomers provides an isomer of even greater potency than the racemic mixture, i.e., NPS R-467 (see Example 17).

Further structure-activity studies on molecules related to R-fendiline, NPS 467, meta-methoxyfendiline and NPS 568 yielded pure isomers with greater potency than these molecules in their racemic forms. For example, the greater potency of NPS R-568 compared to NPS S-568 is shown in FIG. 28b using different cells lines transfected with nucleic acid encoding a human parathyroid calcium receptor (pHuPCaR4.0)

Results obtained with fendiline (NPS 456, FIG. 33) show that it elicits oscillatory increases in Cl^- current at concentrations of 100 μM . The results obtained in this expression system with neomycin and fendiline demonstrate that these molecules act directly on the calcium receptor but not on control cells. NPS R-568 has subsequently been shown to be a potent molecule active on *Xenopus* oocytes expressing the parathyroid cell calcium receptor.

Results of testing some of the compounds shown in FIG. 36 are provided in Tables 7 and 8. The measured EC_{50} values were determined by assaying for increases in intracellular calcium using fura-2 loaded cells (see also Example 11 and Table 6).

6,011,068

79

TABLE 7

Examples of Arylalkylamine Compounds with In Vitro EC ₅₀ Values Greater than 5 μ M at the Parathyroid Cell Calcium Receptor	
Compound Name or Code (from FIG. 36)	EC ₅₀ (μ M)
Fendiline (racemic)	15
R-Fendiline	9
S-Fendiline	>15
NPS S-467	>30
NPS S-568	30
1A	166
1B	776
1C	126
1D	48
1E	123
1S	128
2A	120
7Y	>30
7Z (R-)	>30
7Z (S-)	>100
8Y	>30
20K	>30
20V	>100

TABLE 8

Arylalkylamine Calcimimetics from FIG. 36 Active at the Parathyroid Cell Calcium Receptor In Vitro (EC ₅₀ \leq 5 μ M)			
Compound Code (from FIG. 36)	EC ₅₀ (μ M)	Compound Code (from FIG. 36)	EC ₅₀ (μ M)
NPS R-467	2.0	11D	1.8
NPS R-568	0.60	11X	0.83
3U	0.64	11Y	2.8
3V	1.8	12L	1.7
4A	1.4	12U	1.2
4B	2.0	12V	0.42
4C	2.0	12W	3.2
4D	4.4	12Y	2.0
4G	1.8	13Q	ca. 0.8
4H	>3.0	13R	0.25
4J	2.2	13S	<0.13
4M	2.1	13U	0.19
4N	0.8	13X	<0.75
4P	1.6	14L	0.26
4R/6V	4.2	14Q	0.47
4S	3.3	14U	0.13
4T/4U	1.6	14V	1.7
4V	2.5	14Y	0.38
4W	2.3	15G	ca. 0.5
4Y	1.3	16Q	0.04
4Z/5A	4.4	16R	0.36
5B/5C	2.8	16T	0.04
5W/5Y	3.6	16V	<0.13
6E	2.7	16W	0.59
6F(R,R-)	0.83	16X	0.10
6R	3.4	17M	0.15
6T	2.9	17O	0.04
6X	2.5	17P	0.04
7W	3.2	17R	0.39
7X	1.1	17W	0.43
8D	2.5	17X	0.02
8J	0.78	20F	<1.0
8K	1.3	20I	>1.0
8R	2.6	20J	>3.0
8S	1.7	20R	2.4
8T	1.8	20S	4.2
8U	0.44	21D	3.0
8X	0.76	21F	0.38
8Z	0.40	21G	1.1
9C	0.60	21O	0.26
9D	1.4	21P	0.43
9R	0.25	21Q	1.4

80

TABLE 8-continued

Arylalkylamine Calcimimetics from FIG. 36 Active at the Parathyroid Cell Calcium Receptor In Vitro (EC ₅₀ \leq 5 μ M)			
Compound Code (from FIG. 36)	EC ₅₀ (μ M)	Compound Code (from FIG. 36)	EC ₅₀ (μ M)
9S	4.8	21R	0.37
10F	0.89		

Example 13

Osteoclast Calcium Receptor Lead Molecules

The strategy used for elucidating the mechanism of action of extracellular Ca²⁺ on the osteoclast was similar to that proven effective in parathyroid cells. The first experiments examined the effects of La³⁺ on [Ca²⁺]_i in single rat osteoclasts loaded with the fluorimetric indicator indo-1. As described above, trivalent cations like La³⁺ are impermeant and block Ca²⁺ influx. Low micromolar concentrations of La³⁺ partially depressed extracellular Ca²⁺-induced increases in [Ca²⁺]_i (FIG. 29). The demonstration of a La³⁺-resistant increase in [Ca²⁺]_i provides evidence for the mobilization of intracellular Ca²⁺. The results of these experiments parallel those obtained in parathyroid cells and suggest that similar mechanisms are used by extracellular Ca²⁺ to regulate [Ca²⁺]_i in both cell types.

Another series of experiments showed that extracellular Mn²⁺ evoked transient increases in [Ca²⁺]_i (FIG. 30(b)) that persisted in the absence of extracellular Ca²⁺ (FIG. 30(a)). These results are likewise indicative of the mobilization of intracellular Ca²⁺. Although Mn²⁺ can enter some cells, it is unlikely to do so in the osteoclast because Mn²⁺ quenches the fluorescence of indo-1. Thus, if Mn²⁺ penetrated the cell, a decrease, not an increase in the fluorescent signal would be observed.

The results obtained with a variety of di- and trivalent cations are all consistent with the presence of a calcium receptor on the surface of the osteoclast that is coupled to the mobilization of intracellular Ca²⁺ and influx of extracellular Ca²⁺ through voltage-insensitive channels. Results show evidence for genetic material in human osteoclasts that encodes a calcium receptor protein (see below). Transient increases in [Ca²⁺]_i resulting from the mobilization of intracellular Ca²⁺, are sufficient to inhibit osteoclastic bone resorption in vitro. Thus, as with the parathyroid cell, activation of the calcium receptor appears to be a viable means of inhibiting the activity of osteoclasts.

Prenylamine was examined for its ability to inhibit bone resorption in vitro. This was done by morphometric analysis of pit formation on thin slices of bovine cortical bone using scanning electron microscopy. Rat osteoclasts were incubated for 24 hours in slices of bone in the presence or absence of various concentrations of prenylamine. Prenylamine caused a concentration-dependent inhibition of bone resorption with an IC₅₀ of 10 μ M. The anticipated results provide the first demonstration that molecules acting at this novel site can inhibit osteoclastic bone resorption. More potent analogues of prenylamine will be generated using synthetic chemistry and will be tested and assayed using the methods described herein.

Example 14

C-Cell Calcium Receptor Lead Molecules

Activation of the C-cell calcium receptor stimulates the secretion of calcitonin which then acts on osteoclasts to inhibit bone resorption. Calcimimetic drugs selectively affecting C-cells are useful in the treatment of osteoporosis.

6,011,068

81

The mobilization of intracellular Ca^{2+} is used as a functional index of calcium receptor activity. The screening effort in C-cells is facilitated by the availability of cultured cell lines expressing the C-cell phenotype (e.g., rat medullary thyroid carcinoma cells; rMTC 6-23 cells). Selected for initial study were three naturally occurring arylalkyl polyamines, agatoxin 489, agatoxin 505, and NPS 019. Agatoxin 505 was found to block extracellular Ca^{2+} -induced increases in $[\text{Ca}^{2+}]_i$ with an IC_{50} of 3 μM . The inhibitory effect resulted from a block of the L-type voltage-sensitive Ca^{2+} channel present in these cells. In contrast, agatoxin 489 was found to mobilize intracellular Ca^{2+} in rMTC cells with an EC_{50} of 150 μM . This was the first organic molecule discovered that was found to activate the C-cell calcium receptor. NPS 019 was even more potent and mobilized intracellular Ca^{2+} with an EC_{50} of 5 μM (FIG. 32).

It is significant that the only structural difference between NPS 019 and agatoxin 489 is the presence or absence of an hydroxyl group. The fact that such subtle differences in structure affect profoundly the potency of molecules indicates a structurally specific binding site on the calcium receptor. This, in turn, encourages the view that very potent and selective activators of calcium receptors can be developed.

NPS 019, which is a small molecule (MW<500), is a lead molecule for the development of calcimimetics of the C-cell calcium receptor and can be tested for its ability to stimulate calcitonin secretion in vitro. Subsequent in vivo testing will then determine the ability of this molecule to stimulate calcitonin secretion and inhibit bone resorption. These in vivo studies will be performed in rats. The results obtained in these studies, which are anticipated to be positive, will provide the first evidence showing that a small organic molecule acting on a novel receptor can stimulate calcitonin secretion and depress bone resorption.

Example 15

Calcilytic Activity of NPS 021 on Parathyroid Cells

For a compound to be considered a calcilytic, it must block the effects of extracellular Ca^{2+} or a calcimimetic compound on an extracellular Ca^{2+} -sensing cell. An example of a calcilytic compound is NPS 021, the structure of which is provided in FIG. 1a. In bovine parathyroid cells loaded with fura-2, NPS 021 blocks increases in $[\text{Ca}^{2+}]_i$ elicited by extracellular Ca^{2+} . The IC_{50} of NPS 021 for blocking this response is about 200 μM and, at concentrations around 500 μM , the increase in $[\text{Ca}^{2+}]_i$ evoked by extracellular Ca^{2+} is abolished. Significantly, NPS 021 does not by itself cause any change in $[\text{Ca}^{2+}]_i$, when tested at low $[\text{Ca}^{2+}]_o$ (0.5 mM; FIG. 37). Ga^{3+} is also calcilytic to *Xenopus* oocytes expressing the cloned calcium receptor: Ga^{3+} by itself has no effect on the Cl^- currents activated by Gd^{3+} , a calcimimetic, but pretreatment with Ga^{3+} blocks the action of Gd^{3+} .

Example 16

NPS 467 Lowers Serum Ionized Calcium

Compounds shown to activate the bovine parathyroid cell calcium receptor in vitro were tested for hypocalcemic activity in vivo. Male Sprague-Dawley rats (200 g) were maintained on a low calcium diet for one week prior to receiving test substance or vehicle as control. Blood was collected from the tail vein three hours after the intraperitoneal administration of NPS 467. Ionized Ca^{2+} in whole blood or serum was measured with a Ciba-Corning 634 Analyzer according to the instructions provided with the instrument. Serum total calcium, albumin and phosphate were measured by techniques well known in the art.

82

NPS 467 caused a dose-dependent reduction in serum or whole blood Ca^{2+} (FIG. 38). The fall in blood Ca^{2+} at this time was paralleled by a proportional fall in the levels of blood total calcium. There was no change in serum albumin or phosphate levels at any of the doses examined. In preliminary studies, NPS 467, at doses effective in lowering blood Ca^{2+} , caused a dose-dependent reduction in circulating levels of PTH (FIG. 39). The hypocalcemic effect of NPS 467 was maximal within three hours and returned toward control levels after 24 hours (FIG. 40).

NPS R-467 (see Example 17) was also effective in lowering serum ionized Ca^{2+} in rats maintained on a normal, calcium-replete diet. A single dose of NPS R-467 (10 mg/kg i.p.) caused a rapid fall in serum levels of ionized Ca^{2+} which were maximal by 1 hour (22% decrease from the control level) and remained depressed at or near this level for up to 6 hours.

Example 17

NPS 467 Lowers Serum Ionized Calcium in a Stereospecific Manner

NPS 467 is a racemic mixture. Resolution of NPS 467 into its two enantiomers was achieved by means of chiral HPLC. The R-isomer was about 100-fold more potent than the S-isomer in activating the bovine parathyroid cell calcium receptor in vitro as assessed by the ability of the enantiomers to evoke increases in $[\text{Ca}^{2+}]_i$ in parathyroid cells (FIG. 41). Likewise, similar resolution of the novel compound NPS 568 into its enantiomers showed that the R-isomer was 40-fold more potent than the S-isomer in causing the mobilization of intracellular Ca^{2+} in bovine parathyroid cells (see Table 6, supra).

The isomers of NPS 467 were examined for effects on serum Ca^{2+} as in Example 16. Consistent with the in vitro results, the R-isomer of NPS 467 proved to be more potent than the S-isomer in lowering serum Ca^{2+} in vivo (FIG. 42; each compound was tested at a concentration of 5 mg/kg body weight).

Example 18

NPS R-467 Lowers Serum Ionized Calcium in an In Vivo Model of Secondary Hyperparathyroidism

An accepted and widely used animal model of secondary hyperparathyroidism arising from chronic renal failure is the 5/6 nephrectomized rat. Animals receiving such surgery become initially hypocalcemic and, to maintain serum Ca^{2+} levels, there is a compensatory hyperplasia of the parathyroid glands and elevated levels of circulating PTH. Male Sprague-Dawley rats (250 g) received a 5/6 nephrectomy and were allowed to recover for 2 weeks. At this time they were normocalcemic (due to elevated levels of serum PTH). The administration of NPS R-467 (10 mg/kg i.p.) caused a rapid (within 2 hours) fall in serum ionized Ca^{2+} levels to 83% of controls in an animal model of secondary hyperparathyroidism. This suggests that compounds of this sort will effectively depress PTH secretion in patients with secondary hyperparathyroidism and hyperplastic parathyroid glands.

Example 19

NPS R-467 Fails to Lower Serum Ionized Calcium Levels in Parathyroidectomized Animals

To determine the primary target tissue upon which NPS R-467 acts to cause a hypocalcemic response, the parathyroid glands in rats were surgically removed. Animals receiving a total parathyroidectomy become hypocalcemic and are largely dependent upon dietary calcium to maintain serum Ca^{2+} homeostasis. Parathyroidectomized animals had serum ionized Ca^{2+} levels of 0.92 mM which fell gradually to 0.76

6,011,068

83

mM after 6 hours of fasting. The administration of a single dose of NPS R-467 (10 mg/kg i.p.) did not cause any change in serum ionized Ca^{2+} levels over a period of 6 hours. These results demonstrate that intact parathyroid glands are required for the hypocalcemic effects of NPS R-467. The data additionally demonstrate that NPS R-467 can target the parathyroid glands *in vivo*. The results are consistent with the view that NPS R-467 acts on the parathyroid cell calcium receptor *in vivo* to depress secretion of PTH and thereby cause serum levels of ionized Ca^{2+} to fall.

Example 20

NPS R-467 and NPS S-467 Increase Intracellular Calcium in Human Parathyroid Glands

Dissociated parathyroid cells were prepared from a parathyroid adenoma obtained by surgery from a patient with primary hyperparathyroidism. The cells were loaded with fura-2 and $[\text{Ca}^{2+}]_i$ measured as described above. Both NPS R-467 and NPS R-568 caused concentration-dependent increases in $[\text{Ca}^{2+}]_i$. The EC_{50} 's for NPS R-467 and NPS R-568 were 20 and 3 μM , respectively. Both of these compounds are thus able to increase $[\text{Ca}^{2+}]_i$ in pathological human tissue and would thus be expected to decrease serum levels of PTH and Ca^{2+} in patients with primary hyperparathyroidism.

Example 21

Mechanism of Action of NPS R-467 at the Parathyroid Cell Calcium Receptor

Dissociated bovine parathyroid cells were used to further explore the mechanism of action of NPS R-467 at the receptor level. In the presence of 0.5 mM extracellular Ca^{2+} , NPS R-467 caused a rapid and transient increase in $[\text{Ca}^{2+}]_i$, which persisted in the presence of 1 μM La^{3+} and was partially depressed by pretreatment with PMA (100 nM for 2 minutes). Moreover, 30 μM of NPS R-467 caused a rapid increase in Cl^- current in *Xenopus* oocytes injected with parathyroid cell mRNA. These results are consistent with an action of NPS R-467 on the calcium receptor. However, the cytosolic Ca^{2+} response to NPS R-467 was abolished when parathyroid cells were suspended in Ca^{2+} -free buffer. This suggests that NPS R-467 cannot, by itself, cause the mobilization of intracellular Ca^{2+} . It does, however, elicit responses in parathyroid cells and in oocytes when a small amount of extracellular Ca^{2+} is present. This suggests that partial occupancy of the Ca^{2+} -binding site is required for NPS R-467 to elicit a response.

To test this hypothesis, parathyroid cells were suspended in Ca^{2+} -free buffer and exposed to a submaximal concentration of neomycin. Neomycin was used because it mimics, in nearly all respects, the effects of extracellular Ca^{2+} on parathyroid cells and on *Xenopus* oocytes expressing the parathyroid cell calcium receptor. The addition of 10 μM neomycin did not by itself cause an increase in $[\text{Ca}^{2+}]_i$, under these conditions. However, the subsequent addition of NPS R-467 (30 μM , now elicited a transient increase in $[\text{Ca}^{2+}]_i$, which, because there was no extracellular Ca^{2+} present, must have come from the mobilization of intracellular Ca^{2+} .

When cells bathed in Ca^{2+} -free buffer were exposed to 30 μM NPS R-467, there was no increase in $[\text{Ca}^{2+}]_i$. This concentration of NPS R-467 is maximally effective in increasing $[\text{Ca}^{2+}]_i$ when extracellular Ca^{2+} (0.5 mM) is present. However, the subsequent addition of 10 μM neomycin now evoked a transient increase in $[\text{Ca}^{2+}]_i$. Presumably, neomycin binds to the same site as extracellular Ca^{2+} and can functionally substitute for it. Using a submaximal concentration, which by itself causes no response, achieves partial occupancy of the Ca^{2+} -binding site and allows activation of the calcium receptor by NPS R-467.

84

Additional studies to further define the mechanism of action of NPS R-467 were performed. The cells were once again suspended in Ca^{2+} -free buffer to insure that any observed increase in $[\text{Ca}^{2+}]_i$ resulted from the mobilization of intracellular Ca^{2+} . In these experiments, however, a maximally effective concentration (100 μM) of neomycin was used. In the absence of extracellular Ca^{2+} , 100 μM neomycin evoked a rapid and transient increase in $[\text{Ca}^{2+}]_i$. The subsequent addition of 30 μM NPS R-467 did not cause an increase in $[\text{Ca}^{2+}]_i$.

In the converse experiment, 30 μM NPS R-467 was added before 100 μM neomycin. As expected, NPS R-467 did not cause any increase in $[\text{Ca}^{2+}]_i$. It did not, however, affect the increase in $[\text{Ca}^{2+}]_i$ evoked by the subsequent addition of 100 μM neomycin. These results, obtained with maximally effective concentrations of NPS R-467 and neomycin, suggest that these two compounds do not act at the same site. Rather, the results can be sufficiently explained by postulating two separate sites on the calcium receptor, one to which extracellular Ca^{2+} and neomycin bind, and another to which NPS R-467 and structurally related compounds (such as NPS R-568) bind.

Ligand binding to the former site can result in full activation of the calcium receptor whereas ligand binding to the latter site can only occur and/or be functionally relevant when the extracellular Ca^{2+} -binding site is occupied to some as yet undefined degree. It is possible that ligand binding to the extracellular Ca^{2+} -binding site exposes a previously occluded binding site for NPS R-467. It appears that the NPS R-467-binding site is an allosteric site that augments receptor activation in response to ligand binding at the extracellular Ca^{2+} binding site.

The data demonstrate that the parathyroid cell calcium receptor possesses at least two distinct sites for organic ligands. One site binds the physiological ligand, extracellular Ca^{2+} , and certain organic polycations like neomycin. Binding to this site results in full activation of the calcium receptor, an increase in $[\text{Ca}^{2+}]_i$, and the inhibition of PTH secretion. NPS R-467 and NPS R-568 define a previously unrecognized binding site on the calcium receptor. Binding to this site can only occur and/or results in full activation of the calcium receptor when the extracellular Ca^{2+} -binding site is partially occupied. Ligands acting at either site are effective in suppressing serum Ca^{2+} levels *in vivo*.

Allosteric Site on Parathyroid Cell Calcium Receptor

Calcimimetic compounds that activate the bovine parathyroid cell calcium receptor, such as NPS R-467 and NPS R-568, do not cause the mobilization of intracellular Ca^{2+} in the absence of extracellular Ca^{2+} . Rather, they increase the sensitivity of the calcium receptor to activation by extracellular Ca^{2+} , thus causing a shift to the left in the concentration-response curve for extracellular Ca^{2+} . Because of this, it is unlikely that they act at the same site on the receptor as does extracellular Ca^{2+} . In contrast, organic and inorganic polycations do cause the mobilization of intracellular Ca^{2+} in the absence of extracellular Ca^{2+} and therefore probably act at the same site as does extracellular Ca^{2+} . Compounds like NPS P-568, presumably act in an allosteric manner and their activity is dependent on some minimal level of extracellular Ca^{2+} . This suggests that partial occupancy of the extracellular Ca^{2+} -binding site on the receptor is required for compounds like NPS R-568 to be effective. This model is consistent with the observations described in Example 21.

Other details of the mechanism of action of NPS R-568 on the parathyroid cell calcium receptor, however, are more accurately investigated by binding studies in which the

6,011,068

85

specific binding of radiolabeled (using ^3H for example) NPS R-568 is assessed. There are several molecular mechanisms that could explain the activity of NPS R-568 on the parathyroid cell calcium receptor. In one mechanism (model 1), NPS R-568 could bind to the calcium receptor at a site that, when occupied, is not sufficient to activate the receptor functionally. Activation only occurs when some level of occupancy of the extracellular Ca^{2+} -binding site(s) is achieved. In an alternative mechanism (model 2), the occupation of the extracellular Ca^{2+} -binding site could unmask latent binding sites for compounds such as NPS R-568. Occupancy of this latent site by NPS R-568 then increases the affinity and/or efficacy of binding at the extracellular Ca^{2+} site. Either mechanism involves a form of allosteric activation of the calcium receptor by compounds such as NPS R-568. These are not the only possible mechanisms that could explain the effect of compounds like NPS R-568 on the parathyroid cell calcium receptor. Other mechanisms of action may be suggested by the results of the binding studies described below.

To further investigate the mechanism of action of compounds like NPS R-568 on the parathyroid cell calcium receptor, binding studies using ^3H -NPS R-568 can be performed. The specific binding of ^3H -NPS R-568 to intact parathyroid cells or to membranes prepared from parathyroid cells is initially investigated by techniques well known in the art. The kinetic parameters of binding will then be measured as a function of extracellular Ca^{2+} concentrations. Specifically, Scatchard analysis of the data will reveal the number of binding sites and the apparent affinity of the receptor site for ^3H -NPS R-568. These parameters will then be investigated as a function of changes in the level of extracellular Ca^{2+} in the buffer used for the assay. If model 1 is correct, then a significant level of specific binding should occur in the absence of extracellular Ca^{2+} . Large changes in the kinetic parameters of binding as a function of the level of extracellular Ca^{2+} would favor model 2. It is expected that various other inorganic and organic polycations described above in other examples will cause similar changes in the binding parameters of ^3H -NPS R-568 as does extracellular Ca^{2+} . This would support the view that these polycations act at the extracellular Ca^{2+} -binding site, which is distinct from that to which compounds like NPS R-568 bind.

Example 22

Synthesis and Chiral Resolution of NPS 467

This example describes a protocol used to synthesis NPS 467 and its resolution into individual enantiomers. In a 250-ml round-bottom flask, 10.0 g (100 mmoles) 3'-methoxyacetophenone and 13.5 g (100 mmoles) 3-phenylpropylamine were mixed and treated with 125 mmoles (35.5 g) titanium(IV) isopropoxide. The reaction mixture was stirred 30 minutes at room temperature under a nitrogen atmosphere. After this time 6.3 g (100 mmoles) sodium cyanoborohydride in 100 ml ethanol was added dropwise over the course of 2 minutes. The reaction was stirred at room temperature under nitrogen for 16 hours. After this time the reaction mixture was transferred to a 2-L separatory funnel with 1.5 L of diethyl ether and 0.5 L of water. The phases were equilibrated and the ether layer removed. The remaining aqueous phase was thoroughly extracted with four 1-L portions of diethylether. The washes were combined, dried over anhydrous potassium carbonate and reduced to a clear, light amber oil.

TLC analysis of this material on silica gel using chloroform-methanol-isopropylamine (100:5:1) showed product at R_f 0.65 with traces of the two starting materials

86

at R_f 0.99 (3'-methoxy acetophenone) and R_f 0.0 (3-phenylpropylamine).

The reaction mixture was chromatographed through silica gel (48x4.6 cm) using a gradient of chloroform-methanol-isopropylamine (99:1:0.1) to (90:10:0.1) which yielded 13.66 g of purified NPS 467. This material was dissolved in hexane-isopropanol (99:1) containing 0.1% diethylamine to yield a solution with a concentration of 50 mg/ml. Chiral resolution was accomplished by chromatography of 4 ml of this solution (200 mg, maximum to achieve separation) through ChiralCel OD (25x2 cm) using 0.7% isopropanol, 0.07% diethylamine in hexane at 10 ml/min, monitoring optical density at 260 nm.

Under these conditions (with injections of 100 mg material) the early-eluting isomer (NPS R-467; (R)-(+)-N-(3-phenylpropyl)- α -methyl-3-methoxybenzylamine) began to emerge from the column at about 26 minutes, the late-eluting isomer (NPS S-467) began to emerge at about 34 minutes. Baseline resolution was accomplished under these conditions. Each optical isomer (free base) was converted to the corresponding hydrochloride salt by dissolving 3 g of the free base in 100 ml ethanol and treating it with 100 ml water containing 10 molar equivalents HCl. Lyophilization of these solutions yielded white solids.

Example 23

Synthesis of NPS R-568

NPS R-568, (R)-(+)-N-[3-(2-chlorophenyl)propyl]- α -methyl-3-methoxybenzylamine, was synthesized using the methods described in Example 22 substituting an equivalent amount of 3-(2-chlorophenyl)propylamine for 3-phenylpropylamine. It was found that allowing the mixture of 3'-methoxyacetophenone, 3-(2-chlorophenyl)propylamine and titanium(IV) isopropoxide to stir for 5 hours prior to treatment with $\text{NaCNBH}_3/\text{EtOH}$ resulted in significantly greater yield (98%).

Example 24

NPS R-467 Lowers Serum Ionized Calcium When Administered Orally

Rats (male, Sprague-Dawley, 250-300 g) were fed standard rat chow and fasted overnight prior to the experiment. NPS R-467 was suspended in corn oil and administered as a single oral dose through a gavage needle. Three hours later a sample of blood was taken from the tail vein and assessed for ionized Ca^{2+} levels. FIG. 44 shows that NPS R-467 caused a dose-dependent reduction in serum levels of ionized Ca^{2+} when administered orally.

Example 25

BoPCaR 1 Cloning Method

This example describes the cloning of a bovine parathyroid calcium receptor using an expression cloning strategy. The expression cloning strategy involved assaying the ability of nucleic acid to express a polypeptide which activates Cl^- currents in *Xenopus laevis* oocytes. *X. laevis* oocytes were chosen as hosts, to express nucleic acid encoding the bovine parathyroid calcium receptor, based on the following factors: (i) they exhibit a high level of maturity (i.e., Stage V, VI); (ii) they exhibit a high activity of Cl^- currents activated by Ca^{2+} ionophores like A23187; and (iii) they exhibit a high level of functional expression of Gd^{3+} -induced Cl^- current when injected with 25 ng/oocyte of total poly(A)⁺-mRNA isolated from bovine parathyroid.

The techniques used to clone the parathyroid calcium receptor are briefly described in this example; a more complete description of the techniques is provided in preceding sections, which describe techniques which may be

6,011,068

87

used to clone additional forms of the Ca^{2+} -receptor from other cell types. Poly(A⁺)-enriched mRNA was initially prepared from bovine parathyroid glands by extracting with guanidinium thiocyanate, centrifugation through CsCl and oligo(dT) cellulose chromatography. Injection of the resultant poly(A⁺)-enriched mRNA into oocytes (25–50 ng/oocyte) conferred sensitivity to elevated extracellular concentrations of Ca^{2+} and the trivalent cation (1–100 μM) Gd^{3+} as described herein, such that the two cations elicited calcium-activated chloride currents. No such currents were elicited in control eggs injected with water.

The mRNA was then subjected to size fractionation, utilizing preparative, continuous flow agarose gel electrophoresis (Hediger, M. A., *Anal. Biochem.* 159: 280–286 (1986)) to obtain fractions of poly(A⁺)-mRNA further enriched in transcripts coding for the Ca^{2+} receptor. Oocytes injected with size-fractionated mRNA of about 4–5.5 Kb showed enhanced expression of Gd^{3+} -activated Cl^- currents.

Size-fractionated mRNA of about 4–5.5 Kb in size were used to prepare a size-selected, directional cDNA library in the plasmid pSPORT1 that was enriched in full-length transcripts. Sense complementary RNA (cRNA) was then synthesized from the DNA inserts pooled from 350–500 independent clones from this library and injected into oocytes. Gd^{3+} -activated Cl^- currents were observed following injection of RNA from a single filter containing 350 colonies. Preparation and injection of cRNA from successively smaller pools of clones led to isolation of a single clone (BoPCaR 1) with a cDNA insert of 5.3 kb which expressed greatly enhanced Ca^{2+} -receptor activity following injection of its cRNA into oocytes. A plasmid containing the BoPCaR 1 cDNA (See restriction map, FIG. 45; plasmid, FIG. 46; and nucleotide sequence (SEQ. ID. NO. 1), FIG. 47) has been deposited in the ATCC under deposit number 75416.

The BoPCaR 1 cDNA is outside the size range of the size-selected RNA found to express neomycin elicited Cl^- channel activity in *Xenopus* oocytes. This is consistent with the possibilities that different isoforms of the calcium receptor exist or that multiple genes encode other members of the calcium receptor gene family.

Several pharmacological and biochemical criteria were used to identify this clone as encoding a bona fide bovine parathyroid Ca^{2+} receptor. Oocytes expressing the cloned receptor, but not water-injected oocytes, responded to increasing concentrations of extracellular Ca^{2+} (1.5–5 mM) or Gd^{3+} (20–600 μM) with large increases in Cl^- currents (up to at least 1.8 microamperes) that were several-fold larger than those observed in poly(A⁺)-injected oocytes. These responses increased markedly over a period of one to four days after injection of the eggs with cRNA prepared from the BoPCaR 1 cDNA. Furthermore, the ranges of the concentrations of the two cations eliciting this response were very similar to those shown previously to act on bovine parathyroid cells in vitro. Neomycin (20–100 μM), which is known to closely mimic the effects of Ca^{2+} on parathyroid cells, produced changes in Cl^- current in oocytes essentially identical to those produced by Ca^{2+} or Gd^{3+} , and these occurred over the same range of concentrations over which this antibiotic modulates parathyroid function in vitro.

Finally, in vitro translation of RNA prepared from the clone resulted in a single major protein on polyacrylamide gels with a molecular weight of about 120 kd, whose synthesis was enhanced by inclusion of dog pancreatic microsomes, concomitant with an increase in apparent molecular weight of 10–15%. The latter suggests that the cloned receptor interacts strongly with membranes, as might

88

be expected of an integral membrane protein receptor, and is glycosylated in its native form. Studies with the lectin concanavalin A indicate that the Ca^{2+} receptor is likely a glycoprotein. Thus, the pharmacological properties of the cloned receptor, which is expressed at high levels in oocytes, as well as the biochemical studies carried out to date are completely consistent with its identity as the bovine parathyroid Ca^{2+} receptor.

Oocytes injected with cRNA (50 nl of 0.125 $\mu\text{g}/\text{ml}$) prepared from BoPCaR1 show large inward currents in response to elevated extracellular concentrations of Ca^{2+} (5 mM), Mg^{2+} (10–20 mM), Gd^{3+} (600 μM), or neomycin (200 μM), resulting from activation of the Ca^{2+} -activated chloride currents. These responses are mediated by the following series of biochemical events:

- (1) Activation of phospholipase C by a pertussis toxin-sensitive guanine nucleotide regulatory (G) protein resulting in 4–7 fold increases in the levels of inositol 1,4,5-triphosphate (IP_3). Preincubation with 10 $\mu\text{g}/\text{ml}$ of pertussis toxin for 48 hours inhibits the increase by 75%;
- (2) Release of Ca^{2+} from intracellular stores. The several-fold increase in the $[\text{Ca}^{2+}]_i$ measured in oocytes loaded with the Ca^{2+} -sensitive fluorescent dye, fluo-3, persists even when the oocytes are exposed to Gd^{3+} or neomycin in the absence of extracellular Ca^{2+} . Furthermore, the inward currents elicited by Gd^{3+} or neomycin also persist despite removal of extracellular Ca^{2+} .
- (3) The polyvalent cation-induced increases in $[\text{Ca}^{2+}]_i$ are necessary for the associated electrophysiological responses. The Ca^{2+} chelator, EGTA (100 μM), prevents oocytes expressing the calcium receptor from responding with inward currents to 600 μM Gd^{3+} .
- (4) The activated currents appear to be Ca^{2+} -activated chloride currents. The currents are activated by the divalent cation ionophore, A23187, which raises $[\text{Ca}^{2+}]_i$. The chloride channel-blocker 9AC blocks the currents.

Example 26

Use of NPS R-568, and Other Compounds, as a Diagnostic Tool

NPS R-568 or other compounds active on a calcium receptor can be used as a diagnostic tool. Specifically, a pharmaceutical preparation of such compounds is useful as a diagnostic tool. In one example, a pharmaceutical preparation containing a parathyroid cell calcimimetic compound such as NPS R-568 can be given by oral or another route of administration to hypercalcemic patients with symptoms of mental depression. If these symptoms arise from an underlying hyperparathyroid state, such as primary hyperparathyroidism, then administration of NPS R-568 or a compound that acts similarly will alleviate those symptoms. If the symptoms do not abate, then the mental depression results from some pathological state that is not hyperparathyroidism. Thus, parathyroid cell calcimimetic compounds can be used in the differential diagnosis of mental depression.

Symptoms and signs common to hyperparathyroidism and other disorders can also be differentially diagnosed in the manner described above. Such shared signs and symptoms include, but are not limited to, hypertension, muscular weakness, and a general feeling of malaise. Alleviation of these symptoms following treatment with a parathyroid cell calcium receptor calcimimetic compound would indicate that the problems result from the underlying hyperparathyroidism.

6,011,068

89

In another example, a compound acting as an antagonist (calcilytic) at the C-cell calcium receptor can be administered as described above to diagnose medullary thyroid carcinoma. In this case, administration of the C-cell calcium receptor calcilytic compound will depress serum levels of calcitonin which can be readily measured by radioimmunoassay. Certain symptoms associated with medullary thyroid carcinoma, such as diarrhea, may also be monitored to determine if they are abated or lessened following administration of the calcilytic compound.

In a third example, a compound acting as a calcimimetic at the juxtaglomerular cell calcium receptor can be used in the differential diagnosis of hypertension. In this case, administration of the juxtaglomerular cell calcium receptor calcimimetic compound can be carried out as described above. A decrease in blood pressure to normal levels will occur if the hypertension results mostly or exclusively from elevated levels of renin rather than from an alternative pathological state.

In another example, a compound acting as a specific calcimimetic on the osteoclast calcium receptor can be used in the differential diagnosis of high- and low-turnover forms of osteoporosis. In this case, such a compound can be administered in a suitable pharmaceutical preparation and the levels of serum alkaline phosphatase, osteocalcin, pyridinoline and/or deoxypyridinoline crosslinks, and/or some other predictive marker of bone resorption and/or formation measured by techniques well known in the art. A large decrease in one or more of these parameters would be predictive of high-turnover osteoporosis, whereas a small or no decrease in these parameters would be predictive of low-turnover osteoporosis. Such information would dictate the appropriate treatment. Antiresorptive drugs would not be the appropriate sole therapy for low-turnover osteoporosis.

These examples are not exhaustive but serve to illustrate that specific calcium receptors can be targeted with pharmaceutical preparations and that the observed effects of such preparations on bodily functions and/or chemical constituents can be used diagnostically. In general, calcimimetic and calcilytic compounds that act on calcium receptors of the various cells described above can be used in the diagnosis of the various diseases associated with the particular cell type. These diseases include, but are not limited to, bone and mineral-related disorders (as described in Coe and Favus, *Disorders of Bone and Mineral Metabolism*, Raven Press, 1990), kidney diseases, endocrine diseases, cancer, cardiovascular diseases, neurological diseases, gastrointestinal diseases, and diseases associated with gestation. Examples of human diseases or disorders in which such molecules may be therapeutically effective are as follows:

- (1) A calcimimetic is expected to ameliorate psoriasis by reducing the proliferation of the abnormal skin cells.
- (2) Since Ca^{2+} blocks the effect of vasopressin on MTAL and cortical collecting duct cells, a calcimimetic is expected to reduce water retention in states of vasopressin excess, such as the syndrome of inappropriate vasopressin (ADH) secretion. Conversely, calcium receptor antagonists used in states of ADH deficiency are expected to potentiate the action of any ADH present, such as in partial central diabetes insipidus.
- (3) Calcimimetics may be used to treat hypertension by:
 - (a) reducing renin secretion and/or
 - (b) by stimulating production of vasodilators such as PTHrP (PTH-related peptide) by vascular smooth muscle.
- (4) Calcimimetics are expected to increase platelet aggregability, which may be useful when platelet counts are low. Conversely, calcilytics are expected to inhibit platelet function in states where there is hypercoagulability.

90

- (5) Calcium promotes differentiation of colon and mammary cells. A calcimimetic is expected to reduce the risk of colon or breast cancer.
- (6) Calcium promotes urinary calcium excretion in the MTAL. A calcimimetic is expected to have a useful hypocalcemic action in the therapy of hypercalcemic disorders. The inhibitory effect of calcimimetics on osteoclasts and their stimulation of the secretion of the hypocalcemic peptide calcitonin make them expected to be useful in the therapy of hypercalcemia and its symptoms. A calcimimetic may also improve hypocalcemic symptoms by activating calcium receptors. Conversely, a calcilytic is expected to reduce urinary calcium excretion and be useful in the treatment of kidney stones. In addition, calcium suppresses the formation of 1,25-dihydroxyvitamin D in the proximal renal tubule, and this vitamin D metabolite is frequently overproduced in renal stone patients and contributes to their hypercalciuria. Suppression of 1,25-dihydroxyvitamin D formation by a calcimimetic is expected to be useful in treating renal calcium stone disease.
- (7) Endogenous amines could reproduce the symptoms in uremic patients by calcimimetic or calcilytic actions. Calcimimetic and/or calcilytic agents are expected to improve these symptoms.
- (8) Some of the renal toxicity of aminoglycoside antibiotics may be mediated by interaction of these drugs with renal calcium receptors. Having the calcium receptor is expected to make it possible to carry out drug screening easily when designing new drugs of these classes to minimize renal toxicity. In addition, a renal calcium receptor antagonist would prevent or treat this renal toxicity if it is related to this mechanism.
- (9) Some of the genetic components of calcium-related disorders, such as osteoporosis, renal stones, and hypertension are expected to be related to inherited problems with certain forms of the receptor. These now can be studied and genetic screening/testing carried out using receptor-based reagents. The human disease, familial hypocalciuric hypercalcemia, may be due to a calcium receptor defect. Definitive diagnostic separation from cases of primary hyperparathyroidism could be carried out with receptor-based technology.
- (10) Calcium receptors are present in the placenta and are expected to impact on disorders of placental function and transfer of nutrients to the growing fetus.

Example 27

Cloning of Human Parathyroid Calcium Receptor From a Human Parathyroid Gland Adenoma Tumor

This example describes the cloning of a human parathyroid calcium receptor from a human parathyroid gland adenoma tumor using pBoPCaR1 as a hybridization probe. The probe was used to identify nucleic acid encoding human parathyroid gland calcium receptor by cross-hybridization at reduced stringency.

Messenger RNA was prepared from a human parathyroid gland adenoma tumor removed from a 39-year-old Caucasian male diagnosed with primary hyperparathyroidism. Northern blot analysis of this mRNA using pBoPCaR1 as a hybridization probe identified calcium receptor transcripts of about 5 Kb and about 4 Kb. A cDNA library was constructed from the mRNA. Double-stranded cDNA larger than 3 Kbp were size-selected on an agarose gel and ligated into the cloning vector lambda ZapII. Five hundred thousand primary recombinant phage were screened with the 5.2 Kbp

6,011,068

91

cDNA insert of pBoPCaR1 as a hybridization probe. The pBoPCaR1 insert was labeled by random-primed synthesis using [³²P]-dCTP to a specific activity of 1×10⁹ cpm/μg.

Library screening was performed at a hybridization stringency of 400 mM Na⁺, 50% formamide at a temperature of 38° C. Plaque lift filters were hybridized at a probe concentration of 500,000 cpm/ml for 20 hours. Following hybridization, filters were washed in 1×SSC at 40° C. for 1 hr.

The primary screen identified about 250 positive clones identified by hybridization to pBoPCaR1. Seven of these clones were taken through secondary and tertiary screens to isolate single clones that hybridized to the pBoPCaR1 probe. These seven clones were analyzed by restriction enzyme mapping and Southern blot analysis. Three of the clones contained cDNA inserts of about 5 Kbp and appear to be full-length clones corresponding to the 5 Kb mRNA. Two of the clones contain cDNA inserts of about 4 Kbp and appear to be full-length clones corresponding to the 4 Kb mRNA.

Restriction enzyme mapping of the two different sized inserts indicate that they share regions of sequence similarity in their 5' ends, but diverge in their 3' end sequences. DNA sequence analyses indicate that the smaller insert may result from alternative polyadenylation upstream of the polyadenylation site used in the larger insert.

Representative cDNA inserts for both size classes were subcloned into the plasmid vector pBluescript SK. Linearization followed by in vitro transcription using T7 RNA polymerase produced cRNA transcripts. The cRNA transcripts were injected into *Xenopus* oocytes (150 ng/μl RNA; 50 nl/oocyte) for functional analysis. Following incubation periods of 2-4 days, the oocytes were assayed for the presence of functional calcium receptors. Both clone types gave rise to functional calcium receptors as assessed by the stimulation of calcium-activated chloride currents upon addition of appropriate calcium receptor agonists. Known calcium receptor agonists, including NPS R-467 and NPS R-568, activated the oocyte-expressed receptor at about the same concentrations known to be effective for the native parathyroid cell receptor. Thus, both clones encode a functional, human parathyroid cell calcium receptor.

Plasmids were prepared by subcloning each size class of insert into pBluescript thereby producing pHuPCaR 5.2 and pHuCaR 4.0. The nucleic acid sequence, and amino acid sequence, of the inserts are shown in FIGS. 48 (pHuPCaR 5.2, SEQ. ID. NO. 2) and 49 (pHuPCaR 4.0, SEQ. ID. NO. 3).

Several differences were observed between the nucleic acid sequences of the two cDNA inserts. Sequence analyses of the two cDNA inserts indicate the existence of at least two sequence variants differing in the 3' untranslated region and which may result from alternative polyadenylation (see SEQ. ID. NOs. 2 and 3). In addition, sequence variation exists at the 5' end of the inserts (see SEQ. ID. NOs. 2 and 3). These distinct sequences correspond to untranslated regions and may have arisen due to alternative transcriptional initiation and/or splicing.

Three additional sites of sequence variation are observed within the coding regions of cDNA clones pHuPCaR4.0 and pHuPCaR5.2 (see SEQ. ID. NOs. 2 and 3) demonstrating that these cDNA clones encode distinct proteins. Sequence analysis of the human CaR gene (obtained from overlapping clones as described in Example 29) indicates that the additional 30 base pairs of DNA in cDNA clone pHuPCaR5.2, as compared to the pHuPCaR 4.0 cDNA clone, results from alternative mRNA splicing. The alternative mRNA splicing is predicted to insert 10 additional amino acids into the CaR

92

polypeptide encoded by the pHuPCaR5.2 cDNA at a site between aa#536 and aa#537 in polypeptide encoded by pHuPCaR4.0 cDNA. In addition, pHuPCaR4.0 encodes glutamine (Gln) at aa#925 and glycine (Gly) at position 990 whereas pHuPCaR5.2 encodes arg (Arg) at both equivalent positions. The human CaR gene encodes for Gln and Arg, respectively, at these positions. The difference between the pHuPCaR4.0 cDNA compared to human DNA appears to represent a true sequence polymorphism within the human population while the single base change in pHuPCaR5.2 probably reflects a mutation which occurred during its cloning. Both cDNAs encode functional calcium receptors as demonstrated by the ability of *Xenopus* oocytes injected with cRNA prepared from these cDNA clones to respond to 10 mM extracellular calcium as ascertained by Cl⁻ conductance. However, it is possible that these two receptor isoforms are functionally and/or pharmacologically distinct.

Example 28

Cloning a Calcium Receptor From Normal Human Parathyroid Tissue

This example describes the cloning of a calcium receptor from normal human parathyroid tissue. Experimental evidence has shown that parathyroid cells from adenomatous tissue are less responsive to increases in extracellular calcium (they have an elevated calcium "set-point"). It has been postulated that this change may arise from an alteration of the calcium receptor itself. One of the uses of the cloned receptor found in normal parathyroid tissue is to compare its primary nucleic acid sequence with that of the calcium receptor found in adenomatous tissue to determine if there are any differences in the nucleic acid sequences. Such differences may account for the alteration in the calcium receptor and may be used to further characterize regions of the calcium receptor associated with responsiveness to calcium.

Parathyroid glands (150 mg) were removed at autopsy from a 69-year-old Caucasian female with no history of parathyroid disease. Messenger RNA was prepared from this tissue and used in the construction of a cDNA library. cDNA inserts from this library were not size-selected. Six-hundred-thousand primary recombinants were screened with probe made from the 5.2 Kbp cDNA insert from the human calcium receptor clone, pHuPCaR-5.2. Hybridization was carried out at 42° C. and filters were washed at a stringency of 1×SSC, at 52° C. The primary screen identified about 30 positive clones, twelve of which were isolated and characterized. Partial sequence analysis indicated that these clones are essentially identical to cDNA sequences obtained from adenomatous parathyroid (see Example 27).

Example 29

Isolation of Human Genomic Clones With Homology to the Calcium Receptor

Human calcium receptor genomic clones were isolated using the pBoPCaR1 cDNA insert as a hybridization probe. In particular, a human genomic DNA library, obtained from Stratagene, was screened using the pBoPCaR1 cDNA insert as hybridization probe.

A portion of the library (500,000 clones) was screened with the pBoPCaR1 cDNA insert by hybridizing in 400 mM Na⁺, 50% formamide, at 37° C., and washing with 1×SSC at 40° C. Twenty-four clones were identified. The nucleic acid from these clones were analyzed by restriction mapping and Southern blot analysis using distinct regions of the pHuPCaR-5.2 cDNA insert as hybridization probes. Nine of the 13 clones encoded portions of the human parathyroid calcium receptor gene as evinced by hybridization to

6,011,068

93

pHuPCaR-5.2 cDNA. The complete gene is represented on overlapping clones pHuCaR-#4, #5, #6, #7 and #9. DNA sequence analysis of these clones indicates that the receptor is encoded by seven coding exons. The majority of the receptor mRNA (3' end) appears to be encoded by a single exon. The receptor encoded by these genomic clones is essentially identical to those encoded by cDNA clones pHuPCaR4.0 and pHuPCaR5.2 (Seq. ID. Nos. 2 and 3) (see Example 27, supra, which describes the differences between the human nucleic acid sequence obtained from overlapping clones pHuCaR-#4, #5, #6, #7 and #9, pHuPCaR4.0 and pHuPCaR5.2). Equivalent clones can be isolated as described herein, as can other clones encoding members of this receptor family.

Example 30

Cloning Ion Receptors From the Kidney

This example describes the cloning of ion receptors from rat kidney cells using pBoPCaR1 as a hybridization probe. A cDNA library was prepared from rat kidney outer medulla mRNA size-fractionated to contain transcripts between 3 and 7 Kb. About seventy-five-thousand clones were screened using pBoPCaR1 as a hybridization probe at 42° C. overnight followed by washing in 0.5×SSCP at 42° C. Three positive clones were identified.

Clone 3A (pRakCaR 3A) contained an insert of about 4.0 Kbp. The nucleic acid and amino acid sequence of the 3A insert is shown in FIG. 50 (SEQ. ID. NO. 8). Northern analysis indicated that pRakCaR 3A hybridized to both 7.5 Kb and 4.0 Kb transcripts. DNA sequence analysis of clone 3A (SEQ. ID. No. 4) indicates that it is highly homologous to other calcium receptor sequences. *Xenopus* oocyte analysis of in vitro transcripts of the clone confirmed that clone pRakCaR 3A encodes a functional calcium receptor.

Example 31

Cloning of C-cell Calcium Receptor

This example describes the cloning of human thyroid C-cell calcium receptor using pHuPCaR 5.2 as a hybridization probe. Functional evidence indicates that the calcitonin-secreting C-cells of the thyroid gland express a calcium receptor. Pharmacological evidence indicates that this receptor is functionally distinct from the parathyroid calcium receptor. Northern blot analysis of human, bovine and rat thyroid gland mRNA identifies a faintly hybridizing transcript when pHuPCaR-5.2 is used as hybridization probe. The diminished intensity of the identified transcript may be due either to low abundance (C-cells represent 0.01% to 1% of thyroid cells) or may indicate structural differences between parathyroid and C-cell calcium receptors.

Northern blot analysis of a rat C-cell line (44-2) using a rat calcium receptor genomic clone as hybridization probe identifies a single, moderately abundant transcript about 8.0 Kb. This is similar to the size of the rat parathyroid calcium receptor transcript and provides evidence that C-cells express a calcium receptor. DNA sequence analysis of products from polymerase chain reaction amplification of selected regions of the rat C-Cell calcium receptor showed it to be essentially identical to the calcium receptor encoded by the rat kidney cDNA clone of Example 30 (FIG. 50).

A human C-cell calcium receptor was cloned from a thyroid cDNA library obtained from Clonotech. The library was prepared from tissue obtained at autopsy from normal Caucasian males (trauma victims; no history of thyroid disease). About five-hundred-thousand recombinant phage were screened at a stringency of 400 mM Na⁺, 50% formamide at a temperature of 40° C., and filters were washed at 1×SSC, 42° C. Four cDNA clones hybridizing with

94

pHuPCaR-5.2 were obtained. Insert sizes ranged from 0.8 to 2 Kbp. Initial sequence analysis indicates that this calcium receptor sequence is highly homologous to the human parathyroid calcium receptor. Equivalent clones can be readily isolated as described herein.

Example 32

Cloning Inorganic ion Receptors by Use of Degenerate Sequence PCR

Analysis of the calcium receptor sequences (bovine and human) by sequence database comparison indicates that the calcium receptor sequence is unique. No significant homology is obvious to any known protein or nucleic acid sequence with one exception. The parathyroid calcium receptor exhibits weak, but significant homology (20-30% amino acid identity) with the metabotropic glutamate receptors (mGluRs). This surprising and unexpected result indicates that calcium receptors are structurally related to mGluRs and probably evolved from a common ancestral gene several hundred million years ago. However, calcium receptors are functionally distinct from mGluRs and in experiments on bovine parathyroid cells, or on *Xenopus* oocytes ectopically expressing calcium receptors, did not respond to the mGluR agonists glutamate, trans-ACPD and quisqualate.

The discovery of the calcium receptor sequence makes it possible to determine regions of extremely high sequence conservation. Such regions are useful for guiding the preparation of hybridization and PCR probes which can be used to detect and isolate cDNA and genomic sequences encoding additional inorganic ion receptors.

Analysis of the amino acid sequences of calcium receptors and mGluRs indicates that the homology is highest in several limited regions including portions of both N-terminal putative extracellular domains and the seven-transmembrane domain regions. Based on the later, four degenerate oligonucleotides have been synthesized for use in PCR. These are:

TM2:

CCTGCTCGAGACIA(A,G)(C,T)CGGGA(A,G)CT(C,T)T(C,G)CTA(C,T)(C,A)T;

TM5:

CGGAATCCGTTTCGGG(A,T)(C,T)TTGAA(C,G)GC(A,G)(A,T)A(G,C);

CL1:

CCTGCTCGAGTCAAGGCTACG(A,G)(A,G)I(C,A)G(G,A,C,T)GA(G,A); and

CL3:

CGGAATCCAITTGGCTTCGTTGAAI(T,G)T(A,G,C,T)(G,T).

These oligonucleotides contain restriction sites within "PCR anchors" at their 5' ends to facilitate subcloning amplification products. The sequences were selected based on conservation of sequences within transmembrane domains 2 and 5 and cytoplasmic loops 1 and 3.

Four different primer combinations can be used to obtain ion receptor clones: TM2+TM5, TM2+CL3, CL1+TM5, and CL1+CL3. PCR reactions were carried out using standard conditions (see, e.g., Abe et al. *J. Biol. Chem.*, 19:13361 (1992)) using annealing temperatures between 37° C. and 55° C. Each combination gave rise to products approximately 500 bp when used to amplify cDNAs or genomic DNAs containing ion receptors and/or mGluRs. Libraries of such PCR products have been prepared after amplification of such sequences from cDNAs prepared from a variety of tissues, and from genomic DNA. Analysis of the products resulted in the detection of parathyroid calcium receptor

6,011,068

95

sequences, 5 of 7 known mGluR sequences and additional sequences which are being characterized. The additional new sequences may encode other inorganic ion receptors.

This example, like the other examples described herein, is not meant to be limiting. Various other highly conserved sequence regions can be identified and utilized in a similar fashion. Such advances are made possible by the discovery of the parathyroid calcium receptor sequence, as will be recognized by those of ordinary skill in the art. The cloning of such PCR products enables the isolation of complete genomic clones and of full-length cDNA clones from the tissue sources identified by, for example, Northern analysis using the cloned PCR product. As additional members of the inorganic ion receptor family are discovered and their sequences determined, refinement of this approach will be possible. Thus, the invention herein enables the discovery of more and more members of the ion receptor superfamily via an iterative process.

Example 33

Antibodies Against Calcium Receptors

Cloned human and bovine calcium receptors can be used to produce antibodies which recognize various regions of the receptor including extracellular domains, cytoplasmic domains, extracellular loops and cytoplasmic loops. Recombinant expression of three regions of the N-terminal extracellular domain has been achieved. In particular, GST fusion products have been produced containing amino acids 9-258 and 259-334, respectively, of the bovine parathyroid calcium receptor and amino acids 340-620 from the human parathyroid calcium receptor. These fusion products were isolated by preparative SDS-PAGE and injected into rabbits resulting in polyclonal antibodies against the putative extracellular domain.

In addition, the following synthetic peptides have been produced by Multiple Peptide Systems, Inc:

SEQ. ID. NO. 9: YKDQDLKSRPESVEC,
 SEQ. ID. NO. 10: ADDDYGRPGIEKFREAEERDIC,
 SEQ. ID. NO. 11: CIDFSELISQYSDEEKIQQ,
 SEQ. ID. NO. 12: YHNGFAKEFWETFNFC,
 SEQ. ID. NO. 13: DGEYSDETDASAC,
 SEQ. ID. NO. 14: NTPIVKATNRELSYC,
 SEQ. ID. NO. 15: YRNHELEDEIIFITC, and
 SEQ. ID. NO. 16: RKLPEFNFAKVC.

These amino acid sequence are based upon regions of the bovine parathyroid calcium receptor.

These peptides were conjugated to KLH and injected into rabbits to produce polyclonal antibodies or injected into mice to produce monoclonal antibodies. Such antibodies are capable of recognizing specific regions of the bovine parathyroid calcium receptor and most would be expected to recognize calcium receptors from other species including human calcium receptors. Highly acidic peptides (e.g., SEQ. ID. NOS. 9-12 and 15), derived from acid-rich regions of the calcium receptor may be involved in binding to calcium ion. It is expected, therefore, that such antibodies will be capable, alone or in combination, of neutralizing the calcium receptor by preventing the binding or action of calcium.

Example 34

Recombinant Expression of Parathyroid Calcium Receptors in Vertebrate Cells

Recombinant expression of calcium receptors in vertebrate cells can be achieved by inserting cDNA encoding these receptors into appropriate expression vectors. To assess the best cell line for functional expression, the fol-

96

lowing seven plasmid vectors were constructed using bovine and human cDNAs encoding parathyroid calcium receptors:

- (1) The plasmid pSV-BoPCaR was constructed by subcloning the 5.3 Kbp XbaI-SalI fragment from the bovine parathyroid calcium receptor cDNA into XbaI-XhoI cut pSVL. The expression vector pSVL was purchased from Pharmacia. The vector pSVL contains the SV40 late promoter and VP1 processing signals, and is designed to give high levels of expression in a variety of cell lines.
- (2) The plasmid CMV-BoPCaR was constructed by subcloning the 5.3 Kbp XbaI-SalI fragment from bovine parathyroid calcium receptor into XbaI-XhoI cut pcDNAI/Amp. The vector pcDNAI/Amp was purchased from Invitrogen. This vector utilizes the promoter/enhancer sequences from the immediate early gene of the human cytomegalovirus to drive high-level expression in a variety of cell lines.
- (3) The plasmid -471 SportsCaRB, having 471 bp of noncoding sequence removed from the 5' end of BoPCaR cDNA, was constructed by subcloning a 4.8 Kbp blunt-ended SmaI-XbaI fragment of BPOCaR cDNA into SmaI cut pSV-SPORT. The vector pSV-SPORT was purchased from Gibco-BRL. This vector utilizes the SV40 early promoter to drive transient expression in a variety of cell lines.
- (4) The plasmid CMVHuPCaR4.0 was constructed by subcloning the HindIII-NotI 4.0 Kbp fragment from human calcium receptor cDNA into HindIII-NotI cut pcDNAI/Amp.
- (5) The plasmid CMVHuPCaR5.2 was constructed by subcloning the HindIII-NotI 5.2 Kbp fragment from human calcium receptor cDNA into HindIII-NotI cut pcDNAI/Amp.
- (6) The plasmid pSV-HuPCaR4.0 was constructed by subcloning the SalI-NotI 4.0 Kbp fragment from human calcium receptor cDNA into SalI-NotI cut pcDNAI/Amp.
- (7) The plasmid pSV-HuPCaR5.2 was constructed by subcloning the SalI-NotI 5.2 Kbp fragment from human calcium receptor cDNA into SalI-NotI cut pcDNAI/Amp.

The above expression vectors were first validated for correct construction by *in vitro* transcription and injection into *Xenopus* oocytes. All were found to elicit expression of functional calcium receptors.

Next, these vectors were transfected into a variety of vertebrate cells including: COS7, CHO, DHFR-CHO, HEK293, JEG, Rat2 fibroblasts, MDBK, CV1, UMR, AtT20, Y1, OK, LLC-PK1. Several different transfection techniques were used including calcium phosphate precipitation, DEAE-dextran, electroporation and lipofection. All the transfected cell lines gave rise to substantial levels of calcium receptor transcript.

Functional calcium receptor expression was assessed by loading cells with fura-2 and measuring changes in intracellular calcium levels after addition of calcium receptor agonists. Control constructs were prepared by cloning the substance K receptor and the M1 muscarinic receptor cDNAs into similar commercial vectors as described above. Control constructs were transfected into the various cell lines described above, and the response of the cells containing the control constructs to substance K or to carbachol, respectively, was measured. Classical responses (i.e., a rapid and transient increase in internal calcium followed by a lower, sustained increase in internal calcium) were generally

6,011,068

97

observed for cells containing control receptor constructs when treated with the ligand appropriate for the receptor being expressed, but not when treated with an inappropriate ligand. Neither control responded to increases in extracellular calcium. Similarly, HEK293, CHO and JEG-3 cells transfected with the calcium receptor constructs did not respond to substance K or to carbachol. However, a weak, but significant, response was observed in these cells only when extracellular calcium was increased from 1 mM to 10 mM.

Example 35

Selection of Stable Recombinant Cells Expressing the Calcium Receptor

Clonal cell lines that stably express the two human and the bovine calcium receptors have been isolated. Calcium receptor cDNAs were subcloned in two different, commercially available expression vectors; pMSG (obtained from Pharmacia) and Cep4B (obtained from Invitrogen). The first vector contains the selectable marker gene for xanthine-guanine phosphoribosyltransferase (*gpt*) allowing stably transfected cells to overcome the blockade of the purine biosynthetic pathway imposed by addition of 2 $\mu\text{g/ml}$ aminopterin and 25 $\mu\text{g/ml}$ mycophenolic acid. The second vector encodes a gene conferring resistance to the antibiotic hygromycin (used at 200 $\mu\text{g/ml}$). HuPCaR 5.2 and HuPCaR 4.0 cDNAs (SEQ. ID. NOs. 2 and 3, respectively) were removed from the parent bluescript plasmid with Not I and Hind III restriction enzymes and then either ligated directly into Not I+Hind III digested Cep4B or treated with the klenow fragment of DNA polymerase prior to blunt-end ligation into Sma I digested pMSG.

The pMSG subclone containing the HuPCaR 5.2 insert was transfected into CHO cells as discussed above. Selection has resulted in 20 resistant clones which are being characterized. The Cep4B subclone containing the HuPCaR 5.2 insert was transfected into HEK293 cells as described above. Selection with hygromycin resulted in a pool of stable clones. Clones expressing the HuPCaR 4.0 receptor isoform were prepared similarly.

Cells obtained from the pool of hygromycin selected HEK293 cells transfected with Cep4B containing the HuPCaR 5.2 insert were plated on collagen coated Aklar squares which had been placed into individual wells of 12-well tissue culture plates. Two to six days later, medium was removed and the cells washed with balanced salt solution and 1 ml of buffer containing 1 μM fura2-AM, 1 mM CaCl_2 and 0.1% BSA and 1 mM CaCl_2 . Measurements of fluorescence in response to calcium receptor agonists were performed at 37° C. in a spectrofluorimeter using excitation and emission wavelengths of 340 and 510 nm, respectively. For signal calibration, F_{max} was determined after addition of ionomycin (40 μM) and the apparent F_{min} was determined by addition of 0.3 M EGTA, 2.5 M Tris-HCl; pH 10. Robust increases in intracellular calcium were observed in response to the addition of the following calcium receptor agonists: Ca^{2+} (10 mM), Mg^{2+} (20 mM) and NPS R-467. Control cells expressing functional substance K receptors did not respond to these calcimimetic compounds.

Additional clonal isolates of HEK 293 cells transfected with pHuPCaR4.0 sequence were obtained. These were tested for responsiveness to calcimimetics as described above except that the cells were tested while in suspension. Similar positive results were obtained (FIG. 28b).

98

Example 36

Activity of NPS R-568 in Xenopus Oocytes Expressing a Bovine Parathyroid Cell Calcium Receptor

Xenopus oocytes were injected with BoPCaR 1, the 5.3 Kb cDNA encoding a bovine parathyroid cell calcium receptor as described in Example 25. After two to three days, Cl^- currents were examined in the oocytes using a two-electrode voltage clamp. In the presence of 0.3 or 1 mM extracellular Ca^{2+} , exposure of BoPCaR 1-injected oocytes to NPS R-568 caused increases in the Cl^- current. The EC_{50} for NPS R-568 in this assay was about 3 μM . NPS R-568 failed to evoke responses in uninjected oocytes or in oocytes injected with water or rat liver mRNA. NPS R-568 elicited responses in BoPCaR 1-injected oocytes only at much higher concentrations (100 μM). The results of these experiments demonstrate that NPS R-568 acts in a stereoselective manner in oocytes expressing a bovine parathyroid cell calcium receptor. The data are consistent with a direct action of NPS R-568 on the calcium receptor.

The Cl^- current response to NPS R-568 in oocytes expressing BoPCaR 1 was abolished in the absence of extracellular Ca^{2+} . Increasing the concentration of extracellular Mg^{2+} to 4 mM (in the absence of extracellular Ca^{2+}) restored responsiveness to NPS R-568. NPS R-568 potentiated the responses to submaximal concentrations of extracellular Ca^{2+} and shifted the extracellular Ca^{2+} concentration-response curve to the left without greatly affecting the maximal response (FIG. 51). These effects obtained in oocytes expressing a parathyroid cell calcium receptor mirror those obtained in intact bovine parathyroid cells and offer compelling evidence for a direct effect of NPS R-568 on a parathyroid cell calcium receptor.

The data are also consistent with NPS R-568 increasing the sensitivity of the receptor through an allosteric mechanism by binding to a domain on the calcium receptor distinct from that which binds extracellular Ca^{2+} . Alternatively, NPS R-568, although binding at the extracellular Ca^{2+} domain, may lack intrinsic efficacy unless the domain is partially occupied by extracellular Ca^{2+} . The more likely hypothesis is the former, in which NPS R-568 acts through an allosteric mechanism to increase the sensitivity of the receptor to activation by extracellular Ca^{2+} .

The failure of NPS R-568 to elicit responses in the absence of extracellular Ca^{2+} demonstrates that partial occupancy of the calcium receptor by extracellular Ca^{2+} is necessary for NPS R-568 to activate the receptor. It is not presently known if NPS R-568 binds to the calcium receptor in the absence of extracellular Ca^{2+} or if binding of extracellular Ca^{2+} to the calcium receptor unmasks a cryptic binding site for NPS R-568. These alternative hypotheses can be readily resolved by direct binding studies using ^3H -NPS R-568 as described above under the heading of "Allosteric Site on Parathyroid Cell Calcium Receptor."

Example 37

Activity of Arylalkyl Polyamines in Xenopus Oocytes Expressing a Bovine Parathyroid Cell Calcium Receptor

Xenopus oocytes were injected with BoPCaR 1 as described in Example 25. After two to three days, Cl^- currents were examined in the oocytes using two electrode voltage clamp. In the presence of 1 mM extracellular Ca^{2+} , exposure of BoPCaR 1-injected oocytes to the arylalkyl polyamine compounds NPS 017 (shown as AGA 489 in FIG. 1f) or NPS 019 caused oscillatory increases in the Cl^- current. Increases in Cl^- current evoked by NPS 019 persisted in the absence of extracellular Ca^{2+} . Neither NPS 017 nor NPS 019 elicited changes in Cl^- current in uninjected oocytes or in oocytes injected with water or rat liver mRNA.

6,011,068

99

The results provide compelling evidence for a direct action of arylalkyl polyamine compounds on a parathyroid cell calcium receptor. In authentic bovine parathyroid cells, arylalkyl polyamine compounds mobilize intracellular Ca^{2+} in the absence of extracellular Ca^{2+} ; they have identical effects in oocytes expressing a bovine parathyroid cell calcium receptor. Also, like the inorganic di- and trivalent cations, the arylalkyl polyamines are positively charged. In the aggregate, the results suggest that the arylalkyl polyamines act at the same site on the calcium receptor as does extracellular Ca^{2+} .

These data also distinguish the action of arylalkyl polyamines like NPS 019 from arylalkylamines like NPS R-568 (see Example 36). These two classes of compounds have different mechanisms of action on the parathyroid cell calcium receptor and probably bind at different domains on the receptor. For example, while arylalkyl polyamines can stimulate the parathyroid calcium receptor in the absence of extracellular Ca^{2+} , NPS R-568 requires the presence of extracellular Ca^{2+} or an appropriate agonist, such as an arylalkyl polyamine, to stimulate the receptor. Arylalkyl polyamines can completely restore responses to NPS R-568 in the absence of extracellular Ca^{2+} . Moreover, NPS R-568 shifts the concentration-response curve of NPS 019 to the left.

Arylalkyl polyamines mimic, in all respects tested, the actions of extracellular divalent cations and are true calcimimetic compounds. Arylalkyl polyamines therefore define a new structural class of calcimimetic compounds that act through a different mechanism than compounds like NPS R-568, probably by binding to a different domain on the calcium receptor. Arylalkyl polyamines can be used as structural templates for drugs useful in the treatment of various bone and mineral-related disorders.

Example 38

Analogues of Arylalkyl Polyamines and Polyamines Useful as Antagonists of Calcium Influx in Parathyroid Cells

Arylalkyl polyamines such as NPS 019 and polyamines such as spermine act as calcimimetics at the parathyroid cell calcium receptor presumably by binding to the extracellular Ca^{2+} -binding domain on the receptor (Examples 2, 6 and 36). Certain structural analogues of the arylalkyl polyamines or polyamines, in which the secondary amines are replaced by methylenes, act as blockers of Ca^{2+} influx in parathyroid cells. NPS 384 and NPS 472 (1,12-diaminododecane, see FIG. 1a) are arylalkyl polyamine and polyamine analogues, respectively, lacking secondary amines. When tested at high micromolar concentrations (100 to 1000 μM), either of these compounds causes a prompt fall in $[\text{Ca}^{2+}]_i$ in bovine parathyroid cells bathed in buffer containing 2 mM CaCl_2 . Pretreatment of parathyroid cells with either of these compounds depresses steady-state, but not transient increases in $[\text{Ca}^{2+}]_i$ elicited by increasing the concentration of extracellular Ca^{2+} . In both these respects, the effects of NPS 384 and NPS 472 are similar to low concentrations of La^{3+} or Gd^{3+} which block Ca^{2+} influx.

Structural analogues of NPS 384 and NPS 472 with greater potency for blocking Ca^{2+} influx in parathyroid cells can be synthesized by modification of the aromatic moiety or alkyl chain. Compounds that block the influx of extracellular Ca^{2+} in parathyroid cells may find therapeutic utility in the treatment of various bone and mineral-related disorders. For example, it is known that the level of extracellular Ca^{2+} can regulate the mRNA levels for PTH. Thus, blocking the influx of extracellular Ca^{2+} may increase mRNA levels for PTH. Such an increase in mRNA transcripts would be expected to increase PTH synthesis, resulting in a larger reserve of PTH

100

for secretion. Calcilytic compounds might therefore cause an augmented release of PTH when administered after a drug that blocks influx of extracellular Ca^{2+} in parathyroid cells.

Example 39

Activity of NPS R-568 and Arylalkyl Polyamines in Xenopus Oocytes Expressing a Human Parathyroid Cell Calcium Receptor

Xenopus oocytes were injected with pHuPCaR 5.2, the 5.2 Kb cDNA encoding a parathyroid cell calcium receptor derived from a human parathyroid cell adenoma. (See Example 27.) After two to three days, Cl^- currents were measured in the oocytes using a two-electrode voltage clamp. In the presence of 0.3 mM extracellular Ca^{2+} , both NPS R-568 or NPS 019 (3 to 30 μM) evoked increases in the Cl^- current indicating activation of the expressed calcium receptor. In the absence of extracellular Ca^{2+} , the response to NPS 019 persisted whereas that to NPS R-568 was abolished. In Xenopus oocytes expressing a human parathyroid cell calcium receptor, NPS R-568 shifted the concentration-response curve to the left without greatly altering the maximal response. Thus, a human parathyroid cell calcium receptor responds to NPS R-568 and to NPS 019 similarly to bovine parathyroid cells.

Example 40

Activity of NPS R-467 and NPS R-568 on C-Cells

C-cells appear to express a calcium receptor that is structurally similar to that present on parathyroid cells (see Example 31). The effects of NPS R-467 and NPS R-568 on $[\text{Ca}^{2+}]_i$ in a rat medullary thyroid carcinoma C-cell line (44-2 cells) were examined. In the presence of extracellular Ca^{2+} (1 mM), either compound evoked a concentration-dependent increase in $[\text{Ca}^{2+}]_i$. Both compounds were less potent on C-cells than bovine parathyroid cells. The EC_{50} 's for NPS R-467 and NPS R-568 were 1.9 and 2.2 μM , respectively. Thus, compounds in this structural series appear to activate the C-cell calcium receptor.

Arylalkyl polyamines likewise elicit increases in $(\text{Ca}^{2+})_i$ in C-cells as they do in parathyroid cells (see Examples 6 and 13). Some arylalkyl polyamines are more potent on C-cells than on parathyroid cells. Thus, compounds structurally related to NPS R-568, but with greater potency on C-cells compared to parathyroid cells, may reside in the compound library illustrated in FIG. 36. Compounds more potent on C-cells than parathyroid cells could be used to selectively increase calcitonin secretion while having little or no effect on PTH secretion.

Example 41

NPS R-568 Increases Calcitonin Secretion In Vivo

Normal adult Sprague-Dawley rats were administered various doses of NPS R-568 p.o. At various times following the administration of NPS R-568, blood samples were withdrawn and measured for PTH, ionized Ca^{2+} , and calcitonin. NPS R-568 caused a rapid, dose-dependent decrease in the plasma levels of PTH and Ca^{2+} and an increase in calcitonin. The ED_{50} values for the depression of PTH and Ca^{2+} and stimulation of calcitonin were 1, 8 and 40 mg/kg p.o. Thus, the oral administration of NPS R-568 suppresses plasma levels of PTH at doses lower than those which increase plasma levels of calcitonin.

In subsequent studies, rats received a thyroidectomy (parathyroid glands intact). This surgical procedure effectively removed the C-cells secreting calcitonin and therefore enabled the relative contributions of PTH and calcitonin to the hypocalcemic effect of this compound to be determined.

6,011,068

101

In thyroidectomized animals, the administration of NPS R-568 (3 to 100 mg/kg p.o.) caused a hypocalcemic response equal in magnitude to that produced in sham-operated animals. The only difference was that the rate of onset of the hypocalcemic response was somewhat delayed in thyroidectomized animals. Thus, the major action of NPS R-568 causing the hypocalcemic response is an inhibition of PTH secretion. Stimulatory effects of this compound on calcitonin secretion increases the rate of onset, but not the extent, of hypocalcemia.

Example 42

Effectiveness of NPS R-568 in Humans

NPS R-568 was studied in a placebo-controlled, single-dose, dose-escalation format in a healthy, post-menopausal woman. A range of single oral doses was used to assess safety, tolerance, and changes in primary hyperparathyroidism markers (e.g., plasma concentrations of parathyroid hormone and ionized serum calcium) and of serum calcitonin. The data are shown in Tables 9-11.

TABLE 9

DOSE	TIME (hours)							
	Serum PTH (pg/ml)							
	0	0.5	1	2	4	8	12	24
Placebo	34	32	32	34	32	36	44	32
20 mg	31	23	18	24	34	34	48	32
240 mg	29	18	6	6	10	27	35	34
400 mg	33	13	9	8	11	20	31	31

TABLE 10

DOSE	TIME (hours)							
	Serum Ionized Calcium (mg/dl)							
	0	0.5	1	2	4	8	12	24
Placebo	1.24	1.23	1.24	1.24	1.25	1.23	1.23	1.23
20 mg	1.26	1.26	1.26	1.26	1.26	1.26	1.23	1.29
240 mg	1.26	1.26	1.25	1.23	1.19	1.16	1.18	1.23
400 mg	1.24	1.26	1.25	1.22	1.19	1.13	1.15	1.22

TABLE 11

DOSE	TIME (hours)							
	Serum Calcitonin (pg/ml)							
	0	0.5	1	2	4	8	12	24
Placebo	3.5	4.0	3.8	4.2	3.9	3.6	3.4	3.4
20 mg	3.2	3.8	3.2	4.5	4.2	3.9	3.2	3.6
240 mg	5.8	4.8	6.5	7.5	6.1	4.7	5.3	8.3
400 mg	3.4	4.0	6.0	7.1	5.2	3.8	3.7	3.0

The data illustrated in Tables 9-11 indicate that NPS R-568 causes a transient dose-dependent decrease in plasma PTH concentration (Table 9), and, at higher doses, a decrease in serum ionized calcium concentration (Table 10) in the human subject. There was no apparent change in serum calcitonin at the doses studied (Table 11). Higher doses are expected to affect calcitonin levels as observed in rats (see Example 41).

102

Examples 43-54

Examples 43 to 54 describing the syntheses of compounds 4L, 8J, 8U, 9R, 11X, 12U, 12V, 12Z, 14U, 17M and 17P, are provided below. Compounds 4L, 8J, 8U, 11X and 17M were prepared from the condensation of a primary amine with an aldehyde or ketone in the presence of titanium(IV) isopropoxide. The resulting intermediate imines were then reduced in situ by the action of sodium cyanoborohydride, sodium borohydride, or sodium triacetoxyborohydride. The intermediate enamine for the synthesis of compound 8U was catalytically reduced using palladium hydroxide.

Compounds 9R, 14U, and 17P were synthesized by reductive amination of a commercially available aldehyde or ketone with a primary amine in the presence of sodium cyanoborohydride or sodium triacetoxyborohydride. It was found for the syntheses of these three compounds (9R, 14U, and 17P) that sodium triacetoxyborohydride afforded the desired diastereomers with greater diastereoselectivity than using sodium cyanoborohydride. The enriched mixtures were further purified to a single diastereomer by normal-phase HPLC or by recrystallization.

Compounds 12U, 12V and 12Z were prepared by a diisobutylaluminum hydride (DIBAL-H)-mediated condensation of an amine with a nitrile. The resulting intermediate imine is reduced in situ by the action of sodium cyanoborohydride or sodium borohydride. The intermediate alkenes (compounds 12U and 12V) were reduced by catalytic hydrogenation in EtOH using palladium on carbon. Compounds which were converted to their corresponding hydrochlorides were done so by treatment of the free base with ethereal HCl to afford white solids.

The starting materials for these syntheses were: (1) purchased from Aldrich Chemical Co., Milwaukee, Wis., (2) purchased from Celgene Corp., Warren, N.J., or (3) prepared synthetically using standard techniques known in the art. All other reagent chemicals were purchased from Aldrich Chemical Co.

Example 43

Synthesis of Compound 4L

N-(3-Phenyl-1-propyl-1-(1-naphthyl) ethylamine

A mixture of 3-phenyl-1-propylamine (135 mg, 1 mmol), 1'-acetonaphthone (170 mg, 1 mmol), and titanium (IV) isopropoxide (355 mg, 1.3 mmol) was stirred at room temperature for 1 hour. The reaction was treated with 1 M ethanolic sodium cyanoborohydride (1 mL) and stirred at room temperature for 16 hours. The reaction was diluted with ether and treated with water (0.1 mL). The reaction was centrifuged and the ether layer removed and concentrated to a milky oil. A small portion of this material (10 mg) was purified by HPLC (Phenomenex, 1.0x25 cm, 5- μ m silica) using a gradient of dichloromethane to 10% methanol in dichloromethane containing 0.1% isopropylamine. This afforded the product (free base) as a single component by GC/EI-MS (R_f =10.48 min) m/z (rel. int.) 289 (M^+ , 11), 274 (63), 184 (5), 162 (5), 155 (100), 141 (18), 115 (8), 91 (45), and 77(5).

Example 44

Synthesis of Compound 8J

N-(3-Phenylpropyl)-1-(3-thiomethylphenyl)ethylamine hydrochloride

3'-Aminoacetophenone (2.7 g, 20 mmol) was dissolved in 4 mL of concentrated HCl, 4 g of ice and 8 mL of water. The solution was cooled to 0° C., and sodium nitrite (1.45 g, 21 mmol) dissolved in 3-5 mL of water was added over 5

6,011,068

103

minutes while maintaining the temperature below 6° C. Sodium thiomethoxide (1.75 g, 25 mmol) was dissolved in 5 mL of water and cooled to 0° C. To this solution was added the diazonium salt over 10 minutes while maintaining the temperature below 10° C. The reaction was stirred for an additional hour while allowing the temperature to rise to ambient. The reaction mixture was partitioned between ether and water. The ether layer was separated and washed with sodium bicarbonate and sodium chloride, and dried over sodium sulfate. The ether was evaporated to give a 74% yield of 3'-thiomethylacetophenone. The crude material was purified by distillation at reduced pressure.

3-Phenylpropylamine (0.13 g, 1 mmol), 3'-thiomethylacetophenone (0.17 g, 1 mmol), and titanium (IV) isopropoxide (0.36 g, 1.25 mmol) were mixed together and allowed to stand for 4 hours. Ethanol (1 mL) and sodium cyanoborohydride (0.063 g, 1 mmol) were added and the reaction was stirred overnight. The reaction was worked up by the addition of 4 mL of ether and 200 μ L of water. The mixture was vortexed and then spun in a centrifuge to separate the solids. The ether layer was separated from the precipitate, and the solvent removed in vacuo. The oil was redissolved in dichloromethane and the compound purified by preparative TLC on silica gel eluted with 3% methanol-dichloromethane to yield the title compound as a pure oil: GC/EI-MS (R_f =7.64 min) m/z (rel. int.) 285 (M^+ , 18), 270 (90), 180(17), 151(100), 136(32), 104(17), 91(54), and 77(13).

Example 45

Synthesis of Compound 8U

(R)-(+)-N-3-(2-Methoxyphenyl)-1-propyl-3-methoxy- α -methylbenzylamine hydrochloride

A mixture of (R)-(+)-3-methoxy- α -methylbenzylamine (3.02 g, 20 mmol), 2-methoxycinnamaldehyde (3.24 g, 20 mmol), and titanium (IV) isopropoxide (8.53 g, 30 mmol, 1.5 eq.) was stirred for 2 hours at room temperature and treated with 1 M (20 mL) ethanolic sodium cyanoborohydride. The reaction was stirred overnight (16 hours), diluted with diethyl ether, and treated with water (1.44 mL, 80 mmol, 4 eq.). After mixing for 1 hour, the reaction mixture was centrifuged and the ether layer removed and concentrated to an oil. This material was dissolved in glacial acetic acid, hydrogenated at 60 p.s.i. hydrogen in the presence of palladium hydroxide for 2 hours at room temperature. The catalyst was removed by filtration and the resulting solution concentrated to a thick oil. This material was dissolved in dichloromethane and neutralized with 1 N NaOH. The dichloromethane solution was separated from the aqueous phase, dried over anhydrous potassium carbonate and concentrated to an oil. This material was dissolved in ether and treated with 1 M HCl in diethylether. The resulting precipitate (white solid) was collected, washed with diethyl ether, and air dried. GC/EI-MS (R_f =9.69 min) of this material (free base) showed a single component: m/z (rel. int.) 299 (M^+ , 21), 284 (100), 164 (17), 150 (8), 135 (81), 121 (40), 102 (17), 91 (43), and 77 (18).

Example 46

Synthesis of Compound 9R

(R,R)-N-(1-(2-Naphthyl)ethyl)-1-(1-naphthyl)ethylamine hydrochloride

A mixture of (R)-(+)-1-(1-naphthyl)ethylamine (10.0 g, 58 mmol), 2'-acetonaphthone (9.4 g, 56 mmol), titanium (IV) isopropoxide (20.7 g, 73.0 mmol), and EtOH (abs.) (100 mL) was heated to 60° C. for 3 hours. Sodium cyanoborohydride (NaCNBH_3) (3.67 g, 58.4 mmol) was then added. The reaction mixture was stirred at room temperature for 18

104

hours. Ether (1 L) and H_2O (10 mL) were added to the reaction mixture and the resulting precipitate was removed by centrifugation. The supernatant was evaporated under vacuum and the crude product was recrystallized four times from hot hexane, to provide 1.5 g of pure (98%) diastereomer. The free base was dissolved in hexane, filtered, and then ethereal HCl was added to precipitate the product as a white solid (1.1 g, 6% yield), m.p.: softens 200–240° C. (dec.).

Example 47

Synthesis of Compound 11X

(R)-N-(4-Isopropylbenzyl)-1-(1-naphthyl)ethylamine hydrochloride

A mixture of (R)-(+)-1-(1-naphthyl)ethylamine (1.06 g, 6.2 mmol), 4-isopropylbenzaldehyde (0.92 g, 6.2 mmol), and titanium (IV)-isopropoxide (2.2 g, 7.7 mmol) was heated to 100° C. for 5 min. then allowed to stir at room temperature for 4 hours. Sodium cyanoborohydride (NaCNBH_3) (0.39 g, 6.2 mmol) was then added followed by EtOH (1 mL). The reaction mixture was stirred at room temperature for 18 hours. Ether (100 mL) and H_2O (1 mL) were added to the reaction mixture and the resulting precipitate was then removed by centrifugation. The supernatant was evaporated under vacuum and the crude product was chromatographed on silica gel (50 mm \times 30 cm column) (elution with 1% MeOH/ CHCl_3). The chromatographed material was then dissolved in hexane and ethereal HCl was added to precipitate the product as a white solid (0.67 g, 35% yield); m.p. 257–259° C.

Example 48

Synthesis of Compound 12U

(R)-N-3-(2-Methylphenyl)-1-propyl-3-methoxy- α -methylbenzylamine hydrochloride

A solution of 2-methylcinnamitrile (1.43 g, 10 mmol) in dichloromethane (10 mL) was cooled to 0° C. and treated dropwise (15 minutes) with 1 M diisobutylaluminum hydride (10 mL, dichloromethane). The reaction was stirred at 0° C. for 15 minutes and treated dropwise (15 minutes) with a 1 M solution of (R)-(+)-3-methoxy- α -methylbenzylamine (1.51 g, 10 mmol) in dichloromethane (10 mL). The reaction was stirred for 1 hour at 0° C. and poured into a solution of ethanol (100 mL) containing sodium cyanoborohydride (1 g, 16 mmol). The reaction mixture was stirred 48 hours at room temperature. The reaction was diluted with diethyl ether and neutralized with 1 N NaOH. The diethyl ether layer was removed, dried over anhydrous potassium carbonate and concentrated to an oil. This material was chromatographed through silica using a gradient of dichloromethane to 50% methanol in dichloromethane to afford the unsaturated intermediate, a single component by GC/EI-MS (R_f =10.06 min) m/z (rel. int.) 281 (M^+ , 17), 266 (59), 176 (19), 146 (65), 135 (73), 131 (100), 91 (21), and 77 (13).

The unsaturated intermediate in ethanol was hydrogenated (1 atm H_2) in the presence of palladium on carbon for 16 hours at room temperature. The product from this reaction was converted to the hydrochloride salt by treatment with 1 M HCl in diethyl ether. GC/EI-MS (R_f =9.31 min) of this material (free base) showed a single component: m/z (rel. int.) 283 (M^+ , 21), 268 (100), 164 (12), 148 (8), 135 (85), 121 (12), 105 (49), 91 (23), and 77 (21).

6,011,068

105

Example 49

Synthesis of Compound 12V

(R)-N-3-(3-Methylphenyl)-1-propyl-3-methoxy- α -methylbenzylamine hydrochloride

The compound was prepared following the procedure described in Example 48, but using 2-methylcinnamitrile. The unsaturated intermediate was a single component by GC/EI-MS ($R_t=10.21$ min) m/z (rel. int.) 281 (M^+ , 57), 266 (86), 146 (98), 135 (88), 131 (100), 115 (43), 102 (26), 91 (43), and 77 (18). Reduction of this material and hydrochloride formation using the procedure described in Example 48 afforded the product. GC/EI-MS ($R_t=9.18$ min) of this material (free base) showed a single component; m/z (rel. int.) 283 (M^+ , 19), 268 (100), 164 (11), 148 (8), 135 (76), 121 (16), 105 (45), 91 (23), and 77 (21).

Example 50

Synthesis of Compound 12Z

(R)-N-3-(2-Chlorophenyl)-1-propyl-1-(1-naphthyl)ethylamine hydrochloride

The compound was prepared following the procedures described in Example 48, but using 2-chlorohydrocinnamitrile and (R)-(+)-1-(1-naphthyl)ethylamine on a 10-mmol scale. Chromatography through silica gel using a gradient of dichloromethane to 5% methanol in dichloromethane afforded the product as a single component by silic gel TLC analysis (5% methanol in dichloromethane). The hydrochloride was prepared by treatment with 1 M HCl in diethyl ether.

Example 51

Synthesis of Compound 14U

(R,R)-N-(1-(4-Methoxyphenyl)ethyl)-1-(1-naphthyl)ethylamine hydrochloride

A mixture of (R)-(+)-1-(1-naphthyl)ethylamine (1.1 g, 6.2 mmol), 4'-methoxyacetophenone (0.93 g, 6.2 mmol), titanium (IV) isopropoxide (2.2 g, 7.7 mmol), and EtOH (abs.) (1 mL) was heated to 60° C. for 3 hours. Sodium cyanoborohydride (NaCNBH_3) (0.39 g, 6.2 mmol) was then added, and the reaction mixture was stirred at room temperature for 18 hours. Ether (200 mL) and H_2O (2 mL) were added to the reaction mixture and the resulting precipitate was then removed by centrifugation. The supernatant was evaporated under vacuum and the crude product was chromatographed on silica gel (25 mm \times 25 cm column) (elution with 1% MeOH— CHCl_3). A portion of this material was HPLC chromatographed [Selectosil, 5- μM silica gel; 25 cm \times 10.0 mm (Phenomenex, Torrance, Calif.), 4 mL per minute; UV det. 275 nm; 12% ethyl acetate-88% hexane (elution time, 12.0 min)]. The HPLC purified diastereomer was then dissolved in hexane and ethereal HCl was added to precipitate the product as a white solid (20 mg), m.p. 209–210° C. (dec.).

Example 52

Synthesis of Compound 17M

(R)-N-(3-Chloro-4-methoxybenzyl)-1-(1-naphthyl)ethylamine hydrochloride

A mixture of (R)-(+)-1-(1-naphthyl)ethylamine (6.6 g, 39 mmol), 3'-chloro-4'-methoxybenzaldehyde (6.6 g, 39 mmol), titanium (IV) isopropoxide (13.8 g, 48.8 mmol), and EtOH (abs.) (30 mL) was heated to 80° C. for 30 minutes and then stirred at room temperature for 3 hours. Sodium cyanoborohydride (NaCNBH_3) (2.45 g, 39 mmol) was then added and the reaction mixture was stirred at room temperature for an additional 18 hours. Diethyl ether (100 mL) and H_2O (2 mL) were then added to the reaction mixture and the resulting precipitate was removed by centrifugation. The

106

supernatant was evaporated under vacuum and the crude product was chromatographed on silica gel (50 mm \times 30 cm column) (elution with CH_2Cl_2). The chromatographed material was then dissolved in hexane (500 mL), decolorized with Norit®, filtered (0.2 μM), and then ethereal HCl was added to precipitate the product as a white solid (10.2 g, 56% yield), m.p. 241–242° C. (dec.).

Example 53

Synthesis of Compound 17P

4-Methoxy-3-methylacetophenone [17P Precursor]

A mixture of 4'-hydroxy-3'-methylacetophenone (5.0 g, 33.3 mmol), iodomethane (5.7 g, 40.0 mmol), K_2CO_3 (granular, anhydrous) (23.0 g, 167 mmol), and acetone (250 mL) was refluxed for 3 hours. The reaction mixture was then cooled to room temperature, filtered to remove the inorganic salts, and evaporated under vacuum. The crude product was dissolved in ether (100 mL) and washed with H_2O (2 \times 20 mL). The organic layer was dried (Na_2SO_4) and evaporated to yield 4.5 g, 82.4% yield. The ketone was used in the following reaction without further purification.

(R,R)-N-(1-(4-Methoxy-3-methylphenyl)ethyl)-1-(1-naphthyl)ethylamine hydrochloride [Compound 17P]

A mixture of (R)-(+)-1-(1-naphthyl)ethylamine (4.24 g, 24.8 mmol), 4'-methoxy-3'-methylacetophenone (4.06 g, 24.8 mmol), titanium (IV) isopropoxide (8.8 g, 30.9 mmol), and EtOH (abs.) (1 mL) was heated to 100° C. for 2 hours. Isopropanol (45 mL) was added and the reaction was cooled to 10° C. in an ice bath. Sodium triacetoxyborohydride ($\text{NaHB}(\text{O}_2\text{CCH}_3)_3$, 10.5 g, 49.5 mmol) was then added in portions over 15 minutes. The reaction mixture was then heated to 70° C. for 18 hours. The mixture was cooled to room temperature and poured into ether (400 mL). The suspension was centrifuged, the supernatant was collected and the pellet was washed with ether (400 mL). The combined organic washings were evaporated under vacuum. The residue was dissolved in ether (400 mL) and washed with 1 N NaOH (4 \times 50 mL) and H_2O (2 \times 50 mL). The organic layer was dried (Na_2SO_4), filtered and evaporated under vacuum. EtOH (abs.) was added to the wet residue, which was then dried thoroughly on a rotary evaporator to provide an oil. The mixture was then chromatographed on silica gel (50 mm \times 30 cm) [elution with (1% MeOH-1% isopropylamine- CHCl_3) to give 4.8 g of an oil].

The desired diastereomer was further purified by HPLC chromatography [SUPELCO SIL™ PLC-Si, 18- μM silica gel; 25 cm \times 21.2 mm (Supelco, Inc., Bellefonte, Pa.), 7 mL per minute; UV det. 275 nm; 20% EtOAc-80% hexane (elution time 9.5–11.0 min)]. Injections (800- μL aliquots) of the mixture (100 mg/mL solution in eluent) provided 65 mg of the desired isomer. Multiple HPLC injections provided 1.0 g of purified material. The HPLC-chromatographed material was dissolved in hexane (50 mL) and the hydrochloride salt was precipitated with ethereal HCl. The salt was collected on fritted glass and washed with hexane to provide 1.0 g of a white solid, mp 204–205° C.

Example 54

SYNTHESIS OF COMPOUND 17X

3-Chloro-4-methoxybenzaldehyde

A mixture of 3-chloro-4-hydroxybenzaldehyde (25 g, 160 mmol), iodomethane (27.25 g, 192 mmol), K_2CO_3 (granular, anhydrous) (110.6 g, 800 mmol), and acetone (300 mL) was refluxed for 3 hours. The reaction mixture was then cooled to room temperature. Diethyl ether (500 mL) was added and the mixture was filtered through paper to remove the inorganic solids. The filtrate was evaporated under reduced

6,011,068

107

pressure, dissolved in diethyl ether (800 mL), and washed with 0.1 N NaOH (3x100 mL). The organic layer was dried (Na₂SO₄) and evaporated under vacuum to yield 24 g, 92% yield of crude product. This material was further purified by chromatography on silica gel (50 mmx30 cm) (elution with hexane-EtOAc, 5:1) to give 15.02 g, 56% yield of a white solid; TLC (hexane-EtOAc, 5:1) R_f=0.24; GC R_t=4.75 min; MS (EI) m/z 170(M⁺), 172(M+2).

1-Methyl-(3'-chloro-4'-methoxybenzyl) alcohol

A mixture of 3-chloro-4-methoxybenzaldehyde (13 g, 76.5 mmol), methylmagnesium chloride (52 g, 153 mmol), and THF (300 mL) was refluxed for 3 hours. The reaction mixture was cooled to room temperature. NH₄Cl (satd. solu., 6 mL) was added dropwise followed by diethyl ether (500 mL) and the mixture was filtered through paper to remove the inorganic solids. The filtrate was evaporated under reduced pressure and the resulting solid was dissolved in diethyl ether (300 mL) and washed with water (4x25 mL). The organic layer was dried (Na₂SO₄) and evaporated under vacuum to yield 11.3 g, 80% yield of crude product. This material was further purified by chromatography on silica gel (50 mmx30 cm) (elution with CH₂Cl₂) to yield 11.3 g, 63% yield of an oil; TLC (CH₂Cl₂) R_f=0.25; GC R_t=5.30 min; MS (EI) m/z 186(M⁺), 188(M+2).

3'-Chloro-4'-methoxyacetophenone

A mixture of 1-methyl-(3'-Chloro-4'-methoxybenzyl) alcohol (7.6 g, 41 mmol), pyridinium chlorochromate (PCC) (13.16 g, 61.5 mmol), and CH₂Cl₂ (300 mL) was allowed to stir at room temperature for 2 hours. Diethyl ether (1000 mL) was added and the resulting mixture was placed on a chromatography column of silica gel (50 mmx30 cm) (elution with diethyl ether) to yield 7.3 g, 97% yield of crude solid product. GC analysis of this material showed it to be 99% pure and it was used in the following reaction without further purification. TLC (diethyl ether) R_f=1.0; GC R_t=5.3 min; MS (EI) m/z 184(M+), 184(M+2).

108

(R,R)-N-(1-Ethyl -4' -methoxy-3'-chlorophenyl)-1-(1-naphthylethyl)amine

A mixture of 3'-chloro-4'-methoxyacetophenone (5.3 g, 29 mmol), (R)-(+)-1-(1-naphthyl)ethylamine (4.98 g, 29 mmol), titanium (IV) isopropoxide (10.2 g, 36 mmol), and isopropanol (20 mL) was heated to 100° C. for 3 hours. Sodium triacetoxy-borohydride (NaB(O₂CCH₃)₃; 12.29 g, 58 mmol) was added in portions over 10 minutes. The reaction mixture was heated to reflux for 30 minutes and was then allowed to stir at room temperature for 18 hours. The mixture was then poured into diethyl ether (500 mL); H₂O (2 mL) was added and the suspension was centrifuged to remove the fine precipitate of titanium salts. The supernatant was collected and the pellet was washed with ether (500 mL). The combined organic layers were dried (Na₂SO₄) and evaporated under vacuum to yield 6.81 g, 70% of crude product.

This material was further purified by chromatography on silica gel (50 mmx30 cm) (elution with 3% MeOH-97% CH₂Cl₂) to give 2.01 g of an oil. The diastereomer was further purified by recrystallization. The free base (1.98 g) was converted to its HCl salt with ethereal HCl. This salt was dissolved in hot isopropanol (65 mL) and the solution was filtered through paper. The filtrate was evaporated under vacuum and the resulting solid dissolved in isopropanol (30 mL). After standing at room temperature for 18 hours, the crystalline solid was collected, washed with cold isopropanol (20 mL), and dried to yield 0.87 g, 40% (from free base) of the diastereomerically pure hydrochloride salt: mp 236-237° C. (dec); TLC (MeOH-CH₂Cl₂ [99:1]) R_f=0.25; GC R_t=11.06 min; FTIR (KBr pellet, cm⁻¹) 3433, 2950, 2931, 2853, 2803, 2659, 2608, 2497, 1604, 1595, 1504, 1461, 1444, 1268, 1260, 1067, 1021, 802, 781, 733; MS (EI) m/z 339(M⁺), 341(M+2).

Other embodiments are within the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(iii) NUMBER OF SEQUENCES: 20

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5275 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 515..3769
(C) OTHER INFORMATION:

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```
CGGAAAAAAA AAAAAGTTC CCCACTCTAG TACAGAGAAG GTTGGCAGAG TCGTAAGCCC      60
CCAACCTCTT AAACCTCTCT GCATCTCCAA GGAGAGGAG GGAAGAGGG TTCTTTCCGA      120
CCTGAGGAGC TGGATCTGGG GTCCGAGAAC CCCAAGGTAG CACCGGAAAG AACAGCACAG      180
GAGGCGAGAG CGTGGCCGGT GGCCGGGAGA ACCAGACCCG ACGCGCGGTC CTCGGCGCCG      240
GGGTCCCGGG GACTCAGCTC AGCAGGACTG GGAAGCCGAA AGTACTACAC ACGGTCTCTG      300
```

6,011,068

109

110

-continued

CATGATGTGA CTCTGAAGA CTCAGAGCC ACCCACTTCA CTAGTCTGCA ATGGAGAAGG	360
CAGAAATGGA AAGTCAAACC CCACGGTTCC ATTCTATTAA TTCTGTAGAC ATGTGCCCCC	420
ACTGCAGGGA GTGAGTGCBA CCAAGGGGGA AAGTCTCTCAG GGGCCCCCAG ACCACCAGCG	480
CTTGAGTCCC TCTTCTCTGGA GAGAAAGCAG AACT ATG GCA CTT TAT AGC TGC	532
Met Ala Leu Tyr Ser Cys	
1 5	
TGT TGG ATC CTC TTG GCT TTT TCT ACC TGG TGC ACT TCC GCC TAT GGG	580
Cys Trp Ile Leu Leu Ala Phe Ser Thr Trp Cys Thr Ser Ala Tyr Gly	
10 15 20	
CCT GAC CAG CGA GCC CAA AAG AAA GGG GAC ATT ATC CTC GGG GGG CTC	628
Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile Ile Leu Gly Gly Leu	
25 30 35	
TTT CCT ATT CAT TTT GGG GTT GCA GTG AAA GAT CAG GAT CTA AAG TCG	676
Phe Pro Ile His Phe Gly Val Ala Val Lys Asp Gln Asp Leu Lys Ser	
40 45 50	
AGG CCG GAG TCC GTG GAG TGT ATC AGG TAT AAT TTC CGA GGA TTT CGC	724
Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn Phe Arg Gly Phe Arg	
55 60 65 70	
TGG TTA CAA GCT ATG ATA TTT GCC ATA GAG GAA ATA AAC AGC AGT CCA	772
Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu Ile Asn Ser Ser Pro	
75 80 85	
GCC CTT CTT CCC AAC ATG ACC CTG GGA TAC AGG ATA TTC GAC ACT TGT	820
Ala Leu Leu Pro Asn Met Thr Leu Gly Tyr Arg Ile Phe Asp Thr Cys	
90 95 100	
AAC ACC GTC TCT AAA GCC TTG GAG GCC ACC CTG AGT TTT GTG GCC CAG	868
Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu Ser Phe Val Ala Gln	
105 110 115	
AAC AAA ATT GAC TCT TTG AAC CTT GAT GAG TTC TGC AAC TGC TCA GAG	916
Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe Cys Asn Cys Ser Glu	
120 125 130	
CAC ATC CCC TCT ACC ATC GCA GTG GTG GGA GCT ACT GGC TCG GGC ATC	964
His Ile Pro Ser Thr Ile Ala Val Val Gly Ala Thr Gly Ser Gly Ile	
135 140 145 150	
TCC ACA GCA GTG GCC AAC CTG CTG GGG CTC TTC TAC ATC CCC CAG GTC	1012
Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe Tyr Ile Pro Gln Val	
155 160 165	
AGC TAT GCC TCC TCC AGC AGA CTC CTC AGC AAC AAG AAT CAA TTC AAG	1060
Ser Tyr Ala Ser Ser Ser Arg Leu Leu Ser Asn Lys Asn Gln Phe Lys	
170 175 180	
TCC TTC CTC CGC ACC ATA CCC AAT GAT GAA CAC CAG GCC ACG GCC ATG	1108
Ser Phe Leu Arg Thr Ile Pro Asn Asp Glu His Gln Ala Thr Ala Met	
185 190 195	
GCT GAC ATC ATC GAG TAC TTC CGC TGG AAC TGG GTG GGC ACA ATT GCA	1156
Ala Asp Ile Ile Glu Tyr Phe Arg Trp Asn Trp Val Gly Thr Ile Ala	
200 205 210	
GCT GAC GAT GAC TAT GGC CGG CCA GGG ATC GAG AAG TTT CGA GAG GAA	1204
Ala Asp Asp Asp Tyr Gly Arg Pro Gly Ile Glu Lys Phe Arg Glu Glu	
215 220 225 230	
GCT GAG GAG AGG GAC ATC TGC ATC GAC TTC AGC GAG CTC ATC TCC CAA	1252
Ala Glu Glu Arg Asp Ile Cys Ile Asp Phe Ser Glu Leu Ile Ser Gln	
235 240 245	
TAC TCT GAT GAG GAA AAG ATC CAG CAG GTG GTG GAG GTG ATC CAG AAT	1300
Tyr Ser Asp Glu Glu Lys Ile Gln Gln Val Val Glu Val Ile Gln Asn	
250 255 260	
TCC ACC GCC AAA GTC ATT GTC GTC TTC TCC AGC GGC CCA GAC CTG GAA	1348
Ser Thr Ala Lys Val Ile Val Val Phe Ser Ser Gly Pro Asp Leu Glu	
265 270 275	
CCC CTC ATC AAA GAG ATC GTC CGG CGC AAT ATC ACA GGC AGG ATC TGG	1396

6,011,068

111

112

-continued

Pro	Leu	Ile	Lys	Glu	Ile	Val	Arg	Arg	Asn	Ile	Thr	Gly	Arg	Ile	Trp		
280																	
CTG	GCC	AGC	GAG	GCC	TGG	GCC	AGC	TCT	TCC	CTG	ATT	GCT	ATG	CCC	GAG	1444	
Leu	Ala	Ser	Glu	Ala	Trp	Ala	Ser	Ser	Ser	Leu	Ile	Ala	Met	Pro	Glu		
295					300					305					310		
TAT	TTC	CAT	GTG	GTC	GGA	GCC	ACC	ATT	GGG	TTT	GGT	TTG	AAA	GCT	GGG	1492	
Tyr	Phe	His	Val	Val	Gly	Gly	Thr	Ile	Gly	Phe	Gly	Leu	Lys	Ala	Gly		
					315					320					325		
CAG	ATC	CCA	GGC	TTC	CGG	GAA	TTC	CTG	CAG	AAA	GTC	CAC	CCC	AGG	AAG	1540	
Gln	Ile	Pro	Gly	Phe	Arg	Glu	Phe	Leu	Gln	Lys	Val	His	Pro	Arg	Lys		
			330					335						340			
TCT	GTC	CAC	AAT	GGT	TTT	GCC	AAG	GAG	TPT	TGG	GAA	GAA	ACA	TTT	AAC	1588	
Ser	Val	His	Asn	Gly	Phe	Ala	Lys	Glu	Phe	Trp	Glu	Glu	Thr	Phe	Asn		
			345				350							355			
TGC	CAC	CTG	CAA	GAG	GGT	GCT	AAA	GGC	CCA	TTA	CCG	GTG	GAC	ACC	TTC	1636	
Cys	His	Leu	Gln	Glu	Gly	Ala	Lys	Gly	Pro	Leu	Pro	Val	Asp	Thr	Phe		
			360			365					370						
CTG	AGA	GGT	CAC	GAA	GAA	GGA	GGT	GCC	AGG	TTA	AGC	AAC	AGT	CCC	ACT	1684	
Leu	Arg	Gly	His	Glu	Glu	Gly	Gly	Ala	Arg	Leu	Ser	Asn	Ser	Pro	Thr		
					380					385					390		
GCC	TTC	CGA	CCT	CTG	TGC	ACT	GGG	GAG	GAG	AAC	ATC	AGC	AGT	GTC	GAG	1732	
Ala	Phe	Arg	Pro	Leu	Cys	Thr	Gly	Glu	Glu	Asn	Ile	Ser	Ser	Val	Glu		
				395						400					405		
ACT	CCT	TAC	ATG	GAT	TAT	ACA	CAT	TTA	CGG	ATA	TCC	TAC	AAC	GTC	TAC	1780	
Thr	Pro	Tyr	Met	Asp	Tyr	Thr	His	Leu	Arg	Ile	Ser	Tyr	Asn	Val	Tyr		
			410					415						420			
TTA	GCC	GTC	TAC	TCC	ATT	GCT	CAT	GCC	CTA	CAA	GAT	ATA	TAC	ACC	TGC	1828	
Leu	Ala	Val	Tyr	Ser	Ile	Ala	His	Ala	Leu	Gln	Asp	Ile	Tyr	Thr	Cys		
			425				430							435			
ATA	CCT	GGG	AGA	GGG	CTC	TTC	ACC	AAC	GGT	TCC	TGC	GCA	GAT	ATC	AAG	1876	
Ile	Pro	Gly	Arg	Gly	Leu	Phe	Thr	Asn	Gly	Ser	Cys	Ala	Asp	Ile	Lys		
			440			445					450						
AAG	GTT	GAA	GCT	TGG	CAG	GTC	CTG	AAA	CAC	CTG	CGG	CAC	CTA	AAT	TTT	1924	
Lys	Val	Glu	Ala	Trp	Gln	Val	Leu	Lys	His	Leu	Arg	His	Leu	Asn	Phe		
					460					465					470		
ACC	AGC	AAT	ATG	GGG	GAG	CAA	GTA	ACT	TTC	GAT	GAA	TGT	GGA	GAC	CTG	1972	
Thr	Ser	Asn	Met	Gly	Glu	Gln	Val	Thr	Phe	Asp	Glu	Cys	Gly	Asp	Leu		
				475					480					485			
GCA	GGG	AAC	TAT	TCC	ATC	ATC	AAC	TGG	CAC	CTC	TCC	CCA	GAG	GAC	GGC	2020	
Ala	Gly	Asn	Tyr	Ser	Ile	Ile	Asn	Trp	His	Leu	Ser	Pro	Glu	Asp	Gly		
			490				495							500			
TCC	ATA	GTG	TTT	AAG	GAA	GTT	GGA	TAT	TAC	AAT	GTC	TAT	GCC	AAG	AAA	2068	
Ser	Ile	Val	Phe	Lys	Glu	Val	Gly	Tyr	Tyr	Asn	Val	Tyr	Ala	Lys	Lys		
			505				510							515			
GGA	GAG	AGA	CTC	TTC	ATC	AAT	GAT	GAA	AAA	ATT	CTG	TGG	AGT	GGA	TTC	2116	
Gly	Glu	Arg	Leu	Phe	Ile	Asn	Asp	Glu	Lys	Ile	Leu	Trp	Ser	Gly	Phe		
			520			525					530						
TCA	AGG	GAG	GTG	CCT	TTC	TCC	AAC	TGC	AGT	CGA	GAC	TGC	CTG	GCA	GGG	2164	
Ser	Arg	Glu	Val	Pro	Phe	Ser	Asn	Cys	Ser	Arg	Asp	Cys	Leu	Ala	Gly		
					540					545					550		
ACC	AGG	AAA	GGA	ATC	ATT	GAG	GGG	GAG	CCC	ACC	TGC	TGC	TTT	GAG	TGT	2212	
Thr	Arg	Lys	Gly	Ile	Ile	Glu	Gly	Glu	Pro	Thr	Cys	Cys	Phe	Glu	Cys		
				555					560					565			
GTG	GAA	TGT	CCT	GAT	GGG	GAG	TAC	AGC	GAC	GAG	ACA	GAT	GCA	AGT	GCC	2260	
Val	Glu	Cys	Pro	Asp	Gly	Glu	Tyr	Ser	Asp	Glu	Thr	Asp	Ala	Ser	Ala		
			570					575						580			
TGT	GAT	AAG	TGC	CCT	GAT	GAC	TTC	TGG	TCC	AAT	GAG	AAC	CAC	ACT	TCC	2308	
Cys	Asp	Lys	Cys	Pro	Asp	Asp	Phe	Trp	Ser	Asn	Glu	Asn	His	Thr	Ser		
			585				590							595			
TGC	ATC	GCC	AAG	GAG	ATC	GAG	TTT	CTG	TCG	TGG	ACC	GAG	CCC	TTC	GGG	2356	

6,011,068

113

114

-continued

Cys	Ile	Ala	Lys	Glu	Ile	Glu	Phe	Leu	Ser	Trp	Thr	Glu	Pro	Phe	Gly	
600					605						610					
ATC	GCA	CTC	ACG	CTC	TTT	GCT	GTG	CTG	GGC	ATT	TTC	CTC	ACA	GCC	TTC	2404
Ile	Ala	Leu	Thr	Leu	Phe	Ala	Val	Leu	Gly	Ile	Phe	Leu	Thr	Ala	Phe	
615					620					625					630	
GTG	CTG	GGC	GTC	TTC	ATC	AAG	TTC	CGC	AAC	ACG	CCC	ATC	GTC	AAG	GCC	2452
Val	Leu	Gly	Val	Phe	Ile	Lys	Phe	Arg	Asn	Thr	Pro	Ile	Val	Lys	Ala	
				635					640					645		
ACC	AAC	CGG	GAG	CTC	TCC	TAT	CTC	CTT	CTC	TTC	TCC	CTG	CTC	TGC	TGC	2500
Thr	Asn	Arg	Glu	Leu	Ser	Tyr	Leu	Leu	Leu	Phe	Ser	Leu	Leu	Cys	Cys	
				650					655					660		
TTC	TCC	AGC	TCC	CTG	TTC	TTC	ATC	GGG	GAG	CCC	CAG	GAC	TGG	ACG	TGC	2548
Phe	Ser	Ser	Ser	Leu	Phe	Phe	Ile	Gly	Glu	Pro	Gln	Asp	Trp	Thr	Cys	
				665				670						675		
CGC	CTG	CGC	CAG	CCG	GCC	TTT	GGC	ATC	AGC	TTC	GTG	CTC	TGC	ATC	TCG	2596
Arg	Leu	Arg	Gln	Pro	Ala	Phe	Gly	Ile	Ser	Phe	Val	Leu	Cys	Ile	Ser	
					685									690		
TGC	ATC	CTG	GTG	AAA	ACC	AAT	CGG	GTC	CTC	CTG	GTG	TTT	GAG	GCC	AAG	2644
Cys	Ile	Leu	Val	Lys	Thr	Asn	Arg	Val	Leu	Leu	Val	Phe	Glu	Ala	Lys	
695					700					705					710	
ATT	CCC	ACC	AGC	TTC	CAC	CGG	AAG	TGG	TGG	GGG	CTC	AAC	CTG	CAG	TTC	2692
Ile	Pro	Thr	Ser	Phe	His	Arg	Lys	Trp	Trp	Gly	Leu	Asn	Leu	Gln	Phe	
				715						720					725	
CTG	CTG	GTC	TTC	CTC	TGC	ACC	TTC	ATG	CAG	ATT	GTC	ATC	TGT	GCC	ATT	2740
Leu	Leu	Val	Phe	Leu	Cys	Thr	Phe	Met	Gln	Ile	Val	Ile	Cys	Ala	Ile	
				730					735					740		
TGG	CTC	AAT	ACA	GCG	CCC	CCC	TCG	AGC	TAC	CGC	AAC	CAC	GAG	CTG	GAG	2788
Trp	Leu	Asn	Thr	Ala	Pro	Pro	Ser	Ser	Tyr	Arg	Asn	His	Glu	Leu	Glu	
				745					750					755		
GAC	GAG	ATC	ATC	TTC	ATC	ACC	TGC	CAC	GAG	GGC	TCG	CTC	ATG	GCG	CTG	2836
Asp	Glu	Ile	Ile	Phe	Ile	Thr	Cys	His	Glu	Gly	Ser	Leu	Met	Ala	Leu	
					765									770		
GGC	TTC	CTG	ATC	GGC	TAC	ACC	TGC	TTG	CTG	GCC	GCC	ATC	TGC	TTC	TTC	2884
Gly	Phe	Leu	Ile	Gly	Tyr	Thr	Cys	Leu	Leu	Ala	Ala	Ile	Cys	Phe	Phe	
775					780					785					790	
TTC	GCC	TTC	AAG	TCC	CGG	AAG	CTG	CCA	GAG	AAC	TTC	AAT	GAA	GCC	AAG	2932
Phe	Ala	Phe	Lys	Ser	Arg	Lys	Leu	Pro	Glu	Asn	Phe	Asn	Glu	Ala	Lys	
					795				800						805	
TTC	ATC	ACC	TTC	AGC	ATG	CTC	ATC	TTC	TTC	ATC	GTC	TGG	ATC	TCT	TTC	2980
Phe	Ile	Thr	Phe	Ser	Met	Leu	Ile	Phe	Phe	Ile	Val	Trp	Ile	Ser	Phe	
				810					815					820		
ATC	CCC	GCC	TAC	GCC	AGC	ACT	TAC	GGC	AAG	TTC	GTC	TCT	GCC	GTG	GAG	3028
Ile	Pro	Ala	Tyr	Ala	Ser	Thr	Tyr	Gly	Lys	Phe	Val	Ser	Ala	Val	Glu	
				825				830						835		
GTG	ATC	GCC	ATC	CTG	GCG	GCC	AGC	TTT	GGC	FTG	CTG	GCC	TGT	ATC	TTC	3076
Val	Ile	Ala	Ile	Leu	Ala	Ala	Ser	Phe	Gly	Leu	Leu	Ala	Cys	Ile	Phe	
				840					845					850		
TTC	AAC	AAG	GTC	TAC	ATC	ATC	CTC	TTC	AAG	CCT	TCC	CGG	AAC	ACC	ATC	3124
Phe	Asn	Lys	Val	Tyr	Ile	Ile	Leu	Phe	Lys	Pro	Ser	Arg	Asn	Thr	Ile	
					860					865					870	
GAG	GAG	GTG	CGC	TGC	AGC	ACC	GCG	GCA	CAC	GCC	TTC	AAG	GTG	GCC	GCC	3172
Glu	Glu	Val	Arg	Cys	Ser	Thr	Ala	Ala	His	Ala	Phe	Lys	Val	Ala	Ala	
					875				880					885		
CGA	GCC	ACG	CTG	CGC	CGC	AGC	AAC	GTC	TCC	CGC	CAG	CGG	TCC	AGC	AGC	3220
Arg	Ala	Thr	Leu	Arg	Arg	Ser	Asn	Val	Ser	Arg	Gln	Arg	Ser	Ser	Ser	
				890					895					900		
CTA	GGG	GGC	TCC	ACG	GGA	TCC	ACC	CCC	TCC	TCC	TCC	ATC	AGC	AGC	AAG	3268
Leu	Gly	Ser	Thr	Gly	Ser	Thr	Pro	Ser	Ser	Ser	Ser	Ile	Ser	Ser	Lys	
				905				910						915		
AGC	AAC	AGC	GAG	GAC	CCG	TTC	CCT	CAG	CAG	CAG	CCG	AAG	AGG	CAG	AAG	3316

6,011,068

117

118

-continued

CCCTCCAGCA GTGGGATCTG CCCATGGGTA GTTACAAGAT TGAACGTTGA ATGGCATACT 4999
 GCTGAACAGT CAGTCTCGGA GCTAGAGAGG CCTGGGGTCA AGTGCTGGGT TGTCACTCA 5059
 CAAGTTGGGT GACCACAGGC AGGGAACCTT GACCTCACTC AGCCCCAGCT TCTTTGTGTC 5119
 TAAATGGAG GTAATAATCA TCCTTTTCCC GCAGAGCTCT TATGTGGGTT AAATGAGATA 5179
 AATGTATGTA AAGTATTTTA GCATGSGTCC TAGCCCATAG TAAGCACGCA AATAATATTA 5239
 GTTAATATTA AAAAAAAAAA AAAAAAAAAA AAAAAA 5275

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5006 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 436..3699
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GCTGCTGTGG CCGGACCCGA AGGGGGGCGC CGGGAGCGCA GCGAGCCAGA CGCGCCTCTC 60
 CAAGACCGTG ACCTTGGCAT AGGGAGCGGG GCTGCGCGCA GTCCTGAGAT CAGACCAGAG 120
 CTCATCTCG TGGAGACCCA CGGCCGAGGG GCCGGAGCTG CCTCTGTGCG AGGGAGCCCT 180
 GCGCCGGGCG CAGAAGGCAT CACAGGAGGC CTCTGCATGA TGTGGCTTCC AAAGACTCAA 240
 GGACCACCCA CATTACAAGT CTGGATTGAG GAAGGCAGAA ATGGAGATTC AAACACCACG 300
 TCTTCTATTA TTTTATTAAAT CAATCTGTAG ACATGTGTCC CCACTGCAGG GAGTGAAGT 360
 CTCCAAGGGA GAAACTTCTG GGAGCCTCCA AACTCCTAGC TGTCTCATCC CTTGCCCTGG 420
 AGAGACGGCA GAACC ATG GCA TTT TAT AGC TGC TGC TGG GTC CTC TTG GCA 471
 Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala
 1 5 10
 CTC ACC TGG CAC ACC TCT GCC TAC GGG CCA GAC CAG CGA GCC CAA AAG 519
 Leu Thr Trp His Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys
 15 20 25
 AAG GGG GAC ATT ATC CTT GGG GGG CTC TTT CCT ATT CAT TTT GGA GTA 567
 Lys Gly Asp Ile Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val
 30 35 40
 GCA GCT AAA GAT CAA GAT CTC AAA TCA AGG CCG GAG TCT GTG GAA TGT 615
 Ala Ala Lys Asp Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys
 45 50 55 60
 ATC AGG TAT AAT TTC CGT GGG TTT CGC TGG TTA CAG GCT ATG ATA TTT 663
 Ile Arg Tyr Asn Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe
 65 70 75
 GCC ATA GAG GAG ATA AAC AGC AGC CCA GCC CTT CTT CCC AAC TTG ACG 711
 Ala Ile Glu Glu Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr
 80 85 90
 CTG GGA TAC AGG ATA TTT GAC ACT TGC AAC ACC GTT TCT AAG GCC TTG 759
 Leu Gly Tyr Arg Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu
 95 100 105
 GAA GCC ACC CTG AGT TTT GTT GCT CAA AAC AAA ATT GAT TCT TTG AAC 807
 Glu Ala Thr Leu Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn
 110 115 120
 CTT GAT GAG TTC TGC AAC TGC TCA GAG CAC ATT CCC TCT ACG ATT GCT 855
 Leu Asp Glu Phe Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala
 125 130 135 140

6,011,068

119

120

-continued

GTG	GTG	GGA	GCA	ACT	GGC	TCA	GGC	GTC	TCC	ACG	GCA	GTG	GCA	AAT	CTG	903
Val	Val	Gly	Ala	Thr	Gly	Ser	Gly	Val	Ser	Thr	Ala	Val	Ala	Asn	Leu	
				145						150				155		
CTG	GGG	CTC	TTC	TAC	ATT	CCC	CAG	GTC	AGT	TAT	GCC	TCC	TCC	AGC	AGA	951
Leu	Gly	Leu	Phe	Tyr	Ile	Pro	Gln	Val	Ser	Tyr	Ala	Ser	Ser	Ser	Arg	
			160					165						170		
CTC	CTC	AGC	AAC	AAG	AAT	CAA	TTC	AAG	TCT	TTC	CTC	CGA	ACC	ATC	CCC	999
Leu	Leu	Ser	Asn	Lys	Asn	Gln	Phe	Lys	Ser	Phe	Leu	Arg	Thr	Ile	Pro	
			175				180						185			
AAT	GAT	GAG	CAC	CAG	GCC	ACT	GCC	ATG	GCA	GAC	ATC	ATC	GAG	TAT	TTC	1047
Asn	Asp	Glu	His	Gln	Ala	Thr	Ala	Met	Ala	Asp	Ile	Ile	Glu	Tyr	Phe	
	190					195					200					
CGC	TGG	AAC	TGG	GTG	GGC	ACA	ATT	GCA	GCT	GAT	GAC	GAC	TAT	GGG	CGG	1095
Arg	Trp	Asn	Trp	Val	Gly	Thr	Ile	Ala	Ala	Asp	Asp	Asp	Tyr	Gly	Arg	
	205			210						215				220		
CCG	GGG	ATT	GAG	AAA	TTC	CGA	GAG	GAA	GCT	GAG	GAA	AGG	GAT	ATC	TGC	1143
Pro	Gly	Ile	Glu	Lys	Phe	Arg	Glu	Glu	Ala	Glu	Glu	Arg	Asp	Ile	Cys	
				225					230					235		
ATC	GAC	TTC	AGT	GAA	CTC	ATC	TCC	CAG	TAC	TCT	GAT	GAG	GAA	GAG	ATC	1191
Ile	Asp	Phe	Ser	Glu	Leu	Ile	Ser	Gln	Tyr	Ser	Asp	Glu	Glu	Glu	Ile	
			240					245						250		
CAG	CAT	GTG	GTA	GAG	GTG	ATT	CAA	AAT	TCC	ACG	GCC	AAA	GTC	ATC	GTG	1239
Gln	His	Val	Val	Glu	Val	Ile	Gln	Asn	Ser	Thr	Ala	Lys	Val	Ile	Val	
			255				260						265			
GTT	TTC	TCC	AGT	GGC	CCA	GAT	CIT	GAG	CCC	CTC	ATC	AAG	GAG	ATT	GTG	1287
Val	Phe	Ser	Ser	Gly	Pro	Asp	Leu	Glu	Pro	Leu	Ile	Lys	Glu	Ile	Val	
	270					275					280					
CGG	CGC	AAT	ATC	ACG	GGC	AAG	ATC	TGG	CTG	GCC	AGC	GAG	GCC	TGG	GCC	1335
Arg	Arg	Asn	Ile	Thr	Gly	Lys	Ile	Trp	Leu	Ala	Ser	Glu	Ala	Trp	Ala	
	285			290				295						300		
AGC	TCC	TCC	CTG	ATC	GCC	ATG	CCT	CAG	TAC	TTC	CAC	GTG	GTT	GGC	GGC	1383
Ser	Ser	Ser	Leu	Ile	Ala	Met	Pro	Gln	Tyr	Phe	His	Val	Val	Gly	Gly	
				305				310						315		
ACC	ATT	GGA	TTC	GCT	CTG	AAG	GCT	GGG	CAG	ATC	CCA	GGC	TTC	CGG	GAA	1431
Thr	Ile	Gly	Phe	Ala	Leu	Lys	Ala	Gly	Gln	Ile	Pro	Gly	Phe	Arg	Glu	
			320					325					330			
TTC	CTG	AAG	AAG	GTC	CAT	CCC	AGG	AAG	TCT	GTC	CAC	AAT	GGT	TTT	GCC	1479
Phe	Leu	Lys	Lys	Val	His	Pro	Arg	Lys	Ser	Val	His	Asn	Gly	Phe	Ala	
		335				340						345				
AAG	GAG	TTT	TGG	GAA	GAA	ACA	TTT	AAC	TGC	CAC	CTC	CAA	GAA	GGT	GCA	1527
Lys	Glu	Phe	Trp	Glu	Glu	Thr	Phe	Asn	Cys	His	Leu	Gln	Glu	Gly	Ala	
	350					355					360					
AAA	GGA	CCT	TTA	CCT	GTG	GAC	ACC	TTT	CTG	AGA	GGT	CAC	GAA	GAA	AGT	1575
Lys	Gly	Pro	Leu	Pro	Val	Asp	Thr	Phe	Leu	Arg	Gly	His	Glu	Glu	Ser	
	365				370					375				380		
GGC	GAC	AGG	TTT	AGC	AAC	AGC	TCG	ACA	GCC	TTC	CGA	CCC	CTC	TGT	ACA	1623
Gly	Asp	Arg	Phe	Ser	Asn	Ser	Ser	Thr	Ala	Phe	Arg	Pro	Leu	Cys	Thr	
				385				390						395		
GGG	GAT	GAG	AAC	ATC	AGC	AGT	GTC	GAG	ACC	CCT	TAC	ATA	GAT	TAC	ACG	1671
Gly	Asp	Glu	Asn	Ile	Ser	Ser	Val	Glu	Thr	Pro	Tyr	Ile	Asp	Tyr	Thr	
			400					405					410			
CAT	TTA	CGG	ATA	TCC	TAC	AAT	GTG	TAC	TTA	GCA	GTC	TAC	TCC	ATT	GCC	1719
His	Leu	Arg	Ile	Ser	Tyr	Asn	Val	Tyr	Leu	Ala	Val	Tyr	Ser	Ile	Ala	
		415				420						425				
CAC	GCC	TTG	CAA	GAT	ATA	TAT	ACC	TGC	TTA	CCT	GGG	AGA	GGG	CTC	TTC	1767
His	Ala	Leu	Gln	Asp	Ile	Tyr	Thr	Cys	Leu	Pro	Gly	Arg	Gly	Leu	Phe	
		430				435					440					
ACC	AAT	GGC	TCC	TGT	GCA	GAC	ATC	AAG	AAA	GTT	GAG	GCG	TGG	CAG	GTG	1815
Thr	Asn	Gly	Ser	Cys	Ala	Asp	Ile	Lys	Lys	Val	Glu	Ala	Trp	Gln	Val	
	445				450					455				460		

6,011,068

121

122

-continued

CTG AAG CAC CTA CGG CAT CTA AAC TTT ACA AAC AAT ATG GGG GAG CAG Leu Lys His Leu Arg His Leu Asn Phe Thr Asn Asn Met Gly Glu Gln 465 470 475	1863
GTG ACC TTT GAT GAG TGT GGT GAC CTG GTG GGG AAC TAT TCC ATC ATC Val Thr Phe Asp Glu Cys Gly Asp Leu Val Gly Asn Tyr Ser Ile Ile 480 485 490	1911
AAC TGG CAC CTC TCC CCA GAG GAT GGC TCC ATC GTG TTT AAG GAA GTC Asn Trp His Leu Ser Pro Glu Asp Gly Ser Ile Val Phe Lys Glu Val 495 500 505	1959
GGG TAT TAC AAC GTC TAT GCC AAG AAG GGA GAA AGA CTC TTC ATC AAC Gly Tyr Tyr Asn Val Tyr Ala Lys Lys Gly Glu Arg Leu Phe Ile Asn 510 515 520	2007
GAG GAG AAA ATC CTG TGG AGT GGG TTC TCC AGG GAG CCA CTC ACC TTT Glu Glu Lys Ile Leu Trp Ser Gly Phe Ser Arg Glu Pro Leu Thr Phe 525 530 535 540	2055
GTG CTG TCT GTC CTC CAG GTG CCC TTC TCC AAC TGC AGC CGA GAC TGC Val Leu Ser Val Leu Gln Val Pro Phe Ser Asn Cys Ser Arg Asp Cys 545 550 555	2103
CTG GCA GGG ACC AGG AAA GGG ATC ATT GAG GGG GAG CCC ACC TGC TGC Leu Ala Gly Thr Arg Lys Gly Ile Ile Glu Gly Glu Pro Thr Cys Cys 560 565 570	2151
TTT GAG TGT GTG GAG TGT CCT GAT GGG GAG TAT AGT GAT GAG ACA GAT Phe Glu Cys Val Glu Cys Pro Asp Gly Glu Tyr Ser Asp Glu Thr Asp 575 580 585	2199
GCC AGT GCC TGT AAC AAG TGC CCA GAT GAC TTC TGG TCC AAT GAG AAC Ala Ser Ala Cys Asn Lys Cys Pro Asp Asp Phe Trp Ser Asn Glu Asn 590 595 600	2247
CAC ACC TCC TGC ATT GCC AAG GAG ATC GAG TTT CTG TCG TGG ACG GAG His Thr Ser Cys Ile Ala Lys Glu Ile Glu Phe Leu Ser Trp Thr Glu 605 610 615 620	2295
CCC TTT GGG ATC GCA CTC ACC CTC TTT GCC GTG CTG GGC ATT TTC CTG Pro Phe Gly Ile Ala Leu Thr Leu Phe Ala Val Leu Gly Ile Phe Leu 625 630 635	2343
ACA GCC TTT GTG CTG GGT GTG TTT ATC AAG TTC CGC AAC ACA CCC ATT Thr Ala Phe Val Leu Gly Val Phe Ile Lys Phe Arg Asn Thr Pro Ile 640 645 650	2391
GTC AAG GCC ACC AAC CGA GAG CTC TCC TAC CTC CTC TTC TCC CTG Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Leu Leu Leu Phe Ser Leu 655 660 665	2439
CTC TGC TGC TTC TCC AGC TCC CTG TTC TTC ATC GGG GAG CCC CAG GAC Leu Cys Cys Phe Ser Ser Ser Leu Phe Phe Ile Gly Glu Pro Gln Asp 670 675 680	2487
TGG ACG TGC CGC CTG CGC CAG CCG GCC TTT GGC ATC AGC TTC GTG CTC Trp Thr Cys Arg Leu Arg Gln Pro Ala Phe Gly Ile Ser Phe Val Leu 685 690 695 700	2535
TGC ATC TCA TGC ATC CTG GTG AAA ACC AAC CGT GTC CTC CTG GTG TTT Cys Ile Ser Cys Ile Leu Val Lys Thr Asn Arg Val Leu Leu Val Phe 705 710 715	2583
GAG GCC AAG ATC CCC ACC AGC TTC CAC CGC AAG TGG TGG GGG CTC AAC Glu Ala Lys Ile Pro Thr Ser Phe His Arg Lys Trp Trp Gly Leu Asn 720 725 730	2631
CTG CAG TTC CTG CTG GTT TTC CTC TGC ACC TTC ATG CAG ATT GTC ATC Leu Gln Phe Leu Leu Val Phe Leu Cys Thr Phe Met Gln Ile Val Ile 735 740 745	2679
TGT GTG ATC TGG CTC TAC ACC GCG CCC CCC TCA AGC TAC CGC AAC CAG Cys Val Ile Trp Leu Tyr Thr Ala Pro Pro Ser Ser Tyr Arg Asn Gln 750 755 760	2727
GAG CTG GAG GAT GAG ATC ATC TTC ATC ACG TGC CAC GAG GGC TCC CTC Glu Leu Glu Asp Glu Ile Ile Phe Ile Thr Cys His Glu Gly Ser Leu 765 770 775 780	2775

6,011,068

123

124

-continued

ATG GCC CTG GGC TTC CTG ATC GGC TAC ACC TGC CTG CTG GCT GCC ATC	2823
Met Ala Leu Gly Phe Leu Ile Gly Tyr Thr Cys Leu Leu Ala Ala Ile	
785 790 795	
TGC TTC TTC TTT GCC TTC AAG TCC CGG AAG CTG CCG GAG AAC TTC AAT	2871
Cys Phe Phe Phe Ala Phe Lys Ser Arg Lys Leu Pro Glu Asn Phe Asn	
800 805 810	
GAA GCC AAG TTC ATC ACC TTC AGC ATG CTC ATC TTC TTC ATC GTC TGG	2919
Glu Ala Lys Phe Ile Thr Phe Ser Met Leu Ile Phe Phe Ile Val Trp	
815 820 825	
ATC TCC TTC ATT CCA GCC TAT GCC AGC ACC TAT GGC AAG TTT GTC TCT	2967
Ile Ser Phe Ile Pro Ala Tyr Ala Ser Thr Tyr Gly Lys Phe Val Ser	
830 835 840	
GCC GTA GAG GTG ATT GCC ATC CTG GCA GCC AGC TTT GGC TTG CTG GCG	3015
Ala Val Glu Val Ile Ala Ile Leu Ala Ala Ser Phe Gly Leu Leu Ala	
845 850 855 860	
TGC ATC TTC TTC AAC AAG ATC TAC ATC ATT CTC TTC AAG CCA TCC CGC	3063
Cys Ile Phe Phe Asn Lys Ile Tyr Ile Ile Leu Phe Lys Pro Ser Arg	
865 870 875	
AAC ACC ATC GAG GAG GTG CGT TGC AGC ACC GCA GCT CAC GCT TTC AAG	3111
Asn Thr Ile Glu Glu Val Arg Cys Ser Thr Ala Ala His Ala Phe Lys	
880 885 890	
GTG GCT GCC CGG GCC ACG CTG CGC CGC AGC AAC GTC TCC CGC AAG CGG	3159
Val Ala Ala Arg Ala Thr Leu Arg Arg Ser Asn Val Ser Arg Lys Arg	
895 900 905	
TCC AGC AGC CTT GGA GGC TCC ACG GGA TCC ACC CCC TCC TCC TCC ATC	3207
Ser Ser Ser Leu Gly Gly Ser Thr Gly Ser Thr Pro Ser Ser Ser Ile	
910 915 920	
AGC AGC AAG AGC AAC AGC GAA GAC CCA TTC CCA CGG CCC GAG AGG CAG	3255
Ser Ser Lys Ser Asn Ser Glu Asp Pro Phe Pro Arg Pro Glu Arg Gln	
925 930 935 940	
AAG CAG CAG CAG CCG CTG GCC CTA ACC CAG CAA GAG CAG CAG CAG CAG	3303
Lys Gln Gln Gln Pro Leu Ala Leu Thr Gln Gln Glu Gln Gln Gln Gln	
945 950 955	
CCC CTG ACC CTC CCA CAG CAG CAA CGA TCT CAG CAG CAG CCC AGA TGC	3351
Pro Leu Thr Leu Pro Gln Gln Gln Arg Ser Gln Gln Gln Pro Arg Cys	
960 965 970	
AAG CAG AAG GTC ATC TTT GCC AGC GGC ACG GTC ACC TTC TCA CTG AGC	3399
Lys Gln Lys Val Ile Phe Gly Ser Gly Thr Val Thr Phe Ser Leu Ser	
975 980 985	
TTT GAT GAG CCT CAG AAG AAC GCC ATG GCC CAC AGG AAT TCT ACG CAC	3447
Phe Asp Glu Pro Gln Lys Asn Ala Met Ala His Arg Asn Ser Thr His	
990 995 1000	
CAG AAC TCC CTG GAG GCC CAG AAA AGC AGC GAT ACG CTG ACC CGA CAC	3495
Gln Asn Ser Leu Glu Ala Gln Lys Ser Ser Asp Thr Leu Thr Arg His	
1005 1010 1015 1020	
CAG CCA TTA CTC CCG CTG CAG TGC GGG GAA ACG GAC TTA GAT CTG ACC	3543
Gln Pro Leu Leu Pro Leu Gln Cys Gly Glu Thr Asp Leu Asp Leu Thr	
1025 1030 1035	
GTC CAG GAA ACA GGT CTG CAA GGA CCT GTG GGT GGA GAC CAG CGG CCA	3591
Val Gln Glu Thr Gly Leu Gln Gly Pro Val Gly Gly Asp Gln Arg Pro	
1040 1045 1050	
GAG GTG GAG GAC CCT GAA GAG TTG TCC CCA GCA CTT GTA GTG TCC AGT	3639
Glu Val Glu Asp Pro Glu Glu Leu Ser Pro Ala Leu Val Val Ser Ser	
1055 1060 1065	
TCA CAG AGC TTT GTC ATC AGT GGT GGA GGC AGC ACT GTT ACA GAA AAC	3687
Ser Gln Ser Phe Val Ile Ser Gly Gly Gly Ser Thr Val Thr Glu Asn	
1070 1075 1080	
GTA GTG AAT TCA TAAATGGAA GGAGAAGACT GGGCTAGGGA GAATGCAGAG	3739
Val Val Asn Ser	
1085	

6,011,068

125

126

-continued

```

AGGTTTCTTG GGTCCCAGG GATGAGGAAT CGCCCCAGAC TCCTTTCCTC TGAGGAAGAA 3799
GGGATAATAG ACACATCAA TGCCCCGAAT TTAGTCACAC CATCTTAAAT GACAGTGAAT 3859
TGACCCATGT TCCCTTTAAA ATAAAAAAA AGAAGAGCCT TGTGTTCTG TGGTTGCATT 3919
TGTCAAAGCA TTGAGATCTC CACGGTCAGA TTTGCTGTTT ACCCACATCT AATGTCTCTT 3979
CCTCTGTCT ATCCCACCCA ACAGCTCAGA GATGAACTA TGGCTTTAAA CTCACCTCCA 4039
GAGTGTGCAG ACTGATGGGA CATCAAATTT GCCACCCTA GAGCTGAGAG TGTGAAAGAC 4099
AGAATGTAC CAGTCTGCC CAATGCCTTG ACAACAGACT GAATTTTAAA TGTTCAAC 4159
ATAAGGAGAA TGTATCTCT CCTATTTATG AAAACCATAT GATATTTTGT CTCCTACCTG 4219
CTGCTGCTAT TATGTAACNT CCAGAAGGTT TGCACCCCTC CTATACCATA TGTCTGGTTC 4279
TGTCAGGAC ATGATACTGA TGCCATGTTT AGATTCCAGG ATCACAAGAA TCACCTCAA 4339
TTGTTAGGAA GGGACTGCAT AAACCAATGA GCTGTATCTG TAATTANTAT TCCTATATGT 4399
AGCTTTATCC TTAGGAAAT GCTTCTGTTG TAATAGTCCA TGGACAATAT AACTGAAAA 4459
ATGTCACTCT GGTATATATA AGGCAGTATT ATGAGCTCT ATTTCCCCAC CCCACTATCC 4519
TCACTCCCAT AAGCTAAGCC TTATGTGAGC CCCTTCAGGG ACTCAAGGTT CCAGAAGTCC 4579
CTCCCATCTC TACCCCAAAG AATTCCTGAA GCCAGATCCA CCCTATCCCT GTACAGAGTA 4639
AGTTCTCAAT TATTGGCCTG CTAATAGCTG CTAGGGTAGG AAAGCGTGGT TCCAAGAAA 4699
ATCCACCCTC AAATGTCGGA GCTATGTTCC CTCCAGCAGT GGTATTAATA CTGCCGCTCA 4759
CCCAGGCTCT GGAGCCAGAG AGACAGACCG GGGTTCAAGC CATGGCTTCG TCATTGCAA 4819
GCTGAGTGAC TGTAGGCAGG GAACCTTAAC CTCTCTAAGC CACAGCTTCT TCATCTTTAA 4879
AATAAGGATA ATAATCATT CTTCCTCTCA GAGCTCTTAT GTGGATTAAA CGAGATAATG 4939
TATATAAAGT ACTTTAGCCT GGTACCTAGC ACACAATAAG CATTCAATAA ATATTAGTTA 4999
ATATTAT 5006
    
```

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 3809 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 373..3606
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```

CAACAGGCAC CTGGCTGCAG CCAGGAAGGA CCGCACGCC TTTCGCGCAG GAGAGTGGAA 60
GGAGGGAGCT GTTTCCAGC ACCGAGTCT TCGGCACAG GCAACGCTT ACCTGAGTCT 120
TGCAGAAATG AAGGCATCAC AGGAGGCCTC TGCATGATGT GGCTTCCAAA GACTCAAGGA 180
CCACCACAT TACAAGTCTG GATTGAGGAA GGCAGAAATG GAGATTCAA CACCAGTCT 240
TCTATTATTT TATTAATCAA TCTGTAGACA TGTGTCCCA CTGCAGGGAG TGAAGTCTC 300
CAAGGGAGAA ACTTCTGGGA GCCTCCAAAC TCCTAGCTGT CTCATCCCTT GCCCTGGAGA 360
GACGGCAGAA CC ATG GCA TTT TAT AGC TGC TGC TGG GTC CTC TTG GCA 408
          Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala
          1           5           10
CTC ACC TGG CAC ACC TCT GCC TAC GGG CCA GAC CAG CGA GCC CAA AAG 456
    
```

6,011,068

127

128

-continued

Leu Thr Trp His Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys	
15	20
AAG GGG GAC ATT ATC CTT GGG GGG CTC TTT CCT ATT CAT TTT GGA GTA	504
Lys Gly Asp Ile Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val	
30	35
GCA GCT AAA GAT CAA GAT CTC AAA TCA AGG CCG GAG TCT GTG GAA TGT	552
Ala Ala Lys Asp Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys	
45	50
ATC AGG TAT AAT TTC CGT GGG TTT CGC TGG TTA CAG GCT ATG ATA TTT	600
Ile Arg Tyr Asn Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe	
65	70
GCC ATA GAG GAG ATA AAC AGC AGC CCA GCC CTT CTT CCC AAC TTG ACG	648
Ala Ile Glu Glu Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr	
80	85
CTG GGA TAC AGG ATA TTT GAC ACT TGC AAC ACC GTT TCT AAG GCC TTG	696
Leu Gly Tyr Arg Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu	
95	100
GAA GCC ACC CTG AGT TTT GTT GCT CAA AAC AAA ATT GAT TCT TTG AAC	744
Glu Ala Thr Leu Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn	
110	115
CTT GAT GAG TTC TGC AAC TGC TCA GAG CAC ATT CCC TCT ACG ATT GCT	792
Leu Asp Glu Phe Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala	
125	130
GTG GTG GGA GCA ACT GGC TCA GGC GTC TCC ACG GCA GTG GCA AAT CTG	840
Val Val Gly Ala Thr Gly Ser Gly Val Ser Thr Ala Val Ala Asn Leu	
145	150
CTG GGG CTC TTC TAC ATT CCC CAG GTC AGT TAT GCC TCC TCC AGC AGA	888
Leu Gly Leu Phe Tyr Ile Pro Gln Val Ser Tyr Ala Ser Ser Ser Arg	
160	165
CTC CTC AGC AAC AAG AAT CAA TTC AAG TCT TTC CTC CGA ACC ATC CCC	936
Leu Leu Ser Asn Lys Asn Gln Phe Lys Ser Phe Leu Arg Thr Ile Pro	
175	180
AAT GAT GAG CAC CAG GCC ACT GCC ATG GCA GAC ATC ATC GAG TAT TTC	984
Asn Asp Glu His Gln Ala Thr Ala Met Ala Asp Ile Ile Glu Tyr Phe	
190	195
CGC TGG AAC TGG GTG GGC ACA ATT GCA GCT GAT GAC GAC TAT GGG CGG	1032
Arg Trp Asn Trp Val Gly Thr Ile Ala Ala Asp Asp Tyr Gly Arg	
205	210
CCG GGG ATT GAG AAA TTC CGA GAG GAA GCT GAG GAA AGG GAT ATC TGC	1080
Pro Gly Ile Glu Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp Ile Cys	
225	230
ATC GAC TTC AGT GAA CTC ATC TCC CAG TAC TCT GAT GAG GAA GAG ATC	1128
Ile Asp Phe Ser Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Glu Ile	
240	245
CAG CAT GTG GTA GAG GTG ATT CAA AAT TCC ACG GCC AAA GTC ATC GTG	1176
Gln His Val Val Glu Val Ile Gln Asn Ser Thr Ala Lys Val Ile Val	
255	260
GTT TTC TCC AGT GGC CCA GAT CTT GAG CCC CTC ATC AAG GAG ATT GTC	1224
Val Phe Ser Ser Gly Pro Asp Leu Glu Pro Leu Ile Lys Glu Ile Val	
270	275
CGG CGC AAT ATC ACG GGC AAG ATC TGG CTG GCC AGC GAG GCC TGG GCC	1272
Arg Arg Asn Ile Thr Gly Lys Ile Trp Leu Ala Ser Glu Ala Trp Ala	
285	290
AGC TCC TCC CTG ATC GCC ATG CCT CAG TAC TTC CAC GTG GTT GGC GGC	1320
Ser Ser Ser Leu Ile Ala Met Pro Gln Tyr Ser Asp Glu Glu Gly Ile	
305	310
ACC ATT GGA TTC GCT CTG AAG GCT GGG CAG ATC CCA GGC TTC CGG GAA	1368
Thr Ile Gly Phe Ala Leu Lys Ala Gly Gln Ile Pro Gly Phe Arg Glu	
320	325
TTC CTG AAG AAG GTC CAT CCC AGG AAG TCT GTC CAC AAT GGT TTT GCC	1416

6,011,068

129

130

-continued

Phe	Leu	Lys	Lys	Val	His	Pro	Arg	Lys	Ser	Val	His	Asn	Gly	Phe	Ala		
		335					340					345					
AAG	GAG	TTT	TGG	GAA	GAA	ACA	TTT	AAC	TGC	CAC	CTC	CAA	GAA	GGT	GCA	1464	
Lys	Glu	Phe	Trp	Glu	Glu	Thr	Phe	Asn	Cys	His	Leu	Gln	Glu	Gly	Ala		
		350				355					360						
AAA	GGA	CCT	TTA	CCT	GTG	GAC	ACC	TTT	CTG	AGA	GGT	CAC	GAA	GAA	AGT	1512	
Lys	Gly	Pro	Leu	Pro	Val	Asp	Thr	Phe	Leu	Arg	Gly	His	Glu	Glu	Ser		
		365			370					375					380		
GGC	GAC	AGG	TTT	AGC	AAC	AGC	TCG	ACA	GCC	TTC	CGA	CCC	CTC	TGT	ACA	1560	
Gly	Asp	Arg	Phe	Ser	Asn	Ser	Ser	Thr	Ala	Phe	Arg	Pro	Leu	Cys	Thr		
				385					390					395			
GGG	GAT	GAG	AAC	ATC	AGC	AGT	GTC	GAG	ACC	CCT	TAC	ATA	GAT	TAC	ACG	1608	
Gly	Asp	Glu	Asn	Ile	Ser	Ser	Val	Glu	Thr	Pro	Tyr	Ile	Asp	Tyr	Thr		
			400					405					410				
CAT	TTA	CGG	ATA	TCC	TAC	AAT	GTG	TAC	TTA	GCA	GTC	TAC	TCC	ATT	GCC	1656	
His	Leu	Arg	Ile	Ser	Tyr	Asn	Val	Tyr	Leu	Ala	Val	Tyr	Ser	Ile	Ala		
		415				420							425				
CAC	GCC	TTG	CAA	GAT	ATA	TAT	ACC	TGC	TTA	CCT	GGG	AGA	GGG	CTC	TTC	1704	
His	Ala	Leu	Gln	Asp	Ile	Tyr	Thr	Cys	Leu	Pro	Gly	Arg	Gly	Leu	Phe		
		430				435					440						
ACC	AAT	GGC	TCC	TGT	GCA	GAC	ATC	AAG	AAA	GTT	GAG	CGG	TGG	CAG	GTC	1752	
Thr	Asn	Gly	Ser	Cys	Ala	Asp	Ile	Lys	Lys	Val	Glu	Ala	Trp	Gln	Val		
		445			450					455				460			
CTG	AAG	CAC	CTA	CGG	CAT	CTA	AAC	TTT	ACA	AAC	AAT	ATG	GGG	GAG	CAG	1800	
Leu	Lys	His	Leu	Arg	His	Leu	Asn	Phe	Thr	Asn	Asn	Met	Gly	Glu	Gln		
			465					470					475				
GTG	ACC	TTT	GAT	GAG	TGT	GGT	GAC	CTG	GTG	GGG	AAC	TAT	TCC	ATC	ATC	1848	
Val	Thr	Phe	Asp	Glu	Cys	Gly	Asp	Leu	Val	Gly	Asn	Tyr	Ser	Ile	Ile		
			480				485						490				
AAC	TGG	CAC	CTC	TCC	CCA	GAG	GAT	GGC	TCC	ATC	GTG	TTT	AAG	GAA	GTC	1896	
Asn	Trp	His	Leu	Ser	Pro	Glu	Asp	Gly	Ser	Ile	Val	Phe	Lys	Glu	Val		
		495					500					505					
GGG	TAT	TAC	AAC	GTC	TAT	GCC	AAG	AAG	CGA	GAA	AGA	CTC	TTC	ATC	AAC	1944	
Gly	Tyr	Tyr	Asn	Val	Tyr	Ala	Lys	Lys	Gly	Glu	Arg	Leu	Phe	Ile	Asn		
		510				515						520					
GAG	GAG	AAA	ATC	CTG	TGG	AGT	GGG	TTC	TCC	AGG	GAG	GTG	CCC	TTC	TCC	1992	
Glu	Glu	Lys	Ile	Leu	Trp	Ser	Gly	Phe	Ser	Arg	Glu	Val	Pro	Phe	Ser		
		525			530					535				540			
AAC	TGC	AGC	CGA	GAC	TGC	CTG	GCA	GGG	ACC	AGG	AAA	GGG	ATC	ATT	GAG	2040	
Asn	Cys	Ser	Arg	Asp	Cys	Leu	Ala	Gly	Thr	Arg	Lys	Gly	Ile	Ile	Glu		
				545					550					555			
GGG	GAG	CCC	ACC	TGC	TGC	TTT	GAG	TGT	GTG	GAG	TGT	CCT	GAT	GGG	GAG	2088	
Gly	Glu	Pro	Thr	Cys	Cys	Phe	Glu	Cys	Val	Glu	Cys	Pro	Asp	Gly	Glu		
			560					565					570				
TAT	AGT	GAT	GAG	ACA	GAT	GCC	AGT	GCC	TGT	AAC	AAG	TGC	CCA	GAT	GAC	2136	
Tyr	Ser	Asp	Glu	Thr	Asp	Ala	Ser	Ala	Cys	Asn	Lys	Cys	Pro	Asp	Asp		
		575				580							585				
TTC	TGG	TCC	AAT	GAG	AAC	CAC	ACC	TCC	TGC	ATT	GCC	AAG	GAG	ATC	GAG	2184	
Phe	Trp	Ser	Asn	Glu	Asn	His	Thr	Ser	Cys	Ile	Ala	Lys	Glu	Ile	Glu		
		590				595					600						
TTT	CTG	TCG	TGG	ACG	GAG	CCC	TTT	GGG	ATC	GCA	CTC	ACC	CTC	TTT	GCC	2232	
Phe	Leu	Ser	Trp	Thr	Glu	Pro	Phe	Gly	Ile	Ala	Leu	Thr	Leu	Phe	Ala		
				610						615				620			
GTG	CTG	GGC	ATT	TTC	CTG	ACA	GCC	TTT	GTG	CTG	GGT	GTG	TTT	ATC	AAG	2280	
Val	Leu	Gly	Ile	Phe	Leu	Thr	Ala	Phe	Val	Leu	Gly	Val	Phe	Ile	Lys		
				625					630					635			
TTC	CGC	AAC	ACA	CCC	ATT	GTC	AAG	GCC	ACC	AAC	CGA	GAG	CTC	TCC	TAC	2328	
Phe	Arg	Asn	Thr	Pro	Ile	Val	Lys	Ala	Thr	Asn	Arg	Glu	Leu	Ser	Tyr		
			640					645					650				
CTC	CTC	CTC	TTC	TCC	CTG	CTC	TGC	TGC	TTC	TCC	AGC	TCC	CTG	TTC	TTC	2376	

6,011,068

131

132

-continued

Leu	Leu	Leu	Phe	Ser	Leu	Leu	Cys	Cys	Phe	Ser	Ser	Ser	Leu	Phe	Phe		
		655					660						665				
ATC	GGG	GAG	CCC	CAG	GAC	TGG	ACG	TGC	CGC	CTG	CGC	CAG	CCG	GCC	TTT	2424	
Ile	Gly	Glu	Pro	Gln	Asp	Trp	Thr	Cys	Arg	Leu	Arg	Gln	Pro	Ala	Phe		
		670				675				680							
GGC	ATC	AGC	TTC	GTG	CTC	TGC	ATC	TCA	TGC	ATC	CTG	GTG	AAA	ACC	AAC	2472	
Gly	Ile	Ser	Phe	Val	Leu	Cys	Ile	Ser	Cys	Ile	Leu	Val	Lys	Thr	Asn		
		685			690					695					700		
CGT	GTC	CTC	CTG	GTG	TTT	GAG	GCC	AAG	ATC	CCC	ACC	AGC	TTC	CAC	CGC	2520	
Arg	Val	Leu	Leu	Val	Phe	Glu	Ala	Lys	Ile	Pro	Thr	Ser	Phe	His	Arg		
					705				710					715			
AAG	TGG	TGG	GGG	CTC	AAC	CTG	CAG	TTC	CTG	CTG	GTT	TTC	CTC	TGC	ACC	2568	
Lys	Trp	Trp	Gly	Leu	Asn	Leu	Gln	Phe	Leu	Leu	Val	Phe	Leu	Cys	Thr		
			720					725					730				
TTC	ATG	CAG	ATT	GTC	ATC	TGT	GTG	ATC	TGG	CTC	TAC	ACC	CGC	CCC	CCC	2616	
Phe	Met	Gln	Ile	Val	Ile	Cys	Val	Ile	Trp	Leu	Tyr	Thr	Ala	Pro	Pro		
			735				740					745					
TCA	AGC	TAC	CGC	AAC	CAG	GAG	CTG	GAG	GAT	GAG	ATC	ATC	TTC	ATC	ACG	2664	
Ser	Ser	Tyr	Arg	Asn	Gln	Glu	Leu	Glu	Asp	Glu	Ile	Ile	Phe	Ile	Thr		
			750			755					760						
TGC	CAC	GAG	GGC	TCC	CTC	ATG	GCC	CTG	GGC	TTC	CTG	ATC	GGC	TAC	ACC	2712	
Cys	His	Glu	Gly	Ser	Leu	Met	Ala	Leu	Gly	Phe	Leu	Ile	Gly	Tyr	Thr		
			765			770				775					780		
TGC	CTG	CTG	GCT	GCC	ATC	TGC	TTC	TTC	TTC	TTC	GCC	TTC	AAG	TCC	CGG	AAG	2760
Cys	Leu	Leu	Ala	Ala	Ile	Cys	Phe	Phe	Phe	Ala	Phe	Lys	Ser	Arg	Ly's		
					785					790					795		
CTG	CCG	GAG	AAC	TTC	AAT	GAA	GCC	AAG	TTC	ATC	ACC	TTC	AGC	ATG	CTC	2808	
Leu	Pro	Glu	Asn	Phe	Asn	Glu	Ala	Lys	Phe	Ile	Thr	Phe	Ser	Met	Leu		
			800					805					810				
ATC	TTC	TTC	ATC	GTC	TGG	ATC	TCC	TTC	ATT	CCA	GCC	TAT	GCC	AGC	ACC	2856	
Ile	Phe	Phe	Ile	Val	Trp	Ile	Ser	Phe	Ile	Pro	Ala	Tyr	Ala	Ser	Thr		
			815				820					825					
TAT	GGC	AAG	TTT	GTC	TCT	GCC	GTA	GAG	GTG	ATT	GCC	ATC	CTG	GCA	GCC	2904	
Tyr	Gly	Lys	Phe	Val	Ser	Ala	Val	Glu	Val	Ile	Ala	Ile	Leu	Ala	Ala		
			830			835					840						
AGC	TTT	GGC	TTG	CTG	CGC	TGC	ATC	TTC	TTC	AAC	AAG	ATC	TAC	ATC	ATT	2952	
Ser	Phe	Gly	Leu	Leu	Ala	Cys	Ile	Phe	Phe	Asn	Lys	Ile	Tyr	Ile	Ile		
			845			850				855					860		
CTC	TTC	AAG	CCA	TCC	CGC	AAC	ACC	ATC	GAG	GAG	GTG	CGT	TGC	AGC	ACC	3000	
Leu	Phe	Lys	Pro	Ser	Arg	Asn	Thr	Ile	Glu	Glu	Val	Arg	Cys	Ser	Thr		
					865					870					875		
GCA	GCT	CAC	GCT	TTC	AAG	GTG	GCT	GCC	CGG	GCC	ACG	CTG	CGC	CGC	AGC	3048	
Ala	Ala	His	Ala	Phe	Lys	Val	Ala	Ala	Arg	Ala	Thr	Leu	Arg	Arg	Ser		
					880			885							890		
AAC	GTC	TCC	CGC	AAG	CGG	TCC	AGC	AGC	CTT	GGA	GGC	TCC	ACG	GGA	TCC	3096	
Asn	Val	Ser	Arg	Lys	Arg	Ser	Ser	Ser	Leu	Gly	Gly	Ser	Thr	Gly	Ser		
			895			900						905					
ACC	CCC	TCC	TCC	TCC	ATC	AGC	AGC	AAG	AGC	AAC	AGC	GAA	GAC	CCA	TTC	3144	
Thr	Pro	Ser	Ser	Ser	Ile	Ser	Ser	Lys	Ser	Asn	Ser	Glu	Asp	Pro	Phe		
					910			915				920					
CCA	CAG	CCC	GAG	AGG	CAG	AAG	CAG	CAG	CAG	CCG	CTG	GCC	CTA	ACC	CAG	3192	
Pro	Gln	Pro	Glu	Arg	Gln	Lys	Gln	Gln	Gln	Pro	Leu	Ala	Leu	Thr	Gln		
					925					930					940		
CAA	GAG	CAG	CAG	CAG	CAG	CCC	CTG	ACC	CTC	CCA	CAG	CAG	CAA	CGA	TCT	3240	
Gln	Glu	Gln	Gln	Gln	Gln	Pro	Leu	Thr	Leu	Pro	Gln	Gln	Gln	Arg	Ser		
					945					950					955		
CAG	CAG	CAG	CCC	AGA	TGC	AAG	CAG	AAG	GTC	ATC	TTT	GGC	AGC	GGC	ACG	3288	
Gln	Gln	Gln	Pro	Arg	Cys	Lys	Gln	Lys	Val	Ile	Phe	Gly	Ser	Gly	Thr		
					960				965						970		
GTC	ACC	TTC	TCA	CTG	AGC	TTT	GAT	GAG	CCT	CAG	AAG	AAC	GCC	ATG	GCC	3336	

6,011,068

133

134

-continued

Val Thr Phe Ser Leu Ser Phe Asp Glu Pro Gln Lys Asn Ala Met Ala	
975 980 985	
CAC GGG AAT TCT ACG CAC CAG AAC TCC CTG GAG GCC CAG AAA AGC AGC	3384
His Gly Asn Ser Thr His Gln Asn Ser Leu Glu Ala Gln Lys Ser Ser	
990 995 1000	
GAT ACG CTG ACC CGA CAC CAG CCA TTA CTC CCG CTG CAG TGC GGG GAA	3432
Asp Thr Leu Thr Arg His Gln Pro Leu Leu Pro Leu Gln Cys Gly Glu	
1005 1010 1015 1020	
ACG GAC TTA GAT CTG ACC GTC CAG GAA ACA GGT CTG CAA GGA CCT GTG	3480
Thr Asp Leu Asp Leu Thr Val Gln Glu Thr Gly Leu Gln Gly Pro Val	
1025 1030 1035	
GGT GGA GAC CAG CGG CCA GAG GTG GAG GAC CCT GAA GAG TTG TCC CCA	3528
Gly Gly Asp Gln Arg Pro Glu Val Glu Asp Pro Glu Glu Leu Ser Pro	
1040 1045 1050	
GCA CTT GTA GTG TCC AGT TCA CAG AGC TTT GTC ATC AGT GGT GGA GGC	3576
Ala Leu Val Val Ser Ser Ser Gln Ser Phe Val Ile Ser Gly Gly Gly	
1055 1060 1065	
AGC ACT GTT ACA GAA AAC GTA GTG AAT TCA TAAATGGAA GGAGAAGACT	3626
Ser Thr Val Thr Glu Asn Val Val Asn Ser	
1070 1075	
GGGCTAGGGA GAATGCAGAG AGGTTTCTTG GGGTCCCAGG GATGAGGAAT CGCCCCAGAC	3686
TCCTTTCCTC TGAGGAAGAA GGGATAATAG ACACATCAAA TGCCCCGAAT TTAGTCACAC	3746
CATCTTAAAT GACAGTGAAT TGACCCATGT TCCCTTTAAA AAAAAAAAAA AAAAAAGCGG	3806
CGC	3809
(2) INFORMATION FOR SEQ ID NO: 4:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH:	4131 base pairs
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear
(ii) MOLECULE TYPE:	cDNA to mRNA
(ix) FEATURE:	
(A) NAME/KEY:	CDS
(B) LOCATION:	574..3810
(D) OTHER INFORMATION:	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:	
CGGGACTCTC CAGGCCGGCT CAGGCACCGG ACTGTAGGTG TATTGGAGG GATTGGAGG	60
CTGGAGACCC CAGGAAGCAC GCAGGCGGGA GCAGGCAAGG GCGGGAGCCC CGGGCCCGGC	120
CAAGGTGGCC GTCAGAGGGT CTGCGGGGAG GCAGTAGCTT GACCCAAGGC GACCAGGGAA	180
CTTCAGACGG TAGCACGCCA CTCAAACAAA TTAAGTTGAC ATCGCAAGCT GGCAGGGCTG	240
GTACGACATC CTGACTTCAG CATCCAGCTG TTCCTGGGCA GACAGAGGGC CAACAGGTGT	300
TCCTGTGGAA GAAGCCAGGA CAAGACTCC AGAAAACATC TCGGGCAGCC TCTACATGAT	360
GTCACTTCTC AGGACTCGAG GACCAGCCAC CCTACACCTC TACTACAGAG ARGGCAGAAA	420
TGGAGACCCA AAGGCCATCA CTCCTGCTCT GTCACBAACC ACTCTGTAAT CATGTCTCCC	480
CACCAGAAGG TGTGAACCGC ACCAGGGCCG TGGAGTTCTC GGGCTCCCAA TCCACTGACA	540
CCTTTACCTG TCCCCTGAAG AGAAGGCRAC GCT ATG GCA TCG TAC AGC TGC TGT	594
Met Ala Ser Tyr Ser Cys Cys	
1 5	
TTG GCC CTA TTG GCT CTT GCC TGG CAC TCC TCT GCC TAT GGG CCT GAC	642
Leu Ala Leu Leu Ala Leu Ala Trp His Ser Ser Ala Tyr Gly Pro Asp	
10 15 20	
CAG CGA GCC CAA AAG AAG GGG GAC ATT ATC CTA GGA GGT CTC TTT CCT	690

6,011,068

135

136

-continued

Gln	Arg	Ala	Gln	Lys	Lys	Gly	Asp	Ile	Ile	Leu	Gly	Gly	Leu	Phe	Pro	
	25					30					35					
ATC	CAT	TTT	GGA	GTA	GCA	GCC	AAA	GAT	CAA	GAT	CTG	AAG	TCA	AGA	CCA	738
Ile	His	Phe	Gly	Val	Ala	Ala	Lys	Asp	Gln	Asp	Leu	Lys	Ser	Arg	Pro	
	40				45					50					55	
GAG	TCT	GTG	GAG	TGC	ATT	AGG	TAT	AAC	TTC	CGT	GGA	TTC	CGA	TGG	TTA	786
Glu	Ser	Val	Glu	Cys	Ile	Arg	Tyr	Asn	Phe	Arg	Gly	Phe	Arg	Trp	Leu	
				60				65						70		
CAA	GCC	ATG	ATA	TTC	GCC	ATA	GAG	GAG	ATA	AAC	AGC	AGC	CCC	TCC	CTT	834
Gln	Ala	Met	Ile	Phe	Ala	Ile	Glu	Glu	Ile	Asn	Ser	Ser	Pro	Ser	Leu	
			75					80						85		
CTT	CCC	AAC	ATG	ACA	CTG	GGA	TAT	AGG	ATA	TTT	GAC	ACC	TGT	AAC	ACC	882
Leu	Pro	Asn	Met	Thr	Leu	Gly	Tyr	Arg	Ile	Phe	Asp	Thr	Cys	Asn	Thr	
		90					95						100			
GTC	TCC	AAG	GCG	CTG	GAA	GCC	ACC	TTG	AGT	TTT	GTT	GCC	CAG	AAC	AAA	930
Val	Ser	Lys	Ala	Leu	Glu	Ala	Thr	Leu	Ser	Phe	Val	Ala	Gln	Asn	Lys	
	105					110					115					
ATC	GAT	TCT	TTG	AAC	CTG	GAC	GAG	TTC	TGC	AAC	TGC	TCT	GAG	CAC	ATC	978
Ile	Asp	Ser	Leu	Asn	Leu	Asp	Glu	Phe	Cys	Asn	Cys	Ser	Glu	His	Ile	
	120			125					130					135		
CCT	TCG	ACC	ATT	GCC	GTG	GTG	GGA	GCC	ACC	GGC	TCC	GGT	GTC	TCC	ACG	1026
Pro	Ser	Thr	Ile	Ala	Val	Val	Gly	Ala	Thr	Gly	Ser	Gly	Val	Ser	Thr	
			140					145						150		
GCG	GTA	GCC	AAC	CTG	CTG	GGA	CTT	TTC	TAC	ATC	CCC	CAG	GTG	AGC	TAC	1074
Ala	Val	Ala	Asn	Leu	Leu	Gly	Leu	Phe	Tyr	Ile	Pro	Gln	Val	Ser	Tyr	
			155				160						165			
GCC	TCC	TCC	AGC	AGG	CTC	CTC	AGC	AAT	AAG	AAC	CAG	TAC	AAA	TCC	TTC	1122
Ala	Ser	Ser	Ser	Arg	Leu	Leu	Ser	Asn	Lys	Asn	Gln	Tyr	Lys	Ser	Phe	
		170					175						180			
CTC	CGC	ACC	ATT	CCC	AAT	GAC	GAA	CAC	CAG	GCA	ACC	GCG	ATG	GCC	GAC	1170
Leu	Arg	Thr	Ile	Pro	Asn	Asp	Glu	His	Gln	Ala	Thr	Ala	Met	Ala	Asp	
	185					190					195					
ATC	ATC	GAG	TAC	TTC	CGC	TGG	AAC	TGG	GTG	GGC	ACA	ATT	GCA	GCT	GAT	1218
Ile	Ile	Glu	Tyr	Phe	Arg	Trp	Asn	Trp	Val	Gly	Thr	Ile	Ala	Ala	Asp	
	200			205					210					215		
GAC	GAC	TAT	GGC	AGA	CCT	GGC	ATT	GAG	AAG	TTC	CGA	GAG	GAA	GCC	GAA	1266
Asp	Asp	Tyr	Gly	Arg	Pro	Gly	Ile	Glu	Lys	Phe	Arg	Glu	Glu	Ala	Glu	
			220				225							230		
GAG	AGG	GAT	ATC	TGC	ATT	GAT	TTT	AGC	GAG	CTC	ATC	TCC	CAG	TAC	TCT	1314
Glu	Arg	Asp	Ile	Cys	Ile	Asp	Phe	Ser	Glu	Leu	Ile	Ser	Gln	Tyr	Ser	
			235				240						245			
GAC	GAG	GAA	GAG	ATC	CAG	CAG	GTG	GTC	GAA	GTG	ATC	CAA	AAC	TCT	ACG	1362
Asp	Glu	Glu	Glu	Ile	Gln	Gln	Val	Val	Glu	Val	Ile	Gln	Asn	Ser	Thr	
	250						255					260				
GCC	AAG	GTC	ATT	GTC	GTT	TTC	TCC	AGC	GGC	CCG	GAC	CTA	GAA	CCT	CTC	1410
Ala	Lys	Val	Ile	Val	Val	Phe	Ser	Ser	Gly	Pro	Asp	Leu	Glu	Pro	Leu	
	265					270					275					
ATC	AAG	GAG	ATT	GTG	CGG	CGT	AAC	ATC	ACA	GGC	AGG	ATC	TGG	CTG	GCT	1458
Ile	Lys	Glu	Ile	Val	Arg	Arg	Asn	Ile	Thr	Gly	Arg	Ile	Trp	Leu	Ala	
	280			285					290					295		
AGC	GAG	GCC	TGG	GCC	AGT	TCC	TCG	CTG	ATT	GCT	ATG	CCT	GAG	TAT	TTC	1506
Ser	Glu	Ala	Trp	Ala	Ser	Ser	Ser	Leu	Ile	Ala	Met	Pro	Glu	Tyr	Phe	
			300					305						310		
CAT	GTA	GTC	GGG	GGC	ACC	ATT	GGG	TTC	GGT	CTG	AAG	GCT	GGG	CAG	ATT	1554
His	Val	Val	Gly	Gly	Thr	Ile	Gly	Phe	Gly	Leu	Lys	Ala	Gly	Gln	Ile	
			315					320					325			
CCA	GGC	TTC	AGA	GAA	TTC	CTA	CAG	AAA	GTT	CAT	CCT	AGG	AAG	TCT	GTC	1602
Pro	Gly	Phe	Arg	Glu	Phe	Leu	Gln	Lys	Val	His	Pro	Arg	Lys	Ser	Val	
	330						335					340				
CAC	AAT	GGT	TTT	GCC	AAA	GAG	TTT	TGG	GAA	GAA	ACT	TTT	AAT	TGC	CAC	1650

6,011,068

141

142

-continued

Gln Lys Asn Ala Met Ala His Arg Asn Ser Met Arg Gln Asn Ser Leu	
985	990 995
GAG GCC CAG AGG AGC AAC GAC ACC TTG GGC AGA CAC CAG GCC CTG CTT	3618
Glu Ala Gln Arg Ser Asn Asp Thr Leu Gly Arg His Gln Ala Leu Leu	
1000	1005 1010 1015
CCC CTA CAG TGT GCA GAT GCG GAC TCA GAA ATG ACC ATT CAG GAA ACG	3666
Pro Leu Gln Cys Ala Asp Ala Asp Ser Glu Met Thr Ile Gln Glu Thr	
	1020 1025 1030
GGC CTG CAA GGG CCC ATG GTG GGG GAC CAC CAG CCA GAA ATG GAA AGC	3714
Gly Leu Gln Gly Pro Met Val Gly Asp His Gln Pro Glu Met Glu Ser	
	1035 1040 1045
TCA GAT GAA ATG TCC CCA GCG CTG GTC ATG TCC ACC TCT CGG AGC TTC	3762
Ser Asp Glu Met Ser Pro Ala Leu Val Met Ser Thr Ser Arg Ser Phe	
	1050 1055 1060
GTC AIT AGT GGT GGA GGT AGC TCT GTG ACG GAA AAC GTA TTA CAC TCC	3810
Val Ile Ser Gly Gly Gly Ser Ser Val Thr Glu Asn Val Leu His Ser	
	1065 1070 1075
TAATGGAGGG AAAGGCTATC CAGTTGAGAG GTTTTCTTA GAGCCCTGAG CAAAAGGATG	3870
GGTCCTTCTT TTCTTCCCAG GAAGCCAGGG AGAGTAGGTA CGTCAAAGCC TGTACTCAGT	3930
TGCACCTGCTT TGAATGACAG TGAACCTGACT GGTGTGCTCT TTAGAGTTAA AAGAAGAGCC	3990
ATGTTTTGGG GTCGTTTTCC AGAGCTCAGT ATCACACCTG GGTGTGCTGA AGTCTTTTCC	4050
TCTGCTCTAT CCACCATCAG TTCAGACGAA AGCAAGGCTC TAAGCTACCC ATCTGCTTCC	4110
CTCAAAAAAA AAAAAAAA A	4131

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1085 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Met Ala Leu Tyr Ser Cys Cys Trp Ile Leu Leu Ala Phe Ser Thr Trp	
1	5 10 15
Cys Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp	
	20 25 30
Ile Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Val Lys	
	35 40 45
Asp Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr	
	50 55 60
Asn Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu	
	65 70 75 80
Glu Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Met Thr Leu Gly Tyr	
	85 90 95
Arg Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr	
	100 105 110
Leu Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu	
	115 120 125
Phe Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly	
	130 135 140
Ala Thr Gly Ser Gly Ile Ser Thr Ala Val Ala Asn Leu Leu Gly Leu	
	145 150 155 160
Phe Tyr Ile Pro Gln Val Ser Tyr Ala Ser Ser Arg Leu Leu Ser	
	165 170 175

6,011,068

143

144

-continued

Asn	Lys	Asn	Gln	Phe	Lys	Ser	Phe	Leu	Arg	Thr	Ile	Pro	Asn	Asp	Glu
			180					185							190
His	Gln	Ala	Thr	Ala	Met	Ala	Asp	Ile	Ile	Glu	Tyr	Phe	Arg	Trp	Asn
			195				200						205		
Trp	Val	Gly	Thr	Ile	Ala	Ala	Asp	Asp	Asp	Tyr	Gly	Arg	Pro	Gly	Ile
	210					215					220				
Glu	Lys	Phe	Arg	Glu	Glu	Ala	Glu	Glu	Arg	Asp	Ile	Cys	Ile	Asp	Phe
225						230				235					240
Ser	Glu	Leu	Ile	Ser	Gln	Tyr	Ser	Asp	Glu	Glu	Lys	Ile	Gln	Gln	Val
				245					250					255	
Val	Glu	Val	Ile	Gln	Asn	Ser	Thr	Ala	Lys	Val	Ile	Val	Val	Phe	Ser
			260					265						270	
Ser	Gly	Pro	Asp	Leu	Glu	Pro	Leu	Ile	Lys	Glu	Ile	Val	Arg	Arg	Asn
		275					280						285		
Ile	Thr	Gly	Arg	Ile	Trp	Leu	Ala	Ser	Glu	Ala	Trp	Ala	Ser	Ser	Ser
	290					295						300			
Leu	Ile	Ala	Met	Pro	Glu	Tyr	Phe	His	Val	Val	Gly	Gly	Thr	Ile	Gly
305					310						315				320
Phe	Gly	Leu	Lys	Ala	Gly	Gln	Ile	Pro	Gly	Phe	Arg	Glu	Phe	Leu	Gln
				325					330						335
Lys	Val	His	Pro	Arg	Lys	Ser	Val	His	Asn	Gly	Phe	Ala	Lys	Glu	Phe
			340					345						350	
Trp	Glu	Glu	Thr	Phe	Asn	Cys	His	Leu	Gln	Glu	Gly	Ala	Lys	Gly	Pro
	355						360								
Leu	Pro	Val	Asp	Thr	Phe	Leu	Arg	Gly	His	Glu	Glu	Gly	Gly	Ala	Arg
	370					375						380			
Leu	Ser	Asn	Ser	Pro	Thr	Ala	Phe	Arg	Pro	Leu	Cys	Thr	Gly	Glu	Glu
385					390					395					400
Asn	Ile	Ser	Ser	Val	Glu	Thr	Pro	Tyr	Met	Asp	Tyr	Thr	His	Leu	Arg
				405					410					415	
Ile	Ser	Tyr	Asn	Val	Tyr	Leu	Ala	Val	Tyr	Ser	Ile	Ala	His	Ala	Leu
			420					425						430	
Gln	Asp	Ile	Tyr	Thr	Cys	Ile	Pro	Gly	Arg	Gly	Leu	Phe	Thr	Asn	Gly
			435				440						445		
Ser	Cys	Ala	Asp	Ile	Lys	Lys	Val	Glu	Ala	Trp	Gln	Val	Leu	Lys	His
	450					455					460				
Leu	Arg	His	Leu	Asn	Phe	Thr	Ser	Asn	Met	Gly	Glu	Gln	Val	Thr	Phe
465					470					475					480
Asp	Glu	Cys	Gly	Asp	Leu	Ala	Gly	Asn	Tyr	Ser	Ile	Ile	Asn	Trp	His
			485						490					495	
Leu	Ser	Pro	Glu	Asp	Gly	Ser	Ile	Val	Phe	Lys	Glu	Val	Gly	Tyr	Tyr
		500						505						510	
Asn	Val	Tyr	Ala	Lys	Lys	Gly	Glu	Arg	Leu	Phe	Ile	Asn	Asp	Glu	Lys
		515					520						525		
Ile	Leu	Trp	Ser	Gly	Phe	Ser	Arg	Glu	Val	Pro	Phe	Ser	Asn	Cys	Ser
	530					535						540			
Arg	Asp	Cys	Leu	Ala	Gly	Thr	Arg	Lys	Gly	Ile	Ile	Glu	Gly	Glu	Pro
545					550					555					560
Thr	Cys	Cys	Phe	Glu	Cys	Val	Glu	Cys	Pro	Asp	Gly	Glu	Tyr	Ser	Asp
			565						570					575	
Glu	Thr	Asp	Ala	Ser	Ala	Cys	Asp	Lys	Cys	Pro	Asp	Asp	Phe	Trp	Ser
		580						585						590	
Asn	Glu	Asn	His	Thr	Ser	Cys	Ile	Ala	Lys	Glu	Ile	Glu	Phe	Leu	Ser
		595					600						605		

6,011,068

145

146

-continued

Trp Thr Glu Pro Phe Gly Ile Ala Leu Thr Leu Phe Ala Val Leu Gly
 610 615 620
 Ile Phe Leu Thr Ala Phe Val Leu Gly Val Phe Ile Lys Phe Arg Asn
 625 630 635 640
 Thr Pro Ile Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Leu Leu Leu
 645 650 655
 Phe Ser Leu Leu Cys Cys Phe Ser Ser Ser Leu Phe Phe Ile Gly Glu
 660 665 670
 Pro Gln Asp Trp Thr Cys Arg Leu Arg Gln Pro Ala Phe Gly Ile Ser
 675 680 685
 Phe Val Leu Cys Ile Ser Cys Ile Leu Val Lys Thr Asn Arg Val Leu
 690 695 700
 Leu Val Phe Glu Ala Lys Ile Pro Thr Ser Phe His Arg Lys Trp Trp
 705 710 715 720
 Gly Leu Asn Leu Gln Phe Leu Leu Val Phe Leu Cys Thr Phe Met Gln
 725 730 735
 Ile Val Ile Cys Ala Ile Trp Leu Asn Thr Ala Pro Pro Ser Ser Tyr
 740 745 750
 Arg Asn His Glu Leu Glu Asp Glu Ile Ile Phe Ile Thr Cys His Glu
 755 760 765
 Gly Ser Leu Met Ala Leu Gly Phe Leu Ile Gly Tyr Thr Cys Leu Leu
 770 775 780
 Ala Ala Ile Cys Phe Phe Phe Ala Phe Lys Ser Arg Lys Leu Pro Glu
 785 790 795 800
 Asn Phe Asn Glu Ala Lys Phe Ile Thr Phe Ser Met Leu Ile Phe Phe
 805 810 815
 Ile Val Trp Ile Ser Phe Ile Pro Ala Tyr Ala Ser Thr Tyr Gly Lys
 820 825 830
 Phe Val Ser Ala Val Glu Val Ile Ala Ile Leu Ala Ala Ser Phe Gly
 835 840 845
 Leu Leu Ala Cys Ile Phe Phe Asn Lys Val Tyr Ile Ile Leu Phe Lys
 850 855 860
 Pro Ser Arg Asn Thr Ile Glu Glu Val Arg Cys Ser Thr Ala Ala His
 865 870 875 880
 Ala Phe Lys Val Ala Ala Arg Ala Thr Leu Arg Arg Ser Asn Val Ser
 885 890 895
 Arg Gln Arg Ser Ser Ser Leu Gly Gly Ser Thr Gly Ser Thr Pro Ser
 900 905 910
 Ser Ser Ile Ser Ser Lys Ser Asn Ser Glu Asp Pro Phe Pro Gln Gln
 915 920 925
 Gln Pro Lys Arg Gln Lys Gln Pro Gln Pro Leu Ala Leu Ser Pro His
 930 935 940
 Asn Ala Gln Gln Pro Gln Pro Arg Pro Pro Ser Thr Pro Gln Pro Gln
 945 950 955 960
 Pro Gln Ser Gln Gln Pro Pro Arg Cys Lys Gln Lys Val Ile Phe Gly
 965 970 975
 Ser Gly Thr Val Thr Phe Ser Leu Ser Phe Asp Glu Pro Gln Lys Thr
 980 985 990
 Ala Val Ala His Arg Asn Ser Thr His Gln Thr Ser Leu Glu Ala Gln
 995 1000 1005
 Lys Asn Asn Asp Ala Leu Thr Lys His Gln Ala Leu Leu Pro Leu Gln
 1010 1015 1020
 Cys Gly Glu Thr Asp Ser Glu Leu Thr Ser Gln Glu Thr Gly Leu Gln

6,011,068

147

148

-continued

1025	1030	1035	1040
Gly Pro Val	Gly Glu Asp His Gln Leu Glu Met Glu Asp Pro Glu Glu		
	1045	1050	1055
Met Ser Pro Ala Leu Val Val Ser Asn Ser Arg Ser Phe Val Ile Ser			
	1060	1065	1070
Gly Gly Gly Ser Thr Val Thr Glu Asn Met Leu Arg Ser			
	1075	1080	1085

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1088 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met	Ala	Phe	Tyr	Ser	Cys	Cys	Trp	Val	Leu	Leu	Ala	Leu	Thr	Trp	His
1				5					10					15	
Thr	Ser	Ala	Tyr	Gly	Pro	Asp	Gln	Arg	Ala	Gln	Lys	Lys	Gly	Asp	Ile
			20				25							30	
Ile	Leu	Gly	Gly	Leu	Phe	Pro	Ile	His	Phe	Gly	Val	Ala	Ala	Lys	Asp
		35					40					45			
Gln	Asp	Leu	Lys	Ser	Arg	Pro	Glu	Ser	Val	Glu	Cys	Ile	Arg	Tyr	Asn
		50				55					60				
Phe	Arg	Gly	Phe	Arg	Trp	Leu	Gln	Ala	Met	Ile	Phe	Ala	Ile	Glu	Glu
		65			70				75					80	
Ile	Asn	Ser	Ser	Pro	Ala	Leu	Leu	Pro	Asn	Leu	Thr	Leu	Gly	Tyr	Arg
				85					90					95	
Ile	Phe	Asp	Thr	Cys	Asn	Thr	Val	Ser	Lys	Ala	Leu	Glu	Ala	Thr	Leu
			100						105					110	
Ser	Phe	Val	Ala	Gln	Asn	Lys	Ile	Asp	Ser	Leu	Asn	Leu	Asp	Glu	Phe
		115					120						125		
Cys	Asn	Cys	Ser	Glu	His	Ile	Pro	Ser	Thr	Ile	Ala	Val	Val	Gly	Ala
		130				135					140				
Thr	Gly	Ser	Gly	Val	Ser	Thr	Ala	Val	Ala	Asn	Leu	Leu	Gly	Leu	Phe
		145			150					155				160	
Tyr	Ile	Pro	Gln	Val	Ser	Tyr	Ala	Ser	Ser	Ser	Arg	Leu	Leu	Ser	Asn
				165					170					175	
Lys	Asn	Gln	Phe	Lys	Ser	Phe	Leu	Arg	Thr	Ile	Pro	Asn	Asp	Glu	His
			180					185						190	
Gln	Ala	Thr	Ala	Met	Ala	Asp	Ile	Ile	Glu	Tyr	Phe	Arg	Trp	Asn	Trp
			195				200						205		
Val	Gly	Thr	Ile	Ala	Ala	Asp	Asp	Asp	Tyr	Gly	Arg	Pro	Gly	Ile	Glu
		210				215					220				
Lys	Phe	Arg	Glu	Glu	Ala	Glu	Glu	Arg	Asp	Ile	Cys	Ile	Asp	Phe	Ser
			225			230				235				240	
Glu	Leu	Ile	Ser	Gln	Tyr	Ser	Asp	Glu	Glu	Glu	Ile	Gln	His	Val	Val
				245					250					255	
Glu	Val	Ile	Gln	Asn	Ser	Thr	Ala	Lys	Val	Ile	Val	Val	Phe	Ser	Ser
			260					265						270	
Gly	Pro	Asp	Leu	Glu	Pro	Leu	Ile	Lys	Glu	Ile	Val	Arg	Arg	Asn	Ile
			275				280						285		
Thr	Gly	Lys	Ile	Trp	Leu	Ala	Ser	Glu	Ala	Trp	Ala	Ser	Ser	Ser	Leu
			290				295							300	

6,011,068

149

150

-continued

Ile Ala Met Pro Gln Tyr Phe His Val Val Gly Gly Thr Ile Gly Phe
 305 310 315 320

Ala Leu Lys Ala Gly Gln Ile Pro Gly Phe Arg Glu Phe Leu Lys Lys
 325 330 335

Val His Pro Arg Lys Ser Val His Asn Gly Phe Ala Lys Glu Phe Trp
 340 345 350

Glu Glu Thr Phe Asn Cys His Leu Gln Glu Gly Ala Lys Gly Pro Leu
 355 360 365

Pro Val Asp Thr Phe Leu Arg Gly His Glu Glu Ser Gly Asp Arg Phe
 370 375 380

Ser Asn Ser Ser Thr Ala Phe Arg Pro Leu Cys Thr Gly Asp Glu Asn
 385 390 395 400

Ile Ser Ser Val Glu Thr Pro Tyr Ile Asp Tyr Thr His Leu Arg Ile
 405 410 415

Ser Tyr Asn Val Tyr Leu Ala Val Tyr Ser Ile Ala His Ala Leu Gln
 420 425 430

Asp Ile Tyr Thr Cys Leu Pro Gly Arg Gly Leu Phe Thr Asn Gly Ser
 435 440 445

Cys Ala Asp Ile Lys Lys Val Glu Ala Trp Gln Val Leu Lys His Leu
 450 455 460

Arg His Leu Asn Phe Thr Asn Asn Met Gly Glu Gln Val Thr Phe Asp
 465 470 475 480

Glu Cys Gly Asp Leu Val Gly Asn Tyr Ser Ile Ile Asn Trp His Leu
 485 490 495

Ser Pro Glu Asp Gly Ser Ile Val Phe Lys Glu Val Gly Tyr Tyr Asn
 500 505 510

Val Tyr Ala Lys Lys Gly Glu Arg Leu Phe Ile Asn Glu Glu Lys Ile
 515 520 525

Leu Trp Ser Gly Phe Ser Arg Glu Pro Leu Thr Phe Val Leu Ser Val
 530 535 540

Leu Gln Val Pro Phe Ser Asn Cys Ser Arg Asp Cys Leu Ala Gly Thr
 545 550 555 560

Arg Lys Gly Ile Ile Glu Gly Glu Pro Thr Cys Cys Phe Glu Cys Val
 565 570 575

Glu Cys Pro Asp Gly Glu Tyr Ser Asp Glu Thr Asp Ala Ser Ala Cys
 580 585 590

Asn Lys Cys Pro Asp Asp Phe Trp Ser Asn Glu Asn His Thr Ser Cys
 595 600 605

Ile Ala Lys Glu Ile Glu Phe Leu Ser Trp Thr Glu Pro Phe Gly Ile
 610 615 620

Ala Leu Thr Leu Phe Ala Val Leu Gly Ile Phe Leu Thr Ala Phe Val
 625 630 635 640

Leu Gly Val Phe Ile Lys Phe Arg Asn Thr Pro Ile Val Lys Ala Thr
 645 650 655

Asn Arg Glu Leu Ser Tyr Leu Leu Leu Phe Ser Leu Leu Cys Cys Phe
 660 665 670

Ser Ser Ser Leu Phe Phe Ile Gly Glu Pro Gln Asp Trp Thr Cys Arg
 675 680 685

Leu Arg Gln Pro Ala Phe Gly Ile Ser Phe Val Leu Cys Ile Ser Cys
 690 695 700

Ile Leu Val Lys Thr Asn Arg Val Leu Leu Val Phe Glu Ala Lys Ile
 705 710 715 720

Pro Thr Ser Phe His Arg Lys Trp Trp Gly Leu Asn Leu Gln Phe Leu
 725 730 735

6,011,068

151

152

-continued

Leu Val Phe Leu Cys Thr Phe Met Gln Ile Val Ile Cys Val Ile Trp
 740 745 750
 Leu Tyr Thr Ala Pro Pro Ser Ser Tyr Arg Asn Gln Glu Leu Glu Asp
 755 760 765
 Glu Ile Ile Phe Ile Thr Cys His Glu Gly Ser Leu Met Ala Leu Gly
 770 775 780
 Phe Leu Ile Gly Tyr Thr Cys Leu Leu Ala Ala Ile Cys Phe Phe Phe
 785 790 795 800
 Ala Phe Lys Ser Arg Lys Leu Pro Glu Asn Phe Asn Glu Ala Lys Phe
 805 810 815
 Ile Thr Phe Ser Met Leu Ile Phe Phe Ile Val Trp Ile Ser Phe Ile
 820 825 830
 Pro Ala Tyr Ala Ser Thr Tyr Gly Lys Phe Val Ser Ala Val Glu Val
 835 840 845
 Ile Ala Ile Leu Ala Ala Ser Phe Gly Leu Leu Ala Cys Ile Phe Phe
 850 855 860
 Asn Lys Ile Tyr Ile Ile Leu Phe Lys Pro Ser Arg Asn Thr Ile Glu
 865 870 875 880
 Glu Val Arg Cys Ser Thr Ala Ala His Ala Phe Lys Val Ala Ala Arg
 885 890 895
 Ala Thr Leu Arg Arg Ser Asn Val Ser Arg Lys Arg Ser Ser Ser Leu
 900 905 910
 Gly Gly Ser Thr Gly Ser Thr Pro Ser Ser Ser Ile Ser Ser Lys Ser
 915 920 925
 Asn Ser Glu Asp Pro Phe Pro Arg Pro Glu Arg Gln Lys Gln Gln Gln
 930 935 940
 Pro Leu Ala Leu Thr Gln Gln Glu Gln Gln Gln Gln Pro Leu Thr Leu
 945 950 955 960
 Pro Gln Gln Gln Arg Ser Gln Gln Gln Pro Arg Cys Lys Gln Lys Val
 965 970 975
 Ile Phe Gly Ser Gly Thr Val Thr Phe Ser Leu Ser Phe Asp Glu Pro
 980 985 990
 Gln Lys Asn Ala Met Ala His Arg Asn Ser Thr His Gln Asn Ser Leu
 995 1000 1005
 Glu Ala Gln Lys Ser Ser Asp Thr Leu Thr Arg His Gln Pro Leu Leu
 1010 1015 1020
 Pro Leu Gln Cys Gly Glu Thr Asp Leu Asp Leu Thr Val Gln Glu Thr
 1025 1030 1035 1040
 Gly Leu Gln Gly Pro Val Gly Gly Asp Gln Arg Pro Glu Val Glu Asp
 1045 1050 1055
 Pro Glu Glu Leu Ser Pro Ala Leu Val Val Ser Ser Ser Gln Ser Phe
 1060 1065 1070
 Val Ile Ser Gly Gly Gly Ser Thr Val Thr Glu Asn Val Val Asn Ser
 1075 1080 1085

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1078 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala Leu Thr Trp His

6,011,068

153

154

-continued

1	5	10	15
Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile	20	25	30
Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Ala Lys Asp	35	40	45
Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn	50	55	60
Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu	65	70	80
Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr Leu Gly Tyr Arg	85	90	95
Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu	100	105	110
Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe	115	120	125
Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala	130	135	140
Thr Gly Ser Gly Val Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe	145	150	155
Tyr Ile Pro Gln Val Ser Tyr Ala Ser Ser Ser Arg Leu Leu Ser Asn	165	170	175
Lys Asn Gln Phe Lys Ser Phe Leu Arg Thr Ile Pro Asn Asp Glu His	180	185	190
Gln Ala Thr Ala Met Ala Asp Ile Ile Glu Tyr Phe Arg Trp Asn Trp	195	200	205
Val Gly Thr Ile Ala Ala Asp Asp Asp Tyr Gly Arg Pro Gly Ile Glu	210	215	220
Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp Ile Cys Ile Asp Phe Ser	225	230	235
Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Glu Ile Gln His Val Val	245	250	255
Glu Val Ile Gln Asn Ser Thr Ala Lys Val Ile Val Val Phe Ser Ser	260	265	270
Gly Pro Asp Leu Glu Pro Leu Ile Lys Glu Ile Val Arg Arg Asn Ile	275	280	285
Thr Gly Lys Ile Trp Leu Ala Ser Glu Ala Trp Ala Ser Ser Ser Leu	290	295	300
Ile Ala Met Pro Gln Tyr Phe His Val Val Gly Gly Thr Ile Gly Phe	305	310	315
Ala Leu Lys Ala Gly Gln Ile Pro Gly Phe Arg Glu Phe Leu Lys Lys	325	330	335
Val His Pro Arg Lys Ser Val His Asn Gly Phe Ala Lys Glu Phe Trp	340	345	350
Glu Glu Thr Phe Asn Cys His Leu Gln Glu Gly Ala Lys Gly Pro Leu	355	360	365
Pro Val Asp Thr Phe Leu Arg Gly His Glu Glu Ser Gly Asp Arg Phe	370	375	380
Ser Asn Ser Ser Thr Ala Phe Arg Pro Leu Cys Thr Gly Asp Glu Asn	385	390	395
Ile Ser Ser Val Glu Thr Pro Tyr Ile Asp Tyr Thr His Leu Arg Ile	405	410	415
Ser Tyr Asn Val Tyr Leu Ala Val Tyr Ser Ile Ala His Ala Leu Gln	420	425	430

6,011,068

157

158

-continued

Ser Arg Asn Thr Ile Glu Glu Val Arg Cys Ser Thr Ala Ala His Ala
 865 870 875 880
 Phe Lys Val Ala Ala Arg Ala Thr Leu Arg Arg Ser Asn Val Ser Arg
 885 890 895
 Lys Arg Ser Ser Ser Leu Gly Gly Ser Thr Gly Ser Thr Pro Ser Ser
 900 905 910
 Ser Ile Ser Ser Lys Ser Asn Ser Glu Asp Pro Phe Pro Gln Pro Glu
 915 920 925
 Arg Gln Lys Gln Gln Gln Pro Leu Ala Leu Thr Gln Gln Glu Gln Gln
 930 935 940
 Gln Gln Pro Leu Thr Leu Pro Gln Gln Gln Arg Ser Gln Gln Gln Pro
 945 950 955 960
 Arg Cys Lys Gln Lys Val Ile Phe Gly Ser Gly Thr Val Thr Phe Ser
 965 970 975
 Leu Ser Phe Asp Glu Pro Gln Lys Asn Ala Met Ala His Gly Asn Ser
 980 985 990
 Thr His Gln Asn Ser Leu Glu Ala Gln Lys Ser Ser Asp Thr Leu Thr
 995 1000 1005
 Arg His Gln Pro Leu Leu Pro Leu Gln Cys Gly Thr Asp Leu Asp
 1010 1015 1020
 Leu Thr Val Gln Glu Thr Gly Leu Gln Gly Pro Val Gly Gly Asp Gln
 1025 1030 1035 1040
 Arg Pro Glu Val Glu Asp Pro Glu Glu Leu Ser Pro Ala Leu Val Val
 1045 1050 1055
 Ser Ser Ser Gln Ser Phe Val Ile Ser Gly Gly Gly Ser Thr Val Thr
 1060 1065 1070
 Glu Asn Val Val Asn Ser
 1075

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1079 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Ala Ser Tyr Ser Cys Cys Leu Ala Leu Leu Ala Leu Ala Trp His
 1 5 10 15
 Ser Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile
 20 25 30
 Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Ala Lys Asp
 35 40 45
 Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn
 50 55 60
 Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu
 65 70 75 80
 Ile Asn Ser Ser Pro Ser Leu Leu Pro Asn Met Thr Leu Gly Tyr Arg
 85 90 95
 Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu
 100 105 110
 Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe
 115 120 125
 Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala

6,011,068

159

160

-continued

130			135			140		
Thr Gly Ser	Gly Val Ser	Thr Ala Val	Ala Asn Leu	Leu Gly Leu	Phe			
145		150		155	160			
Tyr Ile Pro	Gln Val Ser	Tyr Ala Ser	Ser Ser Ser	Arg Leu Leu	Ser Asn			
	165		170		175			
Lys Asn Gln	Tyr Lys Ser	Phe Leu Arg	Thr Ile Pro	Asn Asp Glu	His			
	180		185		190			
Gln Ala Thr	Ala Met Ala	Asp Ile Ile	Glu Tyr Phe	Arg Trp Asn	Trp			
	195		200		205			
Val Gly Thr	Ile Ala Ala	Asp Asp Asp	Tyr Gly Arg	Pro Gly Ile	Glu			
	210		215		220			
Lys Phe Arg	Glu Glu Ala	Glu Glu Arg	Asp Ile Cys	Ile Asp Phe	Ser			
	225		230		240			
Glu Leu Ile	Ser Gln Tyr	Ser Asp Glu	Glu Glu Ile	Gln Gln Val	Val			
	245		250		255			
Glu Val Ile	Gln Asn Ser	Thr Ala Lys	Val Ile Val	Val Phe Ser	Ser			
	260		265		270			
Gly Pro Asp	Leu Glu Pro	Leu Ile Lys	Glu Ile Val	Arg Arg Asn	Ile			
	275		280		285			
Thr Gly Arg	Ile Trp Leu	Ala Ser Glu	Ala Trp Ala	Ser Ser Ser	Leu			
	290		295		300			
Ile Ala Met	Pro Glu Tyr	Phe His Val	Val Val Gly	Gly Thr Ile	Gly Phe			
	305		310		315			320
Gly Leu Lys	Ala Gly Gln	Ile Pro Gly	Phe Arg Glu	Phe Leu Gln	Lys			
	325		330		335			
Val His Pro	Arg Lys Ser	Val His Asn	Gly Phe Ala	Lys Glu Phe	Trp			
	340		345		350			
Glu Glu Thr	Phe Asn Cys	His Leu Gln	Glu Gly Ala	Lys Gly Pro	Leu			
	355		360		365			
Pro Val Asp	Thr Phe Val	Arg Ser His	Glu Glu Gly	Gly Asn Arg	Leu			
	370		375		380			
Leu Asn Ser	Ser Thr Ala	Phe Arg Pro	Leu Cys Thr	Gly Asp Glu	Asn			
	385		390		400			
Ile Asn Ser	Val Glu Thr	Pro Tyr Met	Asp Tyr Glu	His Leu Arg	Ile			
	405		410		415			
Ser Tyr Asn	Val Tyr Leu	Ala Val Tyr	Ser Ile Ala	His Ala Leu	Gln			
	420		425		430			
Asp Ile Tyr	Thr Cys Leu	Pro Gly Arg	Gly Leu Phe	Thr Asn Gly	Ser			
	435		440		445			
Cys Ala Asp	Ile Lys Lys	Val Glu Ala	Trp Gln Val	Leu Lys His	Leu			
	450		455		460			
Arg His Leu	Asn Phe Thr	Asn Asn Met	Gly Glu Gln	Val Thr Phe	Asp			
	465		470		475			480
Glu Cys Gly	Asp Leu Val	Gly Asn Tyr	Ser Ile Ile	Asn Trp His	Leu			
	485		490		495			
Ser Pro Glu	Asp Gly Ser	Ile Val Phe	Lys Glu Val	Gly Tyr Tyr	Asn			
	500		505		510			
Val Tyr Ala	Lys Lys Gly	Glu Arg Leu	Phe Ile Asn	Glu Glu Lys	Ile			
	515		520		525			
Leu Trp Ser	Gly Phe Ser	Arg Glu Val	Pro Phe Ser	Asn Cys Ser	Arg			
	530		535		540			
Asp Cys Gln	Ala Gly Thr	Arg Lys Gly	Ile Ile Glu	Gly Glu Pro	Thr			
	545		550		555			560

6,011,068

161

162

-continued

Cys	Cys	Phe	Glu	Cys	Val	Glu	Cys	Pro	Asp	Gly	Glu	Tyr	Ser	Gly	Glu	565	570	575	
Thr	Asp	Ala	Ser	Ala	Cys	Asp	Lys	Cys	Pro	Asp	Asp	Phe	Trp	Ser	Asn	580	585	590	
Glu	Asn	His	Thr	Ser	Cys	Ile	Ala	Lys	Glu	Ile	Glu	Phe	Leu	Ala	Trp	595	600	605	
Thr	Glu	Pro	Phe	Gly	Ile	Ala	Leu	Thr	Leu	Phe	Ala	Val	Leu	Gly	Ile	610	615	620	
Phe	Leu	Thr	Ala	Phe	Val	Leu	Gly	Val	Phe	Ile	Lys	Phe	Arg	Asn	Thr	625	630	635	640
Pro	Ile	Val	Lys	Ala	Thr	Asn	Arg	Glu	Leu	Ser	Tyr	Leu	Leu	Leu	Phe	645	650	655	
Ser	Leu	Leu	Cys	Phe	Ser	Ser	Ser	Ser	Leu	Phe	Phe	Ile	Gly	Glu	Pro	660	665	670	
Gln	Asp	Trp	Thr	Cys	Arg	Leu	Arg	Gln	Pro	Ala	Phe	Gly	Ile	Ser	Phe	675	680	685	
Val	Leu	Cys	Ile	Ser	Cys	Ile	Leu	Val	Lys	Thr	Asn	Arg	Val	Leu	Leu	690	695	700	
Val	Phe	Glu	Ala	Lys	Ile	Pro	Thr	Ser	Phe	His	Arg	Lys	Trp	Trp	Gly	705	710	715	720
Leu	Asn	Leu	Gln	Phe	Leu	Leu	Val	Phe	Leu	Cys	Thr	Phe	Met	Gln	Ile	725	730	735	
Leu	Ile	Cys	Ile	Ile	Trp	Leu	Tyr	Thr	Ala	Pro	Pro	Ser	Ser	Tyr	Arg	740	745	750	
Asn	His	Glu	Leu	Glu	Asp	Glu	Ile	Ile	Phe	Ile	Thr	Cys	His	Glu	Gly	755	760	765	
Ser	Leu	Met	Ala	Leu	Gly	Ser	Leu	Ile	Gly	Tyr	Thr	Cys	Leu	Leu	Ala	770	775	780	
Ala	Ile	Cys	Phe	Phe	Phe	Ala	Phe	Lys	Ser	Arg	Lys	Leu	Pro	Glu	Asn	785	790	795	800
Phe	Asn	Glu	Ala	Lys	Phe	Ile	Thr	Phe	Ser	Met	Leu	Ile	Phe	Phe	Ile	805	810	815	
Val	Trp	Ile	Ser	Phe	Ile	Pro	Ala	Tyr	Ala	Ser	Thr	Tyr	Gly	Lys	Phe	820	825	830	
Val	Ser	Ala	Val	Glu	Val	Ile	Ala	Ile	Leu	Ala	Ala	Ser	Phe	Gly	Leu	835	840	845	
Leu	Ala	Cys	Ile	Phe	Phe	Asn	Lys	Val	Tyr	Ile	Ile	Leu	Phe	Lys	Pro	850	855	860	
Ser	Arg	Asn	Thr	Ile	Glu	Glu	Val	Arg	Ser	Ser	Thr	Ala	Ala	His	Ala	865	870	875	880
Phe	Lys	Val	Ala	Ala	Arg	Ala	Thr	Leu	Arg	Arg	Pro	Asn	Ile	Ser	Arg	885	890	895	
Lys	Arg	Ser	Ser	Ser	Leu	Gly	Gly	Ser	Thr	Gly	Ser	Ile	Pro	Ser	Ser	900	905	910	
Ser	Ile	Ser	Ser	Lys	Ser	Asn	Ser	Glu	Asp	Arg	Phe	Pro	Gln	Pro	Glu	915	920	925	
Arg	Gln	Lys	Gln	Gln	Gln	Pro	Leu	Ser	Leu	Thr	Gln	Gln	Glu	Gln	Gln	930	935	940	
Gln	Gln	Pro	Leu	Thr	Leu	His	Pro	Gln	Gln	Gln	Gln	Gln	Pro	Gln	Gln	945	950	955	960
Pro	Arg	Cys	Lys	Gln	Lys	Val	Ile	Phe	Gly	Ser	Gly	Thr	Val	Thr	Phe	965	970	975	
Ser	Leu	Ser	Phe	Asp	Glu	Pro	Gln	Lys	Asn	Ala	Met	Ala	His	Arg	Asn	980	985	990	

6,011,068

163

164

-continued

Ser Met Arg Gln Asn Ser Leu Glu Ala Gln Arg Ser Asn Asp Thr Leu
 995 1000 1005

Gly Arg His Gln Ala Leu Leu Pro Leu Gln Cys Ala Asp Ala Asp Ser
 1010 1015 1020

Glu Met Thr Ile Gln Glu Thr Gly Leu Gln Gly Pro Met Val Gly Asp
 1025 1030 1035 1040

His Gln Pro Glu Met Glu Ser Ser Asp Glu Met Ser Pro Ala Leu Val
 1045 1050 1055

Met Ser Thr Ser Arg Ser Phe Val Ile Ser Gly Gly Ser Ser Val
 1060 1065 1070

Thr Glu Asn Val Leu His Ser
 1075

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids
 (B) TYPE: amino acids
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Tyr Lys Asp Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids
 (B) TYPE: amino acids
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ala Asp Asp Asp Tyr Gly Arg Pro Gly Ile Glu Lys Phe Arg Glu Glu
 1 5 10 15

Ala Glu Glu Arg Asp Ile Cys
 20

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids
 (B) TYPE: amino acids
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Cys Ile Asp Phe Ser Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Lys
 1 5 10 15

Ile Gln Gln

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids
 (B) TYPE: amino acids
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

6,011,068

165

166

-continued

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Tyr His Asn Gly Phe Ala Lys Glu Phe Trp Glu Glu Thr Phe Asn Cys
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids
 (B) TYPE: amino acids
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Asp Gly Glu Tyr Ser Asp Glu Thr Asp Ala Ser Ala Cys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids
 (B) TYPE: amino acids
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Asn Thr Pro Ile Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Cys
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids
 (B) TYPE: amino acids
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Tyr Arg Asn His Glu Leu Glu Asp Glu Ile Ile Phe Ile Thr Cys
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids
 (B) TYPE: amino acids
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Arg Lys Leu Pro Glu Asn Phe Asn Glu Ala Lys Tyr Cys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs
 (B) TYPE: nucleic
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

167

6,011,068

168

-continued

(iii) FEATURE:
 (A) NAME/KEY: Modified Base
 (B) LOCATION: 13...13
 (C) OTHER INFORMATION: Inosine

(iv) SEQUENCE DESCRIPTION: SEQ ID NO:17:
 CCTGCTCGAG ACNARYCGGG ARCTYTSCTA YMT 33

(2) INFORMATION FOR SEQ ID NO:18:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 31 base pairs
 (B) TYPE: nucleic
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(iii) FEATURE:
 (A) NAME/KEY: Modified Base
 (B) LOCATION: 13...13
 (C) OTHER INFORMATION: Inosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
 CGGAATTCGG TTNCGGGWYT TGAASGCRWA S 31

(2) INFORMATION FOR SEQ ID NO:19:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(iii) FEATURE:
 (A) NAME/KEY: Modified Base
 (B) LOCATION: 24...24
 (C) OTHER INFORMATION: Inosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
 CCTGCTCGAG TCAAGGCTAC GRRNMNGAR 30

(2) INFORMATION FOR SEQ ID NO:20:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(iii) FEATURE:
 (A) NAME/KEY: Modified Base
 (B) LOCATION: 26...26
 (C) OTHER INFORMATION: Inosine


(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
 CGGAATTCCTCA TTGGCTTCG TTGAANKTNK 30

6,011,068

169

We claim:

1. A compound having the chemical formula:



wherein alk is selected from the group consisting of n-propylene, 2,4-butylene and 1,3-butylene;


R₁ is lower alkyl of from 1 to 3 carbon atoms or lower haloalkyl of from 1 to 3 carbon atoms substituted with from 1 to 7 halogen atoms; and

R₂ and R₃ are independently selected monocyclic or bicyclic carbocyclic aryl or cycloalkyl groups, having 5- to 7-membered rings optionally substituted with 1 to 5 substituents independently selected from the group consisting of: OCF₃, lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms; provided that if R₂ is phenyl, then said phenyl R₂ has at least one substituent and is not 4-OH-phenyl; or a pharmaceutically acceptable acid addition salt or complex thereof.

2. The compound of claim 1 wherein alk is n-propylene.

3. The compound of claim 2 wherein R₁ is methyl.4. The compound of claim 3 wherein R₂ is a substituted phenyl and R₃ is an optionally substituted phenyl.

5. A compound having the chemical formula:



wherein alk is either n-propylene, 2,4-butylene, or 1,3-butylene; R₁ is a lower alkyl of from 1 to 3 carbon atoms;

R₂ is either naphthyl or a phenyl substituted with 1 to 5 substituents, and R₃ is either cyclohexyl, naphthyl, or a phenyl optionally substituted with 1 to 5 substituents; wherein each of said R₂ substituents and each of said R₃ substituents are independently selected from the group consisting of: OCF₃, lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms;

provided that R₂ is not 4-OH-phenyl; or

a pharmaceutically acceptable acid addition salt or complex thereof.

6. The compound of claim 5, wherein

R₁ is methyl; and

each of said R₂ substituents and each of said R₃ substituents are independently selected from the group consisting of: lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms,

170

halogen, nitro, amino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms.

7. The compound of claim 6, wherein

R₂ is either naphthyl or said phenyl having 1 to 5 substituents; and

R₃ is either naphthyl or said phenyl optionally substituted with 1 to 5 substituents.

8. The compound of claim 7, wherein alk is 2,4-butylene.

9. The compound of claim 7, wherein alk is 1,3-butylene.

10. The compound of any one of claims 8 or 9, wherein R₃ is naphthyl.11. The compound of any one of claims 8 or 9, wherein R₃ is said optionally substituted phenyl.12. The compound of claim 11, wherein R₂ is naphthyl.13. The compound of claim 11, wherein R₂ is said substituted phenyl.14. The compound of claim 13, wherein said R₂ substituted phenyl is a meta-substituted phenyl.


15. The compound of claim 14, wherein said R₂ meta-substituted phenyl has a meta substituent selected from the group consisting of: halogen, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms.

16. The compound of claim 15, wherein said R₂ meta substituent is methoxy.17. The compound of claim 15, wherein said R₂ meta substituent is trihalomethyl.18. The compound of claim 15, wherein said R₂ meta substituent is lower thioalkyl of 1 to 3 carbon atoms.

19. The compound of claim 16, wherein said R₃ optionally substituted phenyl is a substituted phenyl having one or more substituents each independently selected from the group consisting of: halogen, CF₃, alkoxy of 1 to 3 carbon atoms, and lower alkyl of 1 to 3 carbon atoms.


20. The compound of claim 19, wherein said R₃ substituted phenyl is an ortho-substituted phenyl having either a chloro or fluoro substituent.

21. The compound of any one of claims 5-7, wherein said compound is an R enantiomer having the following chemical structure:



or a pharmaceutically acceptable acid addition salt or complex thereof.


22. The compound of claim 11, wherein said compound is an R enantiomer having the following chemical structure:



or a pharmaceutically acceptable acid addition salt or complex thereof.


23. The compound of claim 15, wherein said compound is an R enantiomer having the following chemical structure:

171



or a pharmaceutically acceptable acid addition salt or complex thereof.

24. The compound of claim 5, wherein said compound




6,011,068

172






or a pharmaceutically acceptable acid addition salt or complex thereof.

25. compound of claim 5, wherein said compound




or a pharmaceutically acceptable acid addition salt or complex thereof.

26. A compound represented by a formula selected from the group consisting of



and




6,011,068

173

wherein m is independently an integer of 0 to 5 for naphthyl rings and m is independently an integer of 1 to 5 for phenyl rings;

x is independently selected from the group consisting of —Br, —Cl, —F, —I, —CN, —NO₂, —OR, —NR₂, —CF₃, —SR, —S(O)R, —S(O)₂R, —C(O)R, —OC(O)R, —C(O)OR, —NRC(O)R, C(O)NR₂, methyl and isopropyl radicals; provided that the X substituent on the phenyl ring of the Ph-CHR-group is other than hydroxy, 4-OCH₃, or 4-CH₃; and


each R is independently either a hydrogen, C₁–C₁₀ alkyl, C₂–C₁₀ alkenyl, C₂–C₁₀ alkynyl, C₃–C₁₀ cycloalkyl, —CF₃, —CF₂H, —CFH₂, —CH₂CF₃ or phenyl radical; provided that if said compound has the chemical formula:



wherein the naphthyl is either unsubstituted or substituted with a lower alkyl or halogen and only one substituent is present on the phenyl, then said one substituent is not lower alkyl or halogen; or a pharmaceutically acceptable acid addition salt or complex thereof.


27. The compound of claim 26, wherein each R is independently C₁–C₃ alkyl.

28. The compound of claim 26, represented by a formula selected from the group consisting of:



174


-continued



wherein each m is independently an integer of 1 to 5; each X is independently selected from the group consisting of —Cl, —F, —I, —CF₃, —OCF₃, —OCH₂CF₃, —SCH₃, methyl, isopropyl and methoxy radicals; and R is a hydrogen, methyl, ethyl or isopropyl radical; or a pharmaceutically acceptable acid addition salt or complex thereof.


29. The compound of claim 28, wherein each m is independently an integer of 1 or 2;

30. The compound of claim 29, wherein said compound has the following formula:




or a pharmaceutically acceptable acid addition salt or complex thereof.

31. The compound of claim 29, wherein said compound has the following formula:



or a pharmaceutically acceptable acid addition salt or complex thereof.

32. The compound of claim 29, wherein said compound has the following formula:




or a pharmaceutically acceptable acid addition salt or complex thereof.

33. The compound of claim 29, wherein said compound has the following formula:


6,011,068

175




or a pharmaceutically acceptable acid addition salt or complex thereof.

34. The compound of claim 29, wherein said compound has the following formula:




or a pharmaceutically acceptable acid addition salt or complex thereof.

35. The compound of claim 29, wherein said compound has the following formula:



or a pharmaceutically acceptable acid addition salt or complex thereof.

36. The compound of claim 26, wherein said compound has a chemical structure selected from the group consisting of:




or a pharmaceutically acceptable acid addition salt or complex thereof.

37. A pharmaceutical composition comprising the compound of any one of claims 26-29 and 30-36, and a pharmaceutically acceptable carrier.

176

38. A compound having the chemical formula:



wherein alk is 1,1-ethylidene or methylene;

R_1 is lower alkyl of from 1 to 3 carbon atoms or lower haloalkyl of from 1 to 3 carbon atoms substituted with from 1 to 7 halogen atoms; and

R_2 and R_3 are independently selected monocyclic or bicyclic carbocyclic aryl or cycloalkyl groups, having 5- to 7-membered rings optionally substituted with 1 to 5 substituents independently selected from the group consisting of: OCF_3 , lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms;

provided that R_2 is not an unsubstituted phenyl and R_3 is not an unsubstituted phenyl;

further provided that if alk is methylene then either, R_2 and R_3 are both substituted phenyls, R_3 does not contain a OH substituent, and R_2 is not 4- OCH_3 -phenyl, or 4- CH_3 -phenyl, or R_2 is an optionally substituted naphthyl and R_3 is a substituted phenyl not containing an OH substituent; and

further provided that if one of R_2 or R_3 is naphthyl or naphthyl substituted with a lower alkyl of 1 to 3 carbons or halogen and the other of R_2 or R_3 is phenyl, then the phenyl has 1-5 substituents and if one substituent is present, then the one substituent is other than 2-OH, lower alkyl of 1 to 3 carbons or halogen; or a pharmaceutically acceptable acid addition salt or complex thereof.

39. The compound of claim 38, wherein R_2 is either naphthyl or a substituted phenyl having 1 to 5 substituents; and

R_3 is either naphthyl or a substituted phenyl having 1 to 5 substituents.

40. The compound of claim 39, wherein each of said substituents are independently selected from the group consisting of: lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms.

41. The compound of claim 40, wherein R_3 is substituted phenyl.

42. The compound of claim 41, wherein R_2 is naphthyl.


43. The compound of claim 41, wherein R_2 is substituted phenyl.

44. The compound of claim 43, wherein said R_3 substituted phenyl is substituted with one or more substituents each independently selected from the group consisting of: halogen, CF_3 , alkoxy of 1 to 3 carbon atoms, and lower alkyl of 1 to 3 carbon atoms.

45. The compound of any one of claims 38-44, wherein said compound is an R enantiomer having the chemical formula:

6,011,068

177










or a pharmaceutically acceptable acid addition salt or complex thereof.

46. The compound of claim 45, wherein said compound causes an increase in $(\text{Ca}^{2+})_i$ with an EC_{50} less than or equal to $5 \mu\text{M}$ as determined by measuring $(\text{Ca}^{2+})_i$ in bovine parathyroid cells loaded with fura-2 using the Cytosolic Ca^{2+} Cell Assay.

47. The compound of any one of claims 38-44, wherein alk is methylene.











48. The compound of any one of claims 38-44, wherein alk is 1,1-ethylidene.

49. A compound selected from the group consisting of:



178

-continued



5

10

15

20

25

30

35

40

45

50

55


60

65

6,011,068


179

-continued



180


-continued



6,011,068


181

-continued



182


-continued



6,011,068


183

-continued



184











-continued



6,011,068












185

-continued



186











-continued



6,011,068











187

-continued



188

-continued




65 and

6,011,068

189









-continued



5


or a pharmaceutically acceptable acid addition salt or complex thereof.

50. The compound of claim 49, wherein said compound is selected from group consisting of:




190


-continued




5




10




20




25




30




35




40



45



50




55

60

6,011,068


191

-continued



192








-continued




6,011,068

193

-continued












and



or a pharmaceutically acceptable acid addition salt or complex thereof.

51. The compound of claim 50, wherein said compound is selected from the group consisting of;

194











65

6,011,068


195

-continued



or a pharmaceutically acceptable acid addition salt or complex thereof.


52. The compound of claim 49, wherein said compound is



196


or a pharmaceutically acceptable acid addition salt or complex thereof.

53. The compound of claim 49, wherein said compound is




or a pharmaceutically acceptable acid addition salt or complex thereof.

54. The compound of claim 49, wherein said compound is




or a pharmaceutically acceptable acid addition salt or complex thereof.

55. The compound of claim 49, wherein said compound is




or a pharmaceutically acceptable acid addition salt or complex thereof.

56. The compound of claim 49, wherein said compound is



or a pharmaceutically acceptable acid addition salt or complex thereof.

57. The compound of claim 49, wherein said compound is




or a pharmaceutically acceptable acid addition salt or complex thereof.

58. The compound of claim 49, wherein said compound is


6,011,068

197




or a pharmaceutically acceptable acid addition salt or complex thereof

59. The compound of claim 49, wherein said compound is selected from the group consisting of:



and



or a pharmaceutically acceptable acid addition salt or complex thereof.

60. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of any one of claims 49-59.

61. The compound of claim 5, wherein

R_1 is methyl; and

each of said R_2 substituents and each of said R_3 substituents are independently selected from the group consisting of: OCF_3 , lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms.

62. The compound of claim 61, wherein alk is n-propylene.

63. The compound of claim 61, wherein alk is 1,1-ethylidene.

64. The compound of claim 61, wherein alk is 2,7-butylene.

65. The compound of claim 61, wherein alk is 1,3-butylene.

66. The compound of any one of claims 61-65, wherein R_3 is naphthyl.

67. The compound of any one of claims 61-65, wherein R_3 is said optionally substituted phenyl.

68. The compound of claim 67, wherein R_2 is naphthyl.

69. The compound of claim 67, wherein R_2 is said substituted phenyl.


70. The compound of claim 69, wherein said R_2 substituted phenyl is a meta-substituted phenyl.

71. The compound of claim 70, wherein said R_2 meta-substituted phenyl has a meta substituent selected from the group consisting of: halogen, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms.

198

72. The compound of claim 71, wherein said R_2 meta substituent is methoxy.

73. The compound of any one of claims 61-65, wherein said compound is an enantiomer having the following chemical structure:



or a pharmaceutically acceptable acid addition salt or complex thereof.

74. The compound of claim 73, wherein said compound causes an increase in $(Ca^{2+})_i$ with an EC_{50} less than or equal to $5 \mu M$ as determined by measuring $(Ca^{2+})_i$ in bovine parathyroid cells loaded with fura-2 using the Cytosolic Ca^{2+} Cell Assay.


75. The pharmaceutical composition of claim 100, wherein said compound causes an increase in $(Ca^{2+})_i$ with an EC_{50} less than or equal to $5 \mu M$ as determined by measuring $(Ca^{2+})_i$ in bovine parathyroid cells loaded with fura-2 using the Cytosolic Ca^{2+} Cell assay.

76. The pharmaceutical composition of claim 101, wherein said compound causes an increase in $(Ca^{2+})_i$ with an EC_{50} less than or equal to $5 \mu M$ as determined by measuring $(Ca^{2+})_i$ in bovine parathyroid cells loaded with fura-2 using the cytosolic Ca^{2+} cell assay.

77. The compound of claim 21, wherein said compound causes an increase in $(Ca^{2+})_i$ with an EC_{50} less than or equal to $5 \mu M$ as determined by measuring $(Ca^{2+})_i$ in bovine parathyroid cells loaded with fura-2 using the Cytosolic Ca^{2+} Cell Assay.

78. The compound of claim 23, wherein said compound causes an increase in $(Ca^{2+})_i$ with an EC_{50} less than or equal to $5 \mu M$ as determined by measuring $(Ca^{2+})_i$ in bovine parathyroid cells loaded with fura-2 using the Cytosolic Ca^{2+} Cell Assay.

79. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the chemical formula:



wherein

alk is a straight- or branched-chain alkylene of from 0 to 6 carbon atoms;

R_1 is a lower alkyl of from 1 to 3 carbon atoms or a lower haloalkyl of from 1 to 3 carbon atoms substituted with from 1 to 7 halogen atoms; and

R_2 and R_3 are each independently selected monocyclic or bicyclic carbocyclic aryl or cycloalkyl groups, having 5- to 7-membered rings optionally substituted with 1 to 5 substituents each independently selected from the group consisting of: OCF_3 , lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms; provided that if R_2 is phenyl, then R_2 is substituted with 1 to 5 substituents; further

6,011,068

199

provided that if R_3 is cycloalk and alk is $-\text{CH}_2-$, then R_2 is not 4 aminophenyl; or a pharmaceutically acceptable acid addition salt or complex thereof.

80. The pharmaceutical composition of claim 79, wherein alk is 1 to 6 carbon atoms;

R_1 is lower alkyl of from 1 to 3 carbon atoms; and

R_2 is either naphthyl or a substituted phenyl having 1 to 5 substituents, and R_3 is either cyclohexyl, naphthyl, or a phenyl optionally substituted with 1 to 5 substituents, wherein each R_2 and R_3 substituent is independently selected from the group consisting of: OCF_3 , lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms.

81. The pharmaceutical composition of claim 79, wherein alk is 1 to 6 carbon atoms;

R_1 is lower alkyl of from 1 to 3 carbon atoms;

R_2 is either naphthyl or a substituted phenyl having 1 to 5 substituents each independently selected from the group consisting of: lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms; and

R_3 is either cyclohexyl, naphthyl, or a phenyl optionally substituted with 1 to 5 substituents each independently selected from the group consisting of: lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms.

82. The pharmaceutical composition of claim 81, wherein alk is an alkylene chain 1 to 3 carbon atoms in length which may be substituted with a methyl.

83. The pharmaceutical composition of claim 81, wherein R_1 is methyl.

84. The pharmaceutical composition of claim 83, wherein alk is n-propylene.

85. The pharmaceutical composition of claim 83, wherein alk is 1,1-ethylidene.

86. The pharmaceutical composition of claim 83, wherein alk is 2,4-butylene.

87. The pharmaceutical composition of claim 83, wherein alk is 1,3-butylene.

88. The pharmaceutical composition of claim 83, wherein alk is methylene.

89. The pharmaceutical composition of any one of claims 84-88, wherein R_3 is naphthyl.

90. The pharmaceutical composition of any one of claims 84-88, wherein R_3 is said optionally substituted phenyl.

91. The pharmaceutical composition of claim 90, wherein R_2 is naphthyl.

92. The pharmaceutical composition of claim 90, wherein R_2 is said substituted phenyl.

93. The pharmaceutical composition of claim 92, wherein said R_2 substituted phenyl is a meta-substituted phenyl.

94. The pharmaceutical composition of claim 93, wherein said R_2 meta-substituted phenyl has a meta substituent

200

selected from the group consisting of: halogen, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms.

95. The pharmaceutical composition of claim 94, wherein said R_2 meta substituent is methoxy.


96. The pharmaceutical composition of claim 94, wherein said R_2 meta substituent is trihalomethyl.

97. The pharmaceutical composition of claim 94, wherein said R_2 meta substituent is a lower thioalkyl of 1 to 3 carbon atoms.

98. The pharmaceutical composition of claim 94, wherein said R_3 optionally substituted phenyl is a substituted phenyl having one or more substituents each independently selected from the group consisting of: halogen, CF_3 , alkoxy of 1 to 3 carbon atoms, and lower alkyl of 1 to 3 carbon atoms.


99. The pharmaceutical composition of claim 98, wherein said R_3 substituted phenyl is an ortho-substituted phenyl having either a chloro or fluoro substituent.

100. The pharmaceutical composition of any one of claims 80-83, wherein said compound is an R enantiomer having the following chemical structure:




or a pharmaceutically acceptable acid addition salt or complex thereof.

101. The pharmaceutical composition of claim 94, wherein said compound is an R enantiomer having the following chemical structure:




or a pharmaceutically acceptable acid addition salt or complex thereof.

102. The pharmaceutical composition of claim 95, wherein said compound is an R enantiomer having the following chemical structure:



or a pharmaceutically acceptable acid addition salt or complex thereof.

103. The pharmaceutical composition of claim 79, wherein said compound is



or a pharmaceutically acceptable acid addition salt or complex thereof.

* * * * *

ATTACHMENT B
COPY OF RECEIPT OF MAINTENANCE FEE PAYMENT FOR US PATENT NO. 6,011,068